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A strategy for protecting the myocardium during ischaemia would reduce the 
mortality associated with ischaernic heart disease. Ischaernic preconditioning (IP) 
refers to the resistance to ischaernic injury that follows brief periods of ischaemia and 
reperfusion. A better understanding of the signalling pathways that underlie 
preconditioning may enable protection without the risk of an ischaernic trigger. 
Aims 
To examine the role of protein kinases in the intracellular signalling pathway 
responsible for protection following ischaernic preconditioning. 
Results 
Protein kinase C (PKC) activation is critical for protection, although the isoform 
responsible is unknown. We used PKCF- deficient mice to study the role of this PKC 
isoform in IP. The hearts from mice lacking PKCF, (-/-) and matched heterozygous 
mice (+/-) were preconditioned by 4x4 minutes ischaemia/6 minutes reperfusion. In 
(+/-) hearts, IP significantly reduced infarction and improved contractile recovery. In 
contrast, there was no difference in infarction between IP and control hearts from (-/-) 
mice, although IP still enhanced contractile recovery in these hearts. These data 
suggest that PKCE is essential for the reduction in infarct size seen following IP, but is 
not associated with the improvement in contractile recovery. 
Mitogen- activated protein kinases (MAPKs) have been implicated downstream of 
PKC. Of all the MAPK isoforms, only p38 was activated during simulated ischaemia 
in neonatal rat cardiac myocytes. Surprisingly, this activity was diminished in cells 
protected by preconditioning. Moreover, pharmacological inhibition of p38 protected 
myocytes during simulated ischaemia. Ectopically expressed p38(X was activated 
during ischaemia and inhibited by preconditioning, whereas p38P was inhibited 
during ischaemia. Specific inhibition of p38(x, using a dominant negative mutant, also 
protected myocytes against simulated ischaemia. 
Conclusions 
These data suggest that PKCF, is the isoform. responsible for preconditioning against 
infarction in the isolated mouse heart. The enhanced recovery after preconditioning in 
PKCE deficient mice, suggests that protection against infarction and contractile 
recovery maybe mutually exclusive. In neonatal rat myocytes, p38(X MAPK is 
activated during simulated ischaernia, which aggravates cell injury. The inhibition of 
p38(x activation that follows ischaernic preconditioning may, at least in part, 
contribute to the resulting protection. 
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Chapter 1 Introduction 
I MYOCARDIAL ISCHAEMIA AND INFARCTION 
Myocardial ischaernia can be simply defined as an inadequate blood supply to the 
heart (1). The blood supply becomes inadequate when the supply of oxygen and 
nutrients is insu icient to meet the heart's demand. In almost all cases this arises due 
to a decreased blood flow, which invariably results in an accumulation of metabolites 
from the ischaernic region, possible contributing to the cellular damage associated 
with ischaernia. 
Myocardial ischaernia usually occurs when one or more of the epicardial. coronary 
arteries becomes narrowed (stenosed) or blocked (occluded). The consequence to the 
heart will depend on the degree and, critically, the duration of ischaernia. In some 
circumstances the degree of ischaemia is mild enough for the heart to function 
normally at rest, but insufficient to maintain supply during exertion or exercise (stable 
angina). If the depth and breadth of ischaernia is sufficiently great however, the pain 
associated with angina cannot be relieved by rest (unstable angina). Unlike stable 
angina, which is usually caused by a narrowed coronary artery, unstable angina is 
probably caused by intermittent blockage of a coronary artery with distal 
embolization. Often unstable angina steadily worsens (crescendo angina) and in a 
proportion of patients leads to myocardial infarction (pre-infarction angina). 
Ischaernia can be relieved by a restoration of normal flow, a process known as 
reperfusion. If reperfusion is not performed soon (20-30 minutes) after a total 
coronary occlusion, injury will progress from reversible to irreversible injury, when 
death of cells within the ischaemic risk zone will begin to occur. This process 
involves coagulative necrosis of the ischaernic tissue and is called acute myocardial 
infarction. 
1.1 The cause of ischaemic heart disease 
The underlying cause of ischaemic heart disease is the narrowing of coronary arteries 
that supply the heart with blood. The constriction of the arterial lumen is brought 
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n t.. about by a thickening of the innermost layer (intima) by the development of fibrous 
tissue and the accumulation of lipid forming atheromatous plaques (atherosclerosis). 
Atherosclerosis is not restricted to the heart, but rather a widespread vascular disease, 
which is more significant in the heart due to the severe consequences of starving the 
heart muscle of blood, although atherosclerosis of arteries supplying the brain may be 
equally severe. Arterial narrowing per se is not the cause of major adverse events, but 
is nonetheless compounded by thrombosis, leading to sudden, total occlusion of the 
coronary artery and ultimately myocardial infarction. Although the final events 
leading to thrombolysis are not completely understood, it is believed to be a result of 
critical changes in plaque status leading to plaque rupture. 
1.2 The determinants of cell death 
A complete cessation of blood flow to the risk region will result in a profound 
reaction on myocardial contractility within one minute. The underlying cause is the 
abolition of oxidative phosphorylation and the consequential decrease in pH and ATP 
generation. Initially anaerobic glycolysis will maintain homeostasis, however this will 
only last for a few minutes, during which acidification of the intracellular milieu and 
build up of extracellular metabolites may only serve to enhance injury. The exact 
cause of cell death is unknown, but acidification, cell swelling, ATP depletion and 
calcium overload are all thought to be contribute to the disruption of sarcolemmal 
integrity and death. 
1.3 The extent of the problem 
Ischaemic heart disease remains a leading cause of death, accounting for one quarter 
of all deaths in the UK (2). Although the annual mortality for this disease is 
decreasing in the UK and other developed countries (3), the figure continues to rise in 
the more populated developing countries (4). The net effect is that ischaemic heart 
disease may soon surpass infectious and nutritional diseases as the most common 
form of death worldwide (4,5). Despite effective preventative treatments, patients 
still present with advanced coronary disease with atherosclerotic plaques vulnerable to 
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events that cause abrupt occlusion, myocardial infarction and death (6). Currently, the 
most effective treatment is to achieve rapid reperfusion by lysis or mechanical 
disruption of the occlusive coronary thrombosis and plaque (7,8). The mortality is 
inversely related to the amount of myocardial salvage achieved by reperfusion (7), 
and hence a treatment that slows the rate of myocardial necrosis would invariably 
increase salvage and decrease mortality (9). 
It was a major goal of academic cardiologists, throughout the 1970s and 1980s, to 
discover a means of protecting the infarcting myocardium (10). Despite a 
considerable volume of work being published on the subjected, no single agent was 
found that could consistently and reproducibly limit infarction. It was reasoned that 
by understanding the biochemical events that lead to irreversible cell injury one might 
be able to design a strategy to combat ischaemic heart disease. It is ironic that whilst 
attempting to discover the cause of cell death, Reimer and colleagues serendipitously 
discovered a method of protecting the myocardium (11), whilst the exact cause of 
myocardial injury still remains unclear today. 
2 INTRODUCTION TO ISCHAEMIC PRECONDITIONING 
2.1 The first description 
By dissociating ATP depletion and catabolite accumulation, Reimer reasoned that it 
should be possible to ascertain their relative contributions to ischaemic injury (11). It 
had been shown in the early 1980s that ATP resynthesis following a single episode of 
ischaernia was slow, taking as long as four days to recover from a 15-minute coronary 
occlusion (12,13). They therefore hypothesised that while ischaemic episodes would 
induce a cumulative, "stair-step" depletion of ATP, intermittent reperfusions should 
wash out ischaemic catabolites. Surprisingly their findings showed that, although 
intermittent reperfusions did cause less cell necrosis, ATP levels were preserved after 
the first ischaernic episode (11). 
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In a subsequent study the same group used four 5-minute episodes of ischaemia, 
interspersed with 5-minute periods of reperfusion, prior to a sustained 40-minute 
occlusion. Control dogs infarcted 29% of the area at risk, while infarcts where only 
7% of the area at risk following brief periods of ischaemia/reperfusion (14). They 
termed this endogenous protection "preconditioning the myocardium with ischaemia. " 
This phenomenon is now commonly referred to as classical (or early) ischaemic 
preconditioning. 
2.2 Limits of classical preconditioning 
The protection against a 40-minute occlusion maybe robust, but this is brought about 
by a delay in the progression of myocardial necrosis, and hence if the duration of 
occlusion is increased, the level of protection is diminished. In most species, 
preconditioning will not protect against an ischaemic time of longer than 90 minutes, 
and will offer no reduction against permanent occlusion. A possible explanation is 
that after 60 minutes cell death is mainly occurring in the subepicardium, which can 
take between 2-5 hours to complete, therefore a delay in this slow progression of 
injury would not be translated into a large infarct size reduction. Prior to 60 minutes 
however, the subendocardium is undergoing rapid infarction, which takes only 40 
minutes to reach confluency (15). 
Unfortunately, the benefit of ischaernic preconditioning is short lived and disappears 
when the interval between the short ischaemic trigger and the subsequent prolonged 
ischaemia is greater than 60 minutes (16). In addition, although initially ischaemic 
preconditioning can be renewed by further brief ischaemic triggers, changes in cell 
surface receptors and ligand availability, eventually result in tachyphylaxis (17,18). 
2.3 Delayed ischaemic preconditioning 
Since the initial discovery of classical preconditioning, a second window has been 
demonstrated during which the heart is also protected, although to a lesser extent, 
against a subsequent ischaernic insult (19). This second window of protection 
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(SWOP) or delayed preconditioning is manifest 12-24 hours after the preconditioning 
stimulus and lasts for up to 76 hours. The time course of protection appears consistent 
with a role for gene expression. Many candidate proteins have been proposed as the 
mediators of delayed preconditioning from inducible nitric oxide synthase (NOS) 
(20) to manganese superoxide dismutase (MnSOD) (21). The strongest evidence 
implicates a member of the heat shock protein (HSP) family, HSP70, since it is 
consistently elevated 24 hours following preconditioning in most models (22-24). 
Moreover, induction by heat stress (25) or overexpression (26) of this protein in the 
absence of preconditioning confers a similar level of protection. It should be noted 
that there is disagreement with regards the role of HSP70, as in some models 
protection does not follow HSP induction (27,28). The mechanisms involved in 
delayed preconditioning are beyond the scope of this thesis, since they are most likely 
distinct from those responsible for classical preconditioning. 
2.4 A conserved phenomena? 
Ischaernic precondlitioning has been demonstrated in nearly all species examined 
including mouse (29), rat (30), rabbit (31), dog (14), and pigs (32). More importantly, 
preconditioning has been demonstrated in humans using myocardial tissue and the 
whole heart (see section 5). Furthermore, protection is not restricted to the heart, as it 
is also seen following brief ischaemia in the kidneys, liver and brain (15). 
It is undoubted that harnessing the therapeutic potential of ischaemic preconditioning 
would save many lives. Unfortunately however, the unpredictability of the moment of 
coronary occlusion necessitates sustained or renewable protection. These limitations 
have therefore caused some investigators to question its clinical utility. However, the 
depth and breadth of the protection afforded by preconditioning are sufficiently 
impressive to have stimulated and maintained an intense research activity with over 
1400 manuscripts published since this phenomenon was described 14 years ago. This 
interest has focused on the notion that a deeper understanding of the mechanisms 
underlying preconditioning will allow specific manipulation of the relevant signalling 
pathways to achieve sustained protection without the risk of an 
ischaernic trigger. 
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3 MECHANISMS OF CLASSICAL ISCHAEMIC PRECONDITIONING 
The exact mechanisms underlying ischaemic preconditioning remain unknown, 
however it is not simply caused by an increased blood flow (14), but rather a complex 
series of intracellular events leading to an adaptive response rendering myocytes 
resistant to an ischaernic insult. But how does the lack of blood cause the cell to 
protect itself against further ischaemia? In truth, the answer probably varies between 
species, but what is common is the requirement for receptor occupancy. 
3.1 Triggers of preconditioning 
The concept that a blood-borne substance has the capacity to precondition is well 
accepted. Studies have shown that regional preconditioning in the dog confers 
protection to a remote area of myocardium that has not been preconditioned (33). 
Furthermore, either preconditioning of remote organs (34-36) or exposure to coronary 
effluent from preconditioned hearts (37) conveys protection to the myocardium. If 
preconditioning can be conveyed in the blood, it is possible that agonists to cell 
surface receptors are capable of initiating protection. 
3.1.1 G-protein coupled receptor agonists 
Adenosine was shown to have cardioprotective effects one year prior to the first 
description of ischaemic preconditioning (38). It was also known that adenosine is 
rapidly produced and released by the heart during brief coronary occlusion, as ATP 
catabolism exceeds synthesis (39). It is not surprising therefore that adenosine was the 
first heptahelical. transmembrane receptor agonist implicated in ischaemic 
preconditioning (40) 
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1.1.1 Adenosine 
Using an open-chest rabbit model, Downey's group originally tested the hypothesis 
that preconditioning is triggered by the activation of cardiac adenosine receptors. 
They demonstrated that adenosine was both necessary and sufficient for protection, 
since antagonists abolished and exogenous adenosine mimicked the protective effect 
of preconditioning (40). Later the same group implicated the A, receptor subtype by 
the use of subtype specific agonists (41), although activation of the A3 receptor, which 
was not examined by Downey's group, has been shown to protect in the rabbit (42). 
The concentration of adenosine may determine the profile of protection because 
agents that augment tissue adenosine levels lower the threshold (43), potentiate (44) 
and extend the window (45) of ischaemic preconditioning. Substantial evidence now 
suggests adenosine receptor activation evokes a preconditioning response, except 
perhaps in the rat were adenosine may not protect (46-48). 
Adenosine is released, not only during preconditioning, but also during the index 
ischaernia. This release is reportedly enhanced in preconditioned myocardium, 
possibly due to the increased activity of 5'-nucleotidase (49,50). The activation of 
adenosine receptors during index ischaemia is also responsible for protection in 
response to preconditioning (51,52). This would suggest that adenosine is not only a 
trigger but also a mediator of protection. The most likely explanation is that adenosine 
receptor activation during preconditioning acutely upregulates adenosine release 
during lethal ischaernia, which contributes to protection. 
Adenosine activates intracellular signalling pathways through heterotrimeric GTP- 
binding proteins (G-proteins). These intracellular pathways maybe conserved between 
different G-protehn coupled receptors (GPCRs), since other GPCR agonists can 





Other GPCRs implicated in preconditioning include bradykinin (53), endothelin-I 
(54), al-adrenergic (55), opioid (56) and angiotensin 11 receptors (57). None of these 
receptors are ubiquitously responsible for protection, but their relative contributions 
are both species- and model-dependent. For example, although blockade of either 
adenosine (58,59) or (xi-adrenergic (55) receptors is sufficient to abolish 
preconditioning in rabbit heart, simultaneous inhibition of both receptors in isolated 
rat heart does not prevent protection (60). Furthermore, although HOE 140 
(bradykinin B2 receptor blocker) abolished protection by 5 minutes ischaemia and 10 
minutes reperfusion in isolated rabbit hearts, when the preconditioning stimulus was 
amplified by four cycles of ischaemia/reperfusion HOE 140 did not alter infarct size 
(53). On the basis of these results, Goto and co-workers proposed that GPCRs couple 
to a unique substrate responsible for protection, and the blockade of either of these 
receptors could diminish the stimulus below a threshold and thus prevent protection. 
A more intense preconditioning stimulus can overcome specific receptor blockade by 
the potentiated agonism of other receptors (Figure 1-1). Goto and co-workers 
proposed that protein kinase C (PKC) was the unique substrate on which these initial 
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Figure 1-1: Schematic representation of the threshold theory for preconditioning. 
If the common downstream substrate needs to be stimulated by 50% to produce an 
effect, then antagonism of either receptor during preconditioning with I cycle of 
ischaemia/reperfusion would abolish protection in rabbit heart. However, after 4 cycles 
of ischaen-iia/reperfusion in the rabbit, combined receptor antagonism would be 
necessary to block protection. 
3.1.2 Free radicals 
Free radicals are released during reperfusion following ischaernia (61), and possibly 
during ischaernia itself (62). Previous studies have shown that low levels of free 
radicals can activate PKC directly (63) or indirectly via phospholipase D (PLD) 
activation and subsequent diacylglycerol (DAG) production (64). It is possible 
therefore that free radical generation during preconditioning may trigger protection by 
mechanisms similar to those initiated by GPCR activation. Unfortunately 
investigations addressing this hypothesis have produced conflicting data. In the rabbit, 
Tanaka et al. reported that protection following a single episode of preconditioning 
was completely abolished by the free radical scavengers superoxide dismutase (SOD) 
or N-2-mercaptopropionylglycine (MPG) (65). In a similar model, but using four 
preconditioning cycles, Iwamoto et al. failed to block the anti-infarct effect by 
scavenging free radicals (66). These apparently contradictory findings may be 
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explained by later work from Downey's group who used a similar rabbit model to 
examine the effects of MPG on different preconditioning protocols (67). Using either 
one or four cycles of preconditioning ischaernia and reperfusion they observed a 
significant infarct size reduction after 30 minutes regional ischaernia in vivo. 
Interestingly, MPG was able to abolish protection resulting from one cycle of 
preconditioning, but not in response to four cycles. The authors concluded that free 
radicals act in concert with other activators of PKC (i. e. GPCR agonists) to achieve a 
threshold for protection, and that free radical inhibition would only abolish protection 
if the stimulus were close to the threshold for preconditioning (i. e. one cycle of 
preconditioning ischaernia). 
3.2 Mediators of protection 
3.2.1 Heterotrimeric GTP-binding proteins (G-proteins) 
Upon ligand binding, the a-helical membrane spanning regions of GPCRs undergo a 
profound change, which affects the conformation of the intracellular loops and 
uncovers previously masked G-protein binding sites (68). The subsequent interaction 
with heterotrimeric G-proteins promotes the release of bound guanosine diphosphate 
(GDP) from the a subunit and its exchange for guanosine triphosphate (GTP). This in 
turn stimulates the dissociation of the a subunit from the Py dimer (68). The activated 
G-protein subunits then initiate intracellular signalling responses by acting on a 
variety of effector molecules. 
Four families of G-protein a subunits have been identified; Gs, Gi, Gq, and G12. The 
subunits involved in preconditioning are (Gi)/Gq since selective inhibition of these 
during preconditioning with pertussis toxin is sufficient to abolish protection (69,70). 
The most likely targets for these subunits are phosphatidylinositol- specific 
phospholipases, in particular phospholipase C (PLC). 
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3.2.2 Phospholipase CID 
Introduction 
Phospholipase C, a downstream substrate for Gq subunits, hydrolyses 
phosphatidylinositol 4,5-biphosphate (PIP2) to inositol 1,4,5- triphosphate (IP3) and 
diacylglycerol (DAG) (7 1). IP3 and DAG in turn lead to the activation of a number of 
protein kinases, including protein kinase C (72). This indirect evidence suggests PLC 
links GPCRs, such as adenosine and bradykinin, to intracellular kinases, such as PKC 
(73). More direct evidence however, favours the involvement of phospholipase D 
(PLD). During preconditioning the activity of PLD is enhanced 2-fold and specific 
activation in the absence of preconditioning is sufficient to protect (74). PLD can 
similarly activate PKC via the production of DAG, although whether it is regulated by 
G-proteins is controversial, as intracellular calcium levels and tyrosine 
phosphorylation are both thought to contribute to PLD activation (75). 
3.2.3 Protein kinase C 
3.2.3.1 The protein kinase C family 
3.2.3.1.1 Classification 
Protein kinase C (PKQ comprises a ubiquitous family of Ser/Thr kinases that play a 
critical role in many intracellular signal-transducing pathways. Members of the PKC 
family exhibit diversity in an N-terminal region, termed the regulatory domain. 
Structural differences within this domain confer variations in cofactor requirement, 
which divide the PKC family into three subfamilies. The conventional subfamily 
(cPKC: cc, P 19 P 11 and y) is dependent upon both Ca2' and diacylglycerol (DAG) for 
activation, the novel subfamily (nPKC: 5, F-, 71 and 0) is Caý' independent but DAG 
dependent, and the atypical subfamily (aPKC: ý and t) is both C2' and DAG 





The primary structure of PKC comprises an N-terminal regulatory region and a C- 
terminal catalytic domain, separated by a hinge region. The N-terminal region 
contains two conserved domains, termed Cl and C2, which constitute the membrane- 
2+ targeting regulatory domains that are required for interaction with Ca , 
phosphatidylserine (PS), DAG and phorbol esters. The classification of PKC isoforms 
is entirely based on the structure of these conserved domains (see section 3.2.3.1.1 
and Figure 1-2). Although PKC isozymes are grouped into subfamilies, each 
individual isoform has up to five unique variable regions (Vl-V5). Although some of 
these variable regions affect substrate specificity (76,77), most mediate protein- 
protein interactions, thereby enabling differential localisation of PKC isozymes within 
the cell (78-81). Through a combination of localisation, activation and perhaps 
substrate specificity, individual PKC isozymes can cause distinct physiological 
effects. For example, members of the same sub-family, PKC8 and F-, have been shown 
to produce opposing effects on growth and morphology (82). 
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Figure 1-2: The sequence homology between the primary structures of protein kinase C 
(PKQ isoforms. 
Members of the PKC family are classified according to the presence of four conserved domains 
(CI-C4). Whilst all members have a C3 and C4 domain in the catalytic region, responsible for 
binding ATP and PKC substrates respectively, the CI and C2 domains within the regulatory 
region are more diverse. The classical Cl domain possesses two cystein-rich zinc fingers which 
co-ordinate the binding of diacylglycerol (DAG) and phorbol esters, whereas the C2 domain binds 
Ca 2' and phosphatidylserine (PS). PKC isoforms containing all these conserved regions are 
termed classical PKCs (cPKC). The novel PKC (nPKQ and atypical PKC (aPKQ groups both 
posses a "C2-like" domain, and the aPKC group only possess one zing-finger domain, rendering it 
resistant to DAG and phorbol ester binding. Diversity within groups is achieved through five 
variable regions (V 1 -5), which mediate protein-protein interactions (Adapted from Newton et al. 
(72)). 
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The chemistry of PKC's catalytic core is comparable to that of protein kinase A 
(PKA), since it has a similar catalytic activity and it utilizes MgATP, with a K,, for 
ATP in the low ýtM range (72). PKC typically phosphorylates serine or threonine 
residues, but displays significantly less specificity than PKA. Unlike PKA, PKC 
displays no clear requirements for positive charge around phosphorylation sites and 
less stereospecificity than PKA. The biological functions of PKC are numerous given 
the plethora of substrates activated by, and the multitude of diverse responses to, 
phorbol esters. Common themes in PKC signalling are (among others) transcriptional 
regulation, receptor desensitisation, learning and memory (72). 
3.2.3.1.4 Regulation 
The function of PKC is regulated by two separate mechanisms. The first classical 
mechanism is pseudosubstrate regulation, where the presence of cofactors, or in some 
cases substrates, is required to remove the inhibitory pseudosubstrate domain from the 
catalytic domain. The second mechanism is regulation by phosphorylation. 
3.2.3.1.5 Pseudosubstrate regulation 
The extreme N-terminal portion of PKC contains a short stretch of amino acids that 
have a strong affinity for the catalytic C4 domain. This short sequence of amino acids, 
which prevents substrate phosphorylation by binding to the catalytic domain itself, is 
termed the pseudosubstrate domain. PKC is activated by the removal of the 
pseudosubstrate region from the kinase core. This is typically brought about by a 
conformational. change in PKC by binding, through the regulatory domain, to lipid 
membranes. Conventional activators of PKC, such as phorbol esters and DAG, work 
by anchoring PKC to the membrane by interaction with the CI domain. The 
regulation of PKC activity by the pseudosubstrate domain is therefore dependent on 
tertiary structure, which is in turn determined by cofactors. 
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The pseudosubstrate regulation of PKC complicates the measurement of PKC activity 
in vitro because kinase assays must be performed in the presence of DAG and PS, 
which makes extrapolations to cellular levels of activity imperfect. These and other 
technical limitations in the direct intracellular measurement of PKC isoform activity 
have prompted investigators to use translocation as a surrogate for PKC activation 
(83). This is based on the premise that cytosolic PKC is inactive, whereas membrane 
bound PKC is active, thus measurement of the movement of PKC between the cytosol 
and membrane will give an indication of activity. 
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Figure 1-3: Diagranunatical representation of PKC activation and degradation. 
PKC contains four conserved domains. The CI and C2 domain, which make up the regulatory 
region, bind diacylglycerol (DAG) and phosphatidylserine (PS) respectively. The C3 and C4 
domains, which are contained within the catalytic region, contain key residues responsible for 
ATP binding and downstream substrate phosphorylation. In the inactive state, PKC resides in 
the cytosol and an inhibitory pseudosubstrate region prevents substrate phosphorylation by 
binding to the C4 domain and blocking the kinase core. Upon binding of DAG to the CI 
domain, and calcium to the C2 domain (for classical PKCs), the affinity of PKC for PS and is 
greatly increased (84). The binding of PS to the C2 domain causes a conformational change 
resulting in removal of the pseudosubstrate region from the catalytic site and exposure of the 
receptor for activated C-kinase (RACK) binding site. The net result is the localisation of 
'active' PKC to its respective RACK and the phosphorylation of localised downstream 
substrates. Adapted from Newton et al. (84). 
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3.2.3.1.6 Regulation by phosphorylation 
Evidence that phosphorylation of PKC isoforms is required for activity has been 
available for some time, with the findings that purified PKC(x could be inactivated by 
phosphatase treatment (85). Mutational analysis has since revealed that the 
phosphorylation of a conserved threonine residue in the activation loop of the 
catalytic domain is either essential for (classical PKCs) or enhances (novel and 
atypical PKCs) activity (86). A phosphorylation and an autophosphorylation site also 
exist in the C-terminus of PKC isoforms, which similarly contribute to PKC activity. 
At least for novel PKCs, these three phosphorylations act as "priming" 
phosphorylations, because in combination they act as a method of amplitude control, 
i. e. when phosphorylated in these sites PKC has a higher specific activity than when 
unphosphorylated. 
Phosphorylation of PKC occurs efficiently in vivo when PKC is in an active, effector- 
bound conformation (86). This parallels the behaviour of protein kinase B (PKB) 
where its interaction with phosphoinositides is required for its phosphorylation by 
phosphoinositide-dependent kinase-I (PDKI) (87). However, unlike PKB, when PKC 
releases its activator (DAG) its phosphorylations are not rapidly lost. In fact, this 
closed conformation of PKC appears relatively resistant to phosphatases, which 
enables PKC to remain phosphorylated for tens of minutes to hours. The individual 
kinases involved in PKC phosphorylation are outline in Figure 1-4. 
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Figure 1-4: Schematical representation of the three 'priming' phosphorylations that increase 
PKC activity. 
In the presence of cofactors, such as PS and DAG, PKC translocates from cytosol to membrane. This 
translocation can be blocked by inhibitors that bind to the regulatory domain, such as calphostin C. 
Upon membrane binding, PKC becomes susceptible to phosphorylation (green circles) on a threonine 
residue within the activation loop. The co-recruitment of phosphoinositide-dependent kinase-1 (PDKI) 
to the membrane probably enables this enzyme to catalyse the phosphorylation of this threonine residue 
within the activation loop. After a fLuther phosphorylation by PKCý and a subsequent 
autophosphorylation, PKC is either targeted for dephosphorylation (and degradation) or released from 
the membrane in its closed catalytically competent form into the cytosol. In this state PKC is relatively 
resistant to dephosphorylation and can remain in this "primed" conformation for many hours. If PKC is 
activated within this time by membrane recruitment, its specific activity will be much greater than 
when unphosphorylated. 
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These two mechanisms of regulation enable PKC activity to be "switched" on and off, 
through the requirement for lipid cofactors, and modulated in amplitude by 
phosphorylation. 
3.2.3.2 Protein kinase C and ischaemic preconditioning 
3.2.3.2.1 The importance ofprotein kinase C activation 
Soon after G-protein coupled receptors were implicated in protection, investigators 
focussed downstream of the receptor in search of a common signalling kinase. Protein 
kinase C was the first enzyme implicated in preconditioning, by the abolition of 
protection with PKC inhibitors in whole hearts (88) and isolated myocytes (59). Later 
work, using PKC inhibitors to abolish (89-96) and activators to mimic (88,92,97,98) 
protection, has supported these initial findings, although in swine the involvement of 
PKC is more ambiguous (99). The exact time-point when PKC activation is required 
for protection remains a topic of controversy. 
3.2.3.2.2 When is protein kinase C activation important? 
Although some groups demonstrate that PKC inhibitors given only before the brief 
preconditioning ischaemia abolish protection (100), others suggest that the inhibitors 
need only be given before the lethal period of ischaemia (94). These apparently 
dichotomous results may simply be due to the continued presence of inhibitor during 
lethal ischaernia either through incomplete washout or the use of in vivo models with 
a closed circulation. Downey and colleagues showed that PKC activity was required 
during index ischaemia, since the catalytic domain inhibitor staurosporine blocked 
protection only when give before the onset of lethal ischaemia (101). They also 
showed however that PKC translocates to the membrane during preconditioning and 
colchicine, which disrupts cytoskeletal microtubules and presumably 
PKC 
translocation, blocks protection during preconditioning. Downey therefore 
hypothesised that PKC translocation is required during preconditioning, whereas its 
activity was necessary during lethal ischaemia. 
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Whilst most PKC inhibitors work by binding to the PKC catalytic domain, others bind 
to the regulatory domain. The catalytic domain of PKC has a high degree of sequence 
homology with other protein kinases, hence most PKC inhibitors also inhibit other 
protein kinases. However, calphostin C and chelerythrine are thought to bind to the 
regulatory domain since they do not affect catalytic activity in vitro (P Cohen, 
personal communication). These inhibitors do however prevent preconditioning and 
cause an altered pattern of PKC distribution on fractionation (102,103). Furthermore, 
although ischaernic preconditioning has no effect on total PKC activity in rabbit 
myocardium, protection is abolished by chelerythrine, which alters the fractionation 
pattern of PKCE andr (88). This requirement for PKC translocation has recently been 
exploited to investigate the individual PKC isoforms responsible for protection. 
3.2.3.2.3 The specific involvement ofprotein kinase C isoforms 
The high sequence homology within the catalytic domain of different PKC isoforms 
complicates the development of isoform-specific inhibitors that block catalytic 
activity. In contrast, variable regions within the regulatory domain, which dictate 
spatial localisation and therefore downstream substrate activation, represent a viable 
target for isoform-specific inhibition. Based on this hypothesis, Mochly-Rosen and 
co-workers discovered unique sequences that co-ordinate binding to discreet 
intracellular receptors (104). These intracellular receptors for activated C-kinase (or 
RACKs) bind specific PKC isoforms in their active conformation and localise them 
with their downstream substrates. The model for the interaction of PKC with RACKs 
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Figure 1-5: Model of interaction between receptors for active 
C-kinase (RACKs) and PKC. 
When inactive, PKC is in a closed conformation, which prevents 
substrate phosphorylation. Upon binding of diacylglycerol (DAG) 
and phosphatidylserine (PS) the RACK binding site becomes 
accessible which promotes translocation to, and binding of, the 
respective isoform- specific RACK. This stabilises PKC in the 
active conformation and localise it with its downstream substrates 
(adapted from Mochly-Rosen et al. (105)). 
Introduction 
By introducing peptides, which correspond to the RACK sequence on PKC isoforms, 
into isolated myocytes, Mochly-Rosen's group were able to prevent the translocation 
of individual PKC isoforms (106). Using this approach during preconditioning, they 
were able to show that PKCF- translocation was necessary for subsequent protection 
(107,108). Moreover, protection can be mimicked by peptides that cause PKCF- 
translocation to its respective RACK (109). 
3.2.4 Mitogen -activated Protein Kinases 
It was in 1988 that Ray and Sturgill noticed that a 42KI)a protein, upon tyrosine and 
threonine phosphorylation, became a serine-threonine kinase (110). The sensitivity of 
this protein to activation by mitogens, such as PMA, resulted in the term mitogen- 
activated protein kinase (MAPK). Later however, after the realisation that it could be 
stimulated by a diverse variety of extracellular signals, the term extracellular signal- 
regulated kinase (ERK) was adopted. 
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3.2.4.1 The Mitogen- activated Protein Kinase family 
Classification 
Introduction 
The classical mammalian MAPK family currently incorporates at least 5 different 
proteins (ERKI-5), although the marked differences in structure between ERK5 (or 
big mitogen- activated protein kinase [BMKI]) and other ERKs has caused some 
investigators to place ERK5 in a phylogenetically separate family. Following the 
discovery of the ERKs, other MAPKs have been identified which are activated by 
cellular stresses such as UV radiation and hyperosmotic shock. This group of 
MAPKs, termed stress -activated protein kinases (SAPKs), can be further subdivided 
into c-Jun N-terminal kinases (or JNKs) and p38-MAPKs (Figure 1-6). 
4 (MNK2, p63) 
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Figure 1-6: Phylogenetic tree of mammalian mitogen-activated protein kinase (NUPK) family 
members. 
Dendrogram was adapted from Zhao et al. (111), were they were created, using human sequences 
when available or mouse sequences otherwise, with CLUSTAL X program. 
3.2.4.1.2 Structure 
In a manner analogous to many other protein kinases, MAPK activity is regulated by 
phosphorylation. The key difference however, is the essential requirement for dual 
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phosphorylation within a canonical amino acid sequence in the activation loop lying 
between subdomains VII and VIII (I 11). This is achieved by dual specificity MAPK 
Kinases (MAPKKs or MKKs) that recognizes and phosphorylate a Thr-Xxx-Tyr 
motif in the activation loop. For each of the three MAPK families the "Xxx" residue 
within this targeting sequence differs, glutamate for the ERKs, proline for JNKs and 
glycine for the p38s. Following dual phosphorylation by upstream MKKs, the 
activation loop refolds and interacts with surface arginine-binding sites that stabilise 
the altered conformation of the loop together with neighbouring sequences, resulting 
in activation of the kinase (112). The activation loop itself has been shown to confer 
differences in substrate recognition between different MAPK family members. For 
example, changes in the amino acid sequence within the loop of p38 to a sequence 
that resembles ERK shifts the selectivity of downstream substrates from p38 to ERK. 
Moreover, replacement of the glycine with glutamate in the dual phosphorylation site 
similarly altered substrate specificity (113). Surprisingly these changes had no effect 
on selectivity to upstream kinases, and it has been suggested that residues within the 
amino terminus are responsible for determining interactions with the upstream 
activator (114). 
3.2.4.1.3 Function 
The three MAPK families (ERKs, JNKs and p38) are proline directed serine/threonine 
kinases, which phosphorylate substrates containing a general consensus Pro-X- 
Ser/Thr-Pro sequence. In mammalian cells, most MAPK substrates defined to date are 
transcription factors, including ELK-1, c-myc, c-jun, and ATF-2 (see Figure 1-7). In 
addition, several cytoskeletal proteins, protein kinases and phospholipases are 
substrates for specific MAPKs. As our understanding of these pathways increase, it is 
likely that additional classes of substrates will be defined. The physiological 
consequences of MAPK activation vary dramatically between different MAPKs, 
different isoforms of the same kinase, and different cell types. For example, p38- 
MAPKs and ERKs have opposing roles on cell survival, with p38 promoting 
apoptosis and ERKI/2 survival (115). A similar dichotomy has been shown in 
neonatal cardiac myocytes regarding the contribution of p38(x and P to apoptosis and 
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survival, respectively (116). Moreover, the same MAPK can cause opposing effects 
dependent on cell type, as p3 8 activation leads to apoptosis in PC 12 cells (117), but 
promotes survival in BaF3 cells (118). In mammalian systems, the activation of these 
protein kinases can lead to a diverse array of regulatory events including 
differentiation, proliferation, development, apoptosis and inflammation. 
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Figure 1-7: Representation of the intracellular signalling pathways that can activate, and are 
activated by, MAPK cascades. 
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3.2.4.1.4 Regulation 
The complex intramolecular change that occurs within MAPK following dual 
phosphorylation causes a 100 to I 000-fold increase in activity (119). Therefore their 
respective upstream activators acutely regulate the functions of MAPKs. The duration 
and magnitude of MAPK activation are critical determinants of physiological 
outcome. This is best illustrated in the differentiation of PC12 cells. These cells 
proliferate in response to epidennal growth factor (EGF), while exposure to nerve 
growth factor (NGF) causes cell differentiation. These disparate responses are entirely 
governed by the ability of NGF, but not EGF, to cause sustained activation of MAPK, 
which leads to nuclear translocation (120). 
The duration and magnitude of MAPK activation can be regulated at multiple points 
within the signalling pathway upstream of MAPK. At the level of MAPK themselvesý 
the ability of phosphatases to dephosphorylate MAPKs, provides and additional level 
of refinement. The activity of MAPK reflects a balance between the activities of the 
upstream activators and protein phosphatases (121). A summary of the phosphatases, 
which have been isolated and characterised in mammalian cells, that can inhibit 
MAPK activity are illustrated in Table 1-1. 
Gene Substrate Speciricity Intracellular localisation 
MY, P-I ERK=JNK=p38 Nucleus 
MKP-2 ERK=JNK>p38 Nucleus 
MKP-3 ERK>>JNK=p38 Cytosol 
MKP-4 ERK>JNK>p38 Cytosol> nucleus 
MKP-5 ND ND 
PAC-I ERK=p38>JNK Nucleus 
B23 ND Nucleus 
M3/6 JNK=p38>>ERK Cytosol, nucleus 
MKPX ND ND 
VHR ND ND 
Table 1-1: The characterisation of members of the mammalian dual-specificity MAPK 
phosphatase (MKP) family. 
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3.2.4.2 Mitogen-activated protein kinases in ischaernic preconditioning 
In 1996, MAPK activation was demonstrated during ischaemia/reperfusion in the 
perfused heart (122) and during hypoxia/re- oxygenation in isolated myocytes (123). 
Shortly afterwards Maulik et al. reported an increase in MAPK activity, and in 
particular MAPKAPK2, a downstream substrate of p38, following preconditioning in 
isolated working rat hearts (124). Since this initial manuscript the involvement of 
MAPK in preconditioning has been a subject of intense investigation. Unfortunately 
however, almost five years later, the relative contributions of MAPK isofonns to 
ischaemic preconditioning remain controversial, with contradictory reports suggesting 
that MAPK activation is good during preconditioning, bad during ischaemia and not 
associated with protection or injury (125). 
3.2.4.2.1 The good, the bad and the ugly 
The first clear evidence of MAPK phosphorylation in response to preconditioning 
came from Downey's group. In particular, the phosphorylation of p38-MAPK on 
tyrosine 182 was enhanced during ischaemia following preconditioning. Moreover, 
this phosphorylation was abolished if protection was blocked pharmacologically 
(126). As discussed earlier, dual phosphorylation of both tyrosine and threonine 
residues is necessary for MAPK activation, and unfortunately phosphorylation of the 
neighbouring threonine residue or total p38 activity was not measured. In a parallel 
study using isolated adult myocytes rendered ischaemic by pelleting under mineral 
oil, inhibition of p38 with SB203580 abolished the resistance to osmotic shock 
following preconditioning (126). Furthermore, preconditioning was mimicked by the 
SAPK activator anisomycin. More recently, the same group have confirmed these 
findings in the isolated perfused rabbit heart by measuring activity of mitogen- 
activated protein kinase activated protein kinase-2 (MAPKAPK-2), a downstream 
substrate of p38 (127). In heart biopsies, a fraction was eluted that was able to 
phosphorylate a peptide sequence that is a known substrate for MAPKAPK-2. This 
activity was present during prolonged ischaemia in preconditioned but not control 
hearts (127). Once again there was no direct measurement of p38-MAPK activation or 
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dual phosphorylation, although MAPKAPK-2 activities correlated with protection, 
even when pharmacological manipulations were used to initiate or prevent 
preconditioning. Other groups have also shown that p38 dual phosphorylation (128) 
and MAPKAPK2 activities (124,129) are enhanced in preconditioned hearts 
compared to controls, and that inhibition of p38 activity with SB203580 abolishes 
protection (128,130). Taken together these data suggest that p38-MAPK activation 
following preconditioning is causally related to protection. 
Unfortunately this body of data contradicts the findings of others with regard to the 
role of p38-MAPK during ischaemia. For example, p38-MAPK is phosphorylated 
during ischaemia/reperfusion and inhibition of this activation with SB203580 is 
protective in isolated cells (13 1) and the whole heart in vitro (132) and in vivo (133). 
Furthermore, prolonging and enhancing p38 activation with a tyrosine phosphatase 
inhibitor aggravates ischaemic injury (134). A similar relationship between p38 and 
injury appears to exist in human myocardium, because inhibition of p38-MAPK 
during simulated ischaemia and re-oxygenation in isolated human atrial trabeculae 
improved post ischaemic functional recovery (135). The authors concluded that TNF(X 
release was responsible for injury in response to p38 activation during ischaemia, 
since this was inhibited with SB203580, and TNF(x suppressed myocardial 
contractility when given alone (136). These findings may have clinical relevance 
since p38 activation has been detected in the human heart during coronary artery 
bypass surgery (137). Taken together these data suggest p38 activation during 
ischaemia contributes to myocardial injury andlor contractile depression. 
These findings are further clouded by a recent study by Behrends et al., which 
measures ERKI/2, JNKI/2 and p38 activation during ischaemia in anaesthetised pigs 
(138). By taking biopsies, they were able to measure activation in hearts subjected to 
ischaemia and/or preconditioning. The variable level of MAPK activation seen during 
ischaemia with or without prior preconditioning was not associated positively or 
negatively with the final levels of injury (138). These data suggest that MAPK 
activation is not related to myocardial protection or injury. 
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3.2.5 Tyrosine kinases 
Introduction 
It is generally accepted that activation of a member(s) of the tyrosine kinase protein 
family is required for preconditioning, because pre-treatment with general tyrosine 
kinase inhibitors such as genestein and lavendustin A block protection (139,140). It is 
unknown however whether this tyrosine kinase acts in series (141) or parallel (142) 
with PKC. 
3.3 End-effectors 
3.3.1 The KATpchannel 
In 1983, Noma discovered the ATP-dependent potassium channel (KATP) using the 
patch clamp technique in isolated guinea pig ventricular myocytes (143). These 
channels were named "ATP-dependent" because of their inhibition in response to 
physiological concentrations of ATP. The name of this channel was subsequently 
changed to ATP-sensitive potassium channels after the discovery of a variety of 
endogenous modulators, including ADP, pH, fatty acids and various GPCR ligands 
(144). 
3.3.1.1 Structure 
KATP is a complex of two different proteins. One subunit is an inward rectifying 
potassium channel (Kir), which is thought to make up the pore as a complex of four 
Kir subunits (145). The sulfonylurea receptor (SUR) is believed to provide regulation 
by altering the sensitivity and response of the pore to pharmacological agents and 
ATP (145). Two subtypes of each subunit are currently known (Kir6.1, Kir6.2, SURI 
and SUR2), and it has been suggested that different combinations of these subunits 
exist in different tissue types, which are responsible for the divergence in channel 





As well as the myocardium, KATP channels are found in other tissues, such as the 
pancreas, central nervous system, kidney and smooth muscle, where they have been 
implicated in insulin secretion, neurotransmitter release, renin secretion and vascular 
muscle relaxation, respectively (146). It is their effect in cardiac myocytes however, 
namely the rapid channel opening during ischaemia in response to falling ATP 
concentrations, that stimulated the interest of researchers investigating the 
pathogenesis of myocardial ischaemia. 
3.3.1.3 Regulation 
Inhibition of KATP is produced not only by ATP, but also by its non-hydrolysable 
analogues, suggesting phosphorylation is not critical (145). ADP also regulates KATP 
activity, possibly by competing for the ATP binding site, although another ADP site is 
thought to mediate weak agonist activity (145). Although phosphorylation is not 
required for inhibition, it is thought that ATP can prime KATPfor opening by causing 
channel phosphorylation (147). This is because in the absence of ATP, channel "run- 
down" occurs, which can be re-activated by MgATP but not non-hydroly sable ATP 
analogues. At present however, it is unclear whether phosphorylation and 
dephosphorylation are involved in the mechanism of "run-down" and reactivation by 
MgATP. Many GPCR agonists, such as adenosine and acetylcholine, are known to 
increase the probability of KATPopening. It is thought that, through the activation of 
PKC, these agonists reduce channel sensitivity to ATP at the SUR (145). 
3.3.1.4 The effect of KATPchannel opening during myocardial ischaemia 
The role of the KATP channel during ischaemia was tested using selective 
pharmacological blockers and openers of the channel in various models. The 
hypothesis at the time being that KATP channel openers would be protective by 
shortening action potential duration and therefore reducing calcium entry. This would 
protect by sparing energy utilisation by inhibiting contractile function in a manner 
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similar to L-type calcium channel blockers. The vasodilatory effect of KATpagonists 
forced the hypothesis to be tested in isolated heart preparations, where their direct 
cardioprotective activity could be ascertained. This hypothesis appears partially 
correct since numerous investigations were able to shown a cardioprotective effect of 
KATPopeners in several species, including dogs, rats and rabbits (148-152). Moreover, 
protection is also seen when KATPopeners are applied to isolated cells in vitro (153, 
154), suggesting that their cardioprotective effect are, at least to an extent, imparted 
onto myocytes. The energy-sparing hypothesis for the mechanism through which 
protection is achieved, was however, later to be disproved (see section 3.3-1-6). 
3.3.1.5 KATpand ischaemic preconditioning 
The ability of KATp agonist to "mimic" preconditioning and the capacity of 
preconditioning triggers to activate KATP channels imply they may be involved in 
mediating protection in response to sublethal ischaemia. It was Gross's group that 
first demonstrated that KATpblockers abolish preconditioning using glibenclamide in 
a canine model (155). Various KATp antagonists have since been shown to abolish 
protection in a wide variety of models (144). In humans, preconditioning displays a 
similar dependence on KATPopening, as glibenclamide blocks the protection against 
ST deviation seen following coronary balloon occlusion (156). The opening of KATP 
channels following classical preconditioning is likely to be downstream from the 
adenosine receptor, since adenosine-mediated protection can be abolished with KATP 
blockers (157-159). 
3.3.1.6 The mechanism of cardioprotection 
Most KATP openers are potent vasodilators, therefore it is possible that they exert 
cardioprotective effects through coronary dilatation. This is unlikely however, 
because KATPopening is still protective when flow is kept constant (150), and isolated 
myocytes can be protected in vitro (153,154). The decrease in action potential 
duration (APD) seen following KATP opening may preserve intracellular ATP by 
slowing myocardial contraction and thus ATP utilisation during ischaernia. Moreover, 
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KATP openers increase the time to ischaemic contracture and have been shown to 
directly preserve myocardial ATP content during ischaemia (160). This preservation 
however, appears unrelated to contractile function, since no negative inotropic effects 
are observed after KATP opening. Furthermore, the KATP openers cromakalim and 
BMS-180448 were found to have additional protective effects over cardioplegia, 
confirming that they function by a mechanism distinct from cardioplegia (161). This 
alternative mechanism is also separate for APD shortening, because doses of 
bimakalim could be used to reduce infarct size in dogs, which have no effect on 
epithelial monophasic APD (162). This dissociation of APD and protection implied 
that sarcolemmal K+ currents where superfluous to the cardioprotective effect of KATP 
openers. 
3.3-1.7 Mitochondrial vs. Sarcolemmal KATP 
Other data, as well as the dissociation of APD and cardioprotection, exist to suggest 
sarcolemmal KATp activation does not contribute to protection. 5-hydroxydecanoate 
(5-HD), a KATp antagonist, has little effect on sarcolemmal channels but blocks the 
cardioprotective effects of a range of KATP openers (163,164). Furthermore, 
pharmacological agents were developed that retain the glyburide-reversible 
cardioprotective activity of cromakalim while being relatively devoid of vasodilator 
activity (165). Interestingly these agents were poor at opening sarcolemmal KATP 
channels, as measured by single channel patches or whole myocyte K' currents (166). 
Taken together, the data described above shows a poor correlation between 
sarcolemmal K+ current and cardioprotection in response to KATPchannel openers or 
preconditioning. 
In 1991, Inoue et al. discovered a potassium channel in mitochondria from patch 
clamp studies on fused mitoplasts (167). This channel was regulated by many ligands 
that regulate plasma membrane KATP channels and, as such, was termed the 
mitochondrial KATPchannel (mitoKATP)- Some ligands do however display specificity 
for mitochondrial over sarcolemmal channels. Diazoxide is about 1000 times more 
potent in opening mitoKATP than opening sarcolemmal KATP channels (144,168). 
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Furthermore, Garlid's group (144) and others (164) reported that 5-HD, under 
appropriate conditions, always inhibits mitoKATPcurrent but never sarcolemmal KATP- 
This differential selectivity provided an ideal opportunity to study the relative 
contribution of these different channels to ischaemic preconditioning and myocardial 
protection. Using these agents, Garlid's group showed that diazoxide was able to 
protect the isolated rat heart against ischaemia when used in the low micromolar 
range, at concentrations that are insufficient to activate sarcolemmal KATPcurrent or 
shorten APD (163). Moreover, both glyburide and 5-HD completely abolish these 
protective effects of diazoxide (163) and protection in response to ischaemic 
preconditioning (169). These data have recently been confirmed by Marban's group 
using the structurally distinct agents HMR1098 and P-1075, which selectively inhibit 
and activated sarcolemmal KATPcurrents respectively. They found that, unlike 5-HD 
and diazoxide, these agents are unable to abolish or mimic the protection afforded by 
preconditioning (170). These data appear to exclude a role for sarcolemmal KATP 
channels in ischaemic protection and suggest that mitoKATP channels are the likely 
effectors of cardioprotection. 
3.3.1.8 A trigger or effector? 
The mitoKATPwas, until recently, thought to be an effector of protection by either 
mitochondrial calcium homeostasis (171), preservation of the inter-membrane space 
(172), interaction with the cytoskeleton (173), or prevention of apoptosis (174). 
Recently however, studies from Downey's group have suggested that the KATP 
channel may serve as a trigger, rather than effector, of protection (175). This 
hypothesis was formed after the KATP channel blockers 5-HD and glibenclamide 
abolished preconditioning when given during the brief ischaernic stimulus and not 
during the lethal index ischaernia (176). This was supported by earlier work with 
diazoxide, a mitoKATPchannel agonist, which protected when given prior to, but not 
during, lethal ischaernia (173). The sudden release of free radicals, as a result of 
potassium influx into mitochondria and subsequent uncoupling of the electron 
transport chain, has been proposed as a possible mechanism by which channel 
opening triggers protection. 
57 
Chapter I Introduction 
3.3.2 A role for anti-apoptotic proteins? 
Programmed cell death, or apoptosis, is believed to contribute to myocardial injury 
during ischaernia/reperfusion in animal models. Furthermore, apoptosis has been 
detected in combination with necrosis in the human heart following myocardial 
infarction (177). In isolated myocytes (178) and the whole heart (179,180), 
preconditioning prior to ischaemia inhibits apoptosis following ischaemia/reperfusion. 
Apoptosis is initiated by a complex series of signalling events, which may be 
triggered during ischaernia and/or reperfusion. These signalling processes can be 
prevented or inhibited by other kinases that promote survival by antagonising the cell 
death signals. Preconditioning has been shown to upregulate the "anti-death" gene 
Bcl-2 (181) and downregulate the pro-apoptotic gene Bax (182). It is of course hard to 
dissociate cause from effect, as the severity of ischaemia may determine the extent of 
apoptosis following ischaemia, and therefore the decrease in apoptosis following 
preconditioning may simply be a consequence, rather than a cause, of protection. 
Nevertheless, the possibility that preconditioning initiates/attenuates signalling 
pathways that prevent/cause apoptosis is appealing from a clinical perspective, since it 
may be possible to mimic these effects pharmacologically following myocardial 
infarction. 
3.3.3 Cytoskeletal strengthening 
The cytoskeleton is a collection of polymeric structures consisting of microtubules, 
microfilaments and intermediate filaments. Disruption of cytoskeletal integrity during 
ischaernia may produce structural alterations in the cell that may contribute to cell 
injury and death (183). Members of the small heat shock protein family (namely 
HSP25/27 and (xB-crystallin) are molecular chaperones that have been implicated in 
ischaernic preconditioning (184,185). It is possible that oligomerisation of the small 
molecular weight (Mw) HSPs improves the mechanical stability of the cytoskeleton 
during preconditioning, thereby protecting myocytes during subsequent ischaemia 
(186,187). 
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The exact mechanism by which preconditioning causes HSPs to protect is unknown, 
although p38-MAPK activation and the subsequent phosphorylation of MAPKAPK-2 
is thought to be involved (128). Although these kinases stimulate HSP27 
phosphorylation, it may be their effect on HSP27 translocation that promotes 
protection. In response to preconditioning in isolated cells (188) and the whole heart 
(189), HSP27 is translocated to the sarcomere. Furthermore, this relocalisation of 
HSP27 is blocked by p38 inhibition with SB203580, which is also known to abolish 
protection in similar models (127). It may be that translocation is dependent on 
phosphorylation, since p38 activation is known to phosphorylate HSP27. However, 
whilst some groups demonstrate phosphorylation and translocation of small heat 
shock proteins following preconditioning (185), others are unable to show either 
(190). Furthermore, whilst HSP27 overexpression is protective in adult 
cardiomyocytes (191), expression of non-phosphorylatable HSP27 mutants do not 
reverse this protection (192). Interestingly, HSP27 phosphorylation appears to prevent 
its oligomerisation (192,193). Therefore, either oligomerisation of HSPs are not 
required for cytoskeletal strengthening or phosphorylation of HSPs/cytoskeletal 
strengthening is not required for protection. In summary, although preconditioning 
may phosphorylate/translocate small Mw HSPs, more direct evidence is required to 
link these processes to protection in whole heart models of preconditioning. These 
studies would obviously be facilitated by the generation of HSP27 knockout mice. 
3.3.4 Ionic balance 
3.3.4.1 Sodium-hydrogen exchanger 
The hypothesis that activation of the sarcolemmal NPH' exchanger may contribute 
to ischaernic injury was formed in 1985, one year prior to the discovery of ischaernic 
preconditioning, (194). Inhibition of exchanger activity with a range of highly 
selective antagonists such as HOE-694, HOE-642, and EMD-85131, have all been 
shown to afford a cardioprotective benefit in a variety of animal models of ischaemia 
and reperfusion (195). The question of whether ischaernic preconditioning modulates 
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Naý/H' exchanger activity is more ambiguous. It is logical to assume that the Na/H' 
exchanger will be activated following preconditioning because intracellular acidosis, 
which occurs during the brief ischaemia, is able to trigger Na/H' exchanger activity 
(196). Furthermore, stimuli that mimic preconditioning, such as al-adrenergic 
receptor activation, also activate the Na/H' exchanger (196). It maybe that activation 
of the exchanger contributes to the reduction in intracellular acidosis by H+ extrusion, 
although studies investigating this hypothesis have yielded contradictory data (197, 
198). Regardless of the activation status of the exchanger following preconditioning, 
the critical question is whether Na/H' exchanger activity is required for protection. 
Although not all studies are in agreement, the large body of evidence suggests that 
inhibition of the exchanger does not prevent preconditioning (196). Actually, in the 
rat, concomitant inhibition of exchanger activity provides additive benefit against 
infarct size reduction (199) and enhanced contractile recovery (200). This suggests 
that, at least in the rat, the mechanisms of protection following ischaemic 
preconditioning and Na/H' exchange inhibition are distinct. 
3.3.4.2 Calcium regulation 
Cytoplasmic calcium overload during ischaemia or early reperfusion is though to 
contribute to myocardial cell injury. The sarcoplasmic reticulum (SR) is a principle 
regulator of cytosolic calcium. There have been several reports in the literature 
suggesting a role for the SR in the mechanism of preconditioning. In 1991, Tani et al. 
were the first to demonstrate a preservation of SR function after preconditioning, in 
that it lost less calcium during ischaemia and recovered more calcium following 
ischaernia (201). Two years later, Murphy's group showed a decrease in calcium 
concentration during ischaemia in preconditioning hearts, although whether this was a 
result of regulation via the SR or calcium exchangers is unknown (202). Although 
others have suggested a critical role for the SR as an effector of preconditioning (203, 
204), a recent study appears to document preconditioning in the absence of a 
functional SR (205). Ryanodine, which locks the SR calcium release channel in the 
open state, inhibited the ability of SR to accumulate calcium but did not abolish the 
protective effect of ischaernic preconditioning (205). 
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Calcium is regulated by a number of mechanisms beyond the role of SR however, 
some of which have also been implicated in preconditioning. L-type calcium channels 
regulate sarcolemmal calcium influx into myocardial cells, thus the inhibition of these 
channels represents a viable target for protection. Early studies, assessing the ability 
of preconditioning to modulate the L-type calcium channel density during ischaemia, 
were unable to detect a difference between preconditioned and control hearts (206, 
207). Interestingly, atrial muscle from patients taking L-type calcium channel 
antagonists could not be preconditioned by transient ischaemia, whereas control atrial 
muscle still exhibited preconditioning (208). The author's conclusion that, "this lack 
of preconditioning may be the basis of the increase cardiovascular mortality 
traditionally associated with calcium channel blockers in patients with coronary artery 
disease", has however been a topic of controversy (209,210). 
3.3.5 A TP preservation 
When Murry and colleagues documented a delay in myocardial necrosis during 
ischaemia following preconditioning, they hypothesised that protection may result 
from a reduction in ATP depletion. The same group later showed that preconditioning 
had no effect on ATP levels at the end of ischaemia, although the utilization of ATP 
during ischaemia was attenuated (211). The exact effect on cellular ATP remains 
unclear since later reports showed end-ischaemic ATP levels are enhanced (212,213), 
and ATP utilisation is accentuated (214), during ischaemia following preconditioning. 
Nevertheless the hypothesis that preconditioning "reduces myocardial energy demand 
during ischaernia, which results in a reduced rate of high energy phosphate utilization 
and a reduced rate of anaerobic glycolysis", proposed by Murry and colleagues (211) 
has received attention from other groups. If Murry's hypothesis were correct, it would 
be important to understand the mechanism whereby preconditioning reduces 
myocardial energy demand during ischaemia. As discussed above, although the initial 
hypothesis was that opening of sarcolemmal KATP channels would preserve 
intracellular ATP by shortening APD and inhibiting myocyte contraction, this theory 
has subsequently been disproved (section 3.3.1.6). Other theories have been proposed 
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for the reduction in ATP utilisation, which have subsequently been disproved. For 
example the concomitant myocardial stunning, that has been demonstrated following 
preconditioning, has been proposed to decrease contractile effort, and therefore 
decrease energy expenditure during the initial phase of lethal ischaemia (215). This 
theory now appears unlikely, because the protection against infarction following 
preconditioning disappears although myocardial stunning persists (216), and 
protection can be achieved in the absence of myocardial stunning (217). One of the 
most intriguing hypotheses however, concerns the mitoKATPchannel and its ability to 
preserve the architecture of the inter-membrane space (IMS). This was proposed by 
Garlid who suggests that ischaemic preconditioning protects mitochondrial function 
in situ by increasing theVmax of respiration, the preservation of functional coupling 
between mitochondrial creatine kinase and adenine nucleotide translocase, and the 
absence of stimulation of respiration by cytochrome c. The net effects of these 
processes are preservation of cellular ATP levels during ischaemia and better 
contractile recovery upon reperfusion (172). 
3.4 Summary of signalling during preconditioning 
In summary, the proximal pathways that trigger preconditioning, such as G-protein- 
coupled receptor activation and protein kinase C translocation, are fairly well 
characterised. In contrast, the exact role of the distal effectors of preconditioning, 
such as mitogen-activated protein kinases and KATP channels, is more controversial 
(175,218). An unbiased schematic of the signalling pathways implicated in 
preconditioning is depicted in Figure 1-8. 
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Figure 1-8: Signalling pathways implicated in early ischaemic preconditioning. 
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4 MODELS OF ISCHAEMIC PRECONDITIONING 
Introduction 
A variety of models have been used to investigate ischaemic preconditioning, each 
with specific advantages and drawbacks. Disparate findings within the 
preconditioning field are frequently attributed to species variations between these 
models, although other concerns are maturity, preconditioning trigger, and choice of 
endpoint. It is for this reason that new experimental findings must be reproducible in 
different animals models and ultimately in humans. This does not depreciate the value 
of models that may appear far removed from the in vivo clinical setting however 
because, as will be discussed, these models enable specific manipulation of signalling 
pathways that would otherwise be inaccessible. 
4.1 Cell-based models 
There is currently little controversy surrounding the surface receptors able to trigger 
preconditioning, thanks to the large volume of studies using receptor agonists and 
antagonist in whole heart models in vitro and in vivo. The intracellular signalling 
pathways evoked following receptor activation have proved more difficult to 
investigate in these models. Pharmacological agents, where available, are often less 
specific and have systemic affects that complicate in vivo data interpretation. 
Associative data can be described by examining the activation of kinases in response 
to a preconditioning stimulus, but this cannot dissociate cause from effect, and the 
heterogeneity in cell types and depth of ischaemia present further difficulties. 
Cell-based models of preconditioning help to overcome these deficiencies by 
providing a homogeneous cell type where it is possible to manipulate specific 
intracellular signalling pathways through the expression of dominant negative or 
constitutively active signalling proteins. For these and other reasons, various cell 
models have been developed to investigate preconditioning. 
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4.1.1 Immature cardiocytes 
Introduction 
Mature (adult) cardiocytes die or dedifferentiate in culture and are relatively resistant 
to standard transfection techniques. This has caused some investigators to use 
immature cardiocytes models such as neonatal rat myocytes, embryonic chick 
myocytes and paediatric human cardiocytes (219). A study in chick embryonic 
myocytes showed that A, and A3 receptor overexpression conferred endogenous 
protection and enhanced preconditioning-induced protection against simulated 
ischaemia, confirming the importance of these particular receptor subtypes (220). 
Neonatal rat cardiocytes have been used to investigate the contribution of PKC 
isoforms to simulated preconditioning. These studies have showed that specific PKCE 
inhibition abolished protection in response to preconditioning (107), whereas 
expression of an active PKC8 mutant provided protection against simulated ischaemia 
alone (221). 
4.1.2 Mature cardiocytes 
Adult cardiornyocytes have a rate of attrition as great as 30% following isolation, 
therefore models usually rely on the suspension of freshly isolated cells. The most 
commonly used is the model developed by Armstrong et al., where lethal ischaernia is 
achieved by overlaying pelleted cardiomyocytes with mineral oil (59). Short periods 
of cell pelleting initiates preconditioning that, like preconditioning in the intact heart, 
is dependent on adenosine, PKC and KATPchannels (219). In particular, these models 
have revealed protection against lethal simulated ischaernia in response to the 
activation of A3receptors (222), PKCF- and ERK1/2-MAPK (223). 
Cell cultures also enable voltage-clamp recordings in single cell electrophysiology. 
This approach has provided a link between the sarcolemmal KATP channel and PKC 
activation. In voltage-clamp studies in adult rabbit and human cardiomyocytes, 
activation of PKQ, in the presence of low intracellular ATP, increased current through 
sarcolemmal KATP channels (224). Similarly, in rabbit cardiomyocytes there was an 
accelerated onset of current through the sarcolemmal KATP channel in response to 
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metabolic inhibition in the presence of both adenosine and PKC pre-activation, but 
not with either alone (225). This effect could be blocked in cell-lines by transfection 
of a dominant negative potassium channel subunit (226). Furthermore, a similar 
relationship is found between PKC activation and the inferred opening of a 
mitochondrial KATPchannel from measurements of mitochondrial redox state (227). 
These studies highlight the advantages of isolated cell models. These advantages are 
however at the expense of a cell phenotype that differs from the intact heart, and 
cannot be subjected to true ischaemia/reperfusion. For these reasons it is imperative 
that preliminary data obtained in these studies is later confirmed in more 
physiologically relevant whole heart models. 
4.2 Animal models 
4.2.1 Whole heart preparations in-vitro 
The isolated whole heart has proved invaluable as a model of ischaemia/reperfusion 
injury since its first description by Langendorff in 1895 (228). The heart can be 
maintained in this mode for many hours by perfusion with blood from a donor animal 
or crystalloid buffer (Kreb's Henseleit Buffer). Ischaemia is mimicked in this model 
by restricting the flow of blood or buffer, through the whole heart (global ischaemia) 
or a coronary artery (regional ischaemia). Myocardial injury can be measured by 
infarct size determination with triphenyl tetrazolium chloride (TTC) staining of viable 
tissue, enzyme release into the perfusate, and recovery of left ventricular developed 
pressure (for full description see: Chapter 2, section 4.2). Preconditioning is best 
characterised in the isolated rat (60,100ý 229) and rabbit heart (54,93,230), although 
it has also been demonstrated in the guinea pig (231) and mouse heart (29,232) in 
vitro. The assessment of protein modification/activation by preconditioning or 
ischaemia/reperfusion is simplified in perfused heart models because the risk zone 
after global ischaemia is simply defined as the whole heart. Furthermore, peripheral 
effects on the vasculature and other organs do not complicate pharmacological 
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approaches, it is relatively easy to implement, and less labour intensive than in vivo 
whole heart models. 
4.2.2 Animal models in-vivo 
The most clinically relevant model, outside of myocardial ischaemia in humans, is 
regional ischaernia in the anaesthetised whole animal. These open-chested models 
have been developed in the pig (142), dog (14), rabbit (66), rat (233) and mouse (234) 
to investigate ischaemic preconditioning in vivo. 
4.3 Human models 
Isolated cells provide an excellent, readily accessible means of examining 
preconditioning in humans. So far human ventricular cardiomyocytes (235), right 
atrial trabeculae (236), and paediatric myocytes (237) have all been shown to 
precondition successfully in culture. Moreover, they appear to be dependent on the 
same critical signalling pathways as animal models, such as adenosine and PKC 
(237). 
A number of clinical settings enable the preconditioning phenomenon to be 
investigated in humans in vivo. These models, which include cardiac surgery and 
percutaneous transluminal coronary angioplasty (PTCA), will be discussed in more 
detail in the following sections. 
5 ISCHAEMIC PRECONDITIONING IN MAN 
Throughout the 1970s and 80s it was a goal of many academic cardiologists to 
discover a method of limiting infarct size following an ischaemic insult (10). It was in 
this light that Murry and colleagues published their seminal paper on ischaemic 
preconditioning (14). This remains today the most effective method of limiting 
infarction other than reperfusion. Whilst the intense research investment has led to a 
clearer understanding of the underlying intracellular pathways in animals, we must 
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now push to reinforce these theories in humans if the protection seen following 
preconditioning is to be translated into a clinical therapy. 
5.1 Evidence for preconditioning in humans 
The preconditioning phenomena has been observed in all species tested thus far 
including rabbit, rat, dog, pig and mouse. The most critical question, and perhaps the 
most difficult to answer due to ethical limitations, is "does preconditioning occur in 
humans? " At least five preconditioning models have been used to address this 
question. 
5.1.1 Preinfarction angina 
The situation where angina precedes ischaemia provides the ideal setting for a 
retrospective study into the beneficial effects of antecedent sublethal ischaemia. Most 
studies of this genre have demonstrated a beneficial effect of angina prior to 
myocardial infarction (238,239). Benefit is defined in some studies as a reduction in 
enzyme-derived infarct size (239) with improved short term and long term prognosis 
(240), although this has been proposed to result from a greater chance of patency 
being achieved rapidly in the infarct related artery if there is antecedent angina. 
Protection may therefore result from facilitated thrombolysis of thrombosed 
atherosclerotic plaques in patients with unstable angina, instead of preconditioning of 
distal myocardium. Although Hata et al. have shown that ischaemic preconditioning 
improves vessel patency in a canine model (241), multivariate analysis of human 
studies suggest that, despite the improved vessel patency, angina itself is 
independently associated with improved survival at 5 years (240). 
The best prospective data comes in an ancillary study to TIMI-9B, where 3002 
patients were asked to report symptoms of angina before their infarct. This study 
showed that patients who reported symptoms within 24 hours of infarction had a 
lower 30-day event rate than those with angina greater than 24 hours before the event 
(242). This suggests a role for either classical and/or delayed preconditioning. The 
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main problem in all these studies is that patients with more frequent angina differ in 
respect to concomitant medication, collateral circulation and time to presentation after 
onset of chest pain. All these factors have been shown to alter prognosis, which only 
serves to confound data interpretation. 
5.1.2 Percutaneous transarterial coronary angioplasty 
Percutaneous transarterial coronary angioplasty (PTCA) provides a controlled model 
of ischaernic preconditioning where the first balloon inflation mimics the 
preconditioning stimulus and lessens ischaemic parameters such as lactate production, 
ST deviation, and chest pain during subsequent inflation. The primary concerns with 
this model are the duration of balloon inflation and the presence of a collateral 
circulation. In studies that report no benefit the first inflation lasts around 2 minutes 
(243), whereas a stimulus of at least 3 minutes is required to protect in animal models 
(244). When protection is seen it is not clear whether this is a result of collateral 
recruitment following the first inflation. However, a recent study from our laboratory 
has shown protection during PTCA in the absence of any significant collateral 
recruitment, providing the most robust evidence of ischaemic preconditioning in man 
(245). 
Pharmacological manipulation of the preconditioning pathway has also been used to 
trigger protection against the first inflation during PTCA. Using a 5-minute 
intracoronary infusion of adenosine, Lesser et al. have shown protection is even 
greater than with ischaemia (246). Moreover, infusion of an adenosine antagonist 
(247), or pretreatment with a KATP channel blocker (156), is able to prevent the 
preconditioning effect of the first balloon inflation. 
5.1.3 Warm-up angina 
Warm-up or walk-through angina describes the ability of patients to exert for longer 
during a second exercise than the first, when the two are separated by no longer than 
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60 minutes rest. The mechanism of the induced tolerance has been ascribed to 
ischaernic preconditioning, although this topic has received much debate (248). 
Traditionally, warm-up angina was attributed to coronary vasodilatation, with perhaps 
the concomitant opening of collateral vessels to support the ischaemic myocardium 
(249). This hypothesis was accepted even though arterial vasodilators such as 
aminophylline had little effect on exercise tolerance (250), and the presence of 
collaterals on angiography where not predictors of warm-up angina (251). A study 
from our laboratory on patients that show no collateral recruitment during PTCA, 
demonstrates that these patients still exhibit the warm-up phenomenon on exercise 
(245). Moreover, the time frame of warm-up is congruous with preconditioning since 
the second exercise reproducibly exceeds the first provided that the two are separated 
by a rest period of no longer than 60 minutes. 
5.1.4 Cardiac surgery 
Cross clamping of the aorta during coronary artery bypass isolates the coronary 
circulation to allow fashioning of the grafts. This model has been exploited by Yellon 
et al. who were able to show that two 3 minute cross clamping periods slows the rate 
of ATP depletion and attenuates troponin T release during a 10 minute ischaemic 
stimulus (252). Some groups do not find an additive protective effect of 
preconditioning in this model (253). Since cardioplegic solutions are known to 
preserve ATP by reducing cellular metabolic demand, it is possible that they are 
acting in the same fashion as ischaemic preconditioning, although Lee et al. did 
successfully precondition using a presurgical infusion of adenosine (254). 
5.1.5 Isolated muscle and cultured myocyte experiments 
Ischaernic preconditioning has been demonstrated in vitro using small atrial 
trabeculae harvested during cardiac surgery (154). This protection, measured as an 
improvement in contractile function, is also dependent on the activation of PKC and 
the opening Of KATP channels (154). Moreover, protection occurs in response to 
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preconditioning of human adult cardiac myocytes, which have been successfully 
cultured from patients with congenital heart disease (235). 
5.2 Therapeutic potential of ischaemic preconditioning 
5.2.1 Acute myocardial infarction 
The most obvious therapeutic use for a cardioprotective treatment against ischaemia is 
in the treatment of acute myocardial infarction. Unfortunately the need to predict the 
onset of ischaemia poses a difficult challenge. It is possible that preconditioning 
initiates a signalling pathway that protects the heart during ischaemia and/or 
reperfusion. In this instance, pathways could be activated or inhibited after the onset 
of ischaernia. It has been suggested that adenosine is required as a trigger before 
ischaernia and a mediator during ischaemia. Todd et al. showed in a rabbit model that 
an adenosine agonist given during the index ischaemia exerted a cardioprotective 
effect and reduced infarct size (255). However, although unrelated groups show a 
similar benefit (256,257), others in similar models show no benefit of adenosine 
infusion (258,259). This technique has been tested in man in the AMISTAD trial, 
which was a prospective, open label trial of thrombolysis with randomisation to 
adenosine or placebo in 236 patients within 6 hours after the onset of infarction (260). 
In the study adenosine caused a 33% reduction in infarct size, which supports the 
need for a large-scale clinical outcome trial. 
It has been suggested in animal models that protection is achieved, at least in part, 
during reperfusion following index ischaemia. For example, in canine hearts blockade 
of the adenosine receptor during reperfusion reverses the infarct-limiting effect of 
preconditioning (261). Preconditioning has also been proposed to attenuate oxidant 
stress during reperfusion (262). It may therefore be possible to harness the potential of 
ischaernic preconditioning against myocardial infarction without the need to predict 
the onset of ischaemia. 
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5.2.2 Prophylactic myocardial protection 
If the heart was in a permanently protected state this would negate the need to predict 
the onset of ischaemia. The feasibility of "bottling protection" so that a drug could be 
administered to an "at risk" population, thus placing their heart in a permanently 
protected state, has been discussed (263). Unfortunately adenosine, one of the obvious 
candidates, if given as repeated infusions, downregulates its receptor (264). It may be 
possible to overcome this problem by including an adenosine free period in the 
regime (265). 
If, as discussed previously, adenosine is protective during ischaemia and/or 
reperfusion it may be possible to enhance endogenous adenosine during these periods. 
Dralfalazine inhibits nucleoside transport, thus bolstering adenosine concentrations 
during low flow ischaemia and, in isolated porcine hearts, elicits a cardioprotective 
effect (256). 
The same principle can be applied to other triggers of preconditioning. Angiotensin 
converting enzyme (ACE) inhibitors augment bradykinin levels through inhibition of 
their breakdown. Large clinical trials such as GISSI-3 (266), ISIS-4 (267), SAVE 
(268), and SOLVD (269), which were designed to assess the ability of these agents as 
effective heart failure drugs, revealed unexpected findings. Patients who received 
these drugs post-infarction had a decreased incidence of adverse ischaemic events and 
a significant reduction in early mortality, at a time when the remodelling effects had 
probably not yet become effective. 
ACE inhibitors, given prior to ischaemia in animal models, lead to a reduction in 
infarct size, decrease in reperfusion-induced dysrhythmias and improved contractile 
function compared to controls (270-272). It is likely that in future patients with 
coronary artery disease receive ACE inhibitors and not just those post myocardial 
infarction. 
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Pharmacological manipulation distal to the receptor may also represent a viable 
clinical target. Nicorandil, a drug used to treat angina, has two moieties, a nitrate 
group and a KATP opener. Although it's use in angina is primarily due to the 
vasodilatory effect of the nitrate group, it is its effect on KATP channels that has 
generated most interest. A nicorandil infusion prior to ischaemia protects against 
stunning and infarction in a variety of animal models (273,274). More interestingly, 
these effects are not mimicked by pure nitrate donors and are abolished by KATP 
channel antagonists (275,276). In a recent placebo controlled study, nicorandil, 
administered to patients with unstable angina, reduced myocardial ischaemia. and 
dysrhythmias (277). The authors suggested that pharmacological preconditioning was 
responsible for these effects. 
5.2.3 Surgically induced ischaemia 
The ischaemia deliberately induced during cardiac surgery offers the ideally 
controlled setting to precondition the myocardium. The ischaemia is anticipated, of 
short duration and always associated with reperfusion. Very successful use of 
buffered hypothermic solutions means that fortunately irreversible myocardial injury 
rarely occurs. In complex procedures however, troponin-T release has been detected, 
indicating discrete necrosis, which may be attenuated by prior preconditioning in 
combination with cardioplegia. 
Transplant surgery may represent another therapeutic target for preconditioning. For 
the heart to remain suitable for transplantation it should be stored hypothermically for 
no longer than 4-6 hours. Animal studies suggest that preconditioning may increase 
this therapeutic window, which may decrease the current burden on donor hearts (273, 
274). 
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6 AIMS AND SCOPE OF THE THESIS 
Classical ischaernic preconditioning provides a powerful means of protecting the heart 
against ischaernia. A better understanding of the underlying signalling pathways may 
enable protection to be "bottled" phan-nacologic ally. PKC is a well-characterised 
family of signalling proteins involved in ischaernic preconditioning, but the 
involvement of specific PKC isoforms is more controversial. Furthermore, the kinases 
downstream of PKC are also less well understood. A better understanding of the role 
of individual PKC isoforms and their downstream targets should reveal more specific 
therapeutic targets. The purpose of the studies described within this thesis is to further 
characterise the signalling proteins involved in mediating protection in response to 
ischaernic preconditioning. 
The specific questions that the studies contained within this thesis were designed to 
answer were: 
What kinases are activated during preconditioning in neonatal cardiac 
myocytes? 
Do kinases activated during preconditioning contribute to protection? 
Do isolated mouse hearts precondition? 
Is PKCF- necessary for preconditioning in the mouse? 
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Chapter 2 Materials and Methods 
The constituents of all solutions stated within this methods chapter can found in the 
appendix section of this thesis (page 199). 
1 VECTOR PRODUCTION 
1.1 Virus production 
1. LI Principles of adenoviral growth and purification 
The recombinant adenovirus has essential regions deleted from its viral genome and 
as such can only be grown efficiently in cells expressing proteins that complement 
these deleted regions. The HEK 293 cell line was used, since these have been shown 
to allow growth of such viruses (278). After infection into the cell, the virus replicates 
leading eventually to cell death. Immediately prior to cell death (when previously 
attached cells begin to float in the media), the cells are harvested and lysed by 
repetitive freeze-thaw cycles. The virus can then be purified on caesium chloride 
gradients from not only cellular constituents, but also empty capsid and protein, since 
viable virus has a higher buoyant density. A final step of dialysis allows the removal 
of caesium chloride from the viral preparation. 
1.1.2 Generation and growth 
HEK 293 cells were cultured using standard tissue culture techniques. When cells 
were 80-90% confluent (typically in 10 x 140mm dishes), they were washed briefly in 
PBS followed by addition of 5mls of serum free media (SFM) containing recombinant 
adenovirus at an multiplicity of infection (MOI) of 10 (=I X107 plaque forming units 
(pfu) per dish). Cells were then returned to the incubator for I hour prior to addition 
of 10mls of full growth media (FGM). Cells were then cultured until a cytopathic 
effect was seen in the majority of cells, typically 2-3 days post infection. 
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1.1.3 Purification 
Cells were harvested in virus storage media (lOmM Tris [pH 7.4], IMM MgC12 and 
10% (v/v) glycerol) and subjected to 3 freeze-thaw cycles (liquid nitrogen to a 37'C 
water bath). The lysate was then spun at 800g to remove cellular debris (30OOrpm, 
Universal 16, Heffion Ltd., Tattlingem, Germany). Supernatant was then transferred 
onto a 1.25g/ml (4mls) to 1.4g/ml (4mls) caesium chloride step gradient and 
centrifuged at 150,000g using a SW41Ti swing-out rotor (Beckman Ltd., Paolo Alto, 
California, USA) for 2 hours at 20'C. The upper viral band was then removed and 
further purified on a second caesium chloride gradient (1.35g/ml) at 150,000g using a 
70Ti fixed angle rotor (Beckman Ltd. ) for 18 hours at 20'C. The purified viable virus 
was dialysed using 2000 MWCO dialysis cassettes (Slide-A-Lyzer@ 2K, Pierce, 
Rockford, Illinois, USA) with virus storage medium at 4'C over 24 hours with 3-4 
dialysis changes. Purified virus was then stored, in aliquots of I and 10ýfl, at -70'C. 
1.1.4 Screening to exclude wild type contamination 
Recombinant adenoviral preparations were added to HeLa cells (in 100mm. dishes) in 
4mls of SFM, at an MOI of approximately 20. After 2 hours an additional 4mls of 
FGM was added. Three days later the media was aspirated and centrifuged to remove 
cellular debris. 
HeLa cells, grown to 80-90% confluency in 24 well plates, were exposed to 300ýtl of 
supernatant. Six hours later, cells were washed briefly with PBS and 0.5mls of FGM 
was added. At day 4, cells were microscopically examined for a cytopathic effect. The 
presence of wild type contamination will be detected as a cytopathic effect9 since wild 




1.1.5 Plaque titration 
Materials and Methods 
Following growth to confluence in aIx 75CM2 tissue culture flask (Nunc, Rosklide, 
Denmark), HEK 293 cells were split into four 6-well plates. 24 hours later, 100[d of 
virus was serially diluted (1: 10) into Iml of SFM. Virus was pipetted into 6-well 
plates, from most dilute upwards, and left for I hour, at which point 1ml of FGM was 
added to each well. 48 hours later, viral titre was assessed by counting the number of 
plaques using a light microscope at IN magnification (Nikon TMS, Nikon, Japan). 
1.2 Expression plasmid production 
1.2.1 Principles ofplasmid DNA growth andpurification 
The plasmid DNA is introduced into Escherichia coli (DH5(x) by first using divalent 
cations to attach the DNA to the bacterial membrane. The membrane is then 
permeabilised by rapid warming, which allows the DNA to be taken into the cell. The 
bacteria are then grown in media supplemented with an antibiotic, the resistance to 
which is encoded within the plasmid DNA, thus allowing selective growth of bacteria 
containing the plasmid DNA. Following bacterial growth and amplification, plasmid 
DNA is recovered following a series of steps that denature the plasmid and 
chromosomal DNA. Plasmid DNA can be purified from chromosomal DNA since 
only covalently closed plasmid DNA is rehybridised, whereas chromosomal DNA and 
cellular debris remain insoluble. Further purification rids the preparation of remaining 
protein and RNA. 
1.2.2 Competent cells 
Competent cells were prepared by growing a single colony of DH5(x bacteria 
overnight in 10mls of LB media in an orbital incubator (Innova 4300, New Brunswick 
Scientific Co. Inc., Edison, New Jersey, USA) at 200rpm and 37'C. 100ýLl was 
transferred into 100mls of LB media and incubated for approximately 2 hours until 
swirls of bacteria were visible (absorbance at 600nm =0.4-0.6). The culture was then 
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centrifuged at 4500g (30OOrpm, Universal 16, Heffion Ltd., Tattlingem, Germany) 
and the pellet was resuspended in 10mls of 100m. M CaCl2at 4'C and left on ice for I 
hour. The bacteria were pelleted again and resuspended in 4mls of 100m. M CaC12- 
1.2.3 Transformation of competent cells 
I 00gl of competent cells were incubated with I OOng of plasmid DNA (in I ORI) for an 
hour at 4'C prior to heat shock at 42'C for 90 seconds. The mixture was then placed 
on ice for a further 30 minutes, at which time they were plated on LB-agar plates, 
containing ampicillin at 100ýtg/ml, and incubated overnight at 37C. 
1.2.4 Small-scale preparation ofplasmid DNA 
A single colony was picked and incubated overnight in 10mls of LB, containing 
ampicillin at 100gg/ml, in a 50ml conical flask at 200rpm in an orbital incubator at 
37C. Bacteria were pelleted as before and resuspended in 200gl of TE pH 8.0 
followed by addition of 400gg/ml of RNAse A. 200gl of solution 2 was then added, 
the suspension vortexed and kept at room temperature for 5 minutes. 200ýtl of 
solution 3 was then added and the suspension spun at 15,000g in a microfuge 
(13,000rpm, Heraeus Biofuge pico, Heraeos Instruments, Germany). The supernatant 
was transferred to a new hours tube and I volume of isopropranolol added and 
incubated on ice for 10 minutes prior to centrifugation again. The pellet was 
resuspended in 200gl of TE and phenol: chloroform cleaned. 
1.2.5 Phenol: chloroform extraction of DNA 
Phenol treatment causes protein denaturation, thus allowing protein removal. DNA is 
then purified from phenol by chloroform: isoamylalcohol washes, and finally 
chloroform is removed by ethanol precipitation. Phenol was added to the DNA in 
solution (1: 1, v/v),, the mixture vortexed and the upper aqueous layer removed, with 
care being taken not to remove denatured protein at the interface between the aqueous 
and phenol layer. The aqueous phase is then mixed with an equal volume of 
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chloroform: isoarnylalcohol, vortexed and the aqueous layer removed again and 
ethanol precipitated. 
1.2.6 Ethanol precipitation 
2.5 volumes absolute ethanol and 0.1 volumes of 3M sodium acetate (pH 5.2) is 
added to the DNA solution and the mixture left on ice for 10 minutes. Following 
centrifugation at 13,000rpm in a microcentrifuge, the pellet was washed in 70% (v/v) 
ethanol to remove traces of salt. After further centrifugation, the DNA pellet was 
dried to remove all trace of ethanol and then resuspended in the appropriate volume of 
DI H20- 
1.2.7 Large-scale preparation of DNA 
Frozen stocks were used to inoculate 10mls of LB medium (with lOgI ampicillin at 
100mg/ml), which was grown for 6 hours in an orbital incubator at 37C. The 10mls 
culture was then added to a2 litre conical flask containing 400mls of LB medium, 
with lOOgg/ml of ampicillin, and placed in an orbital incubator overnight at 200rpm 
and 37C. The culture was centrifuged at 50OOrpm in a Sorvall GSA rotor (Sorvall 
Ltd., Stevenage, UK) for 10 minutes at 4'C and the pellet was resuspended in 20mls 
of solution 1. The cells were lysed and DNA denatured by addition of 40mls of 
solution 2. After leaving cells on ice for 10 minutes, 30mls of solution 3 was added 
and the cells incubated on ice for a further 10 minutes to aggregate proteins and 
promote intrastrand aggregation of chromosomal DNA, whilst plasmid DNA 
rehybridises. 
Cellular debris was pelleted by centrifugation as before, the supernatant removed to 
another centrifuge pot and 50mls ice-cold isopropranolol added. Following incubation 
on ice for 10 minutes the suspension was centrifuged at 90OOrpm in a Sorvall GSA 
rotor for 15 minutes at 4'C. The supernatant was discarded, leaving about Iml into 
which the pellet was resuspended and transferred to a 1.5ml Eppendorf tube. 
Following a 10-minute centrifugation in a microfuge at 4'C, the pellet was 
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resuspended in 720ý11 of TE buffer, to which 1.26g of caesium chloride and 120gl of 
20mg/ml ethidium bromide was added. Once dissolved, the tubes were left overnight 
in the dark at room temperature. The tubes were centrifuged at 13,000rpm in the 
microfuge for 30 minutes to remove residual protein, which forms as a precipitate. 
The DNA solution was underlayed below a 65% (w/v) caesium chloride gradient, and 
the gradient centrifuged at 100,000rpm in a TLA100.4 rotor using a Beckman Optima 
TI ultracentrifuge (Beckman Ltd., Paolo Alto, California, USA) for 4 hours, during 
which a gradient is formed in the caesium chloride, allowing the separation of DNA. 
The plasmid DNA (red band) was recovered and washed repeatedly in water-saturated 
butanol to remove residual ethidium bromide. The DNA-containing aqueous phase 
was phenol: chloroform cleaned, ethanol precipitated, and the resulting DNA 
quantified. 
1.2.8 Quantification of DNA 
Plasmid DNA was diluted 100 fold in a total volume of 500ýtl of DI H20 and the 
absorbance at 260 and 280nm measured with a spectrophotometer (Jenway 6105 
U. V. Nis Spectrophotometer, Jenway Ltd., Dunmow, Essex, UK), after initial 
standardization to a blank reading with DI H20 alone. The DNA concentration (gg/gl) 
can be calculated by: 5(absorbance at 620nm [units]), since at 260nm an absorbance 
of 1 unit is equivalent to 50ýtg of DNA. The purity of DNA is calculated by 260nm: 
280nm ratios, which were always between 1.8 and 1.9. 
2 NEONATAL RAT VENTRICULAR MYOCYTE CULTURE 
2.1 Isolation and purification 
Neonates were rinsed briefly in 70% (v/v) ethanol and a midline incision made 
through the sternum. After removal of the heart, the ventricle was trisected into ADS 
buffer (see Appendix, section 1.2.1). Following removal of 20-30 hearts, the ADS 
was aspirated and replaced by 7mls digestion buffer (ADS + 0.5 mg/mI collagenase 
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and 0.6 mg/ml pancreatin). The digestion mixture was then incubated at 37'C for 7 
minutes. Thereafter, the buffer was aspirated and replaced by another 7mls digestion 
solution and digested again at 37'C for a further 7 minutes. The digestion buffer is 
discarded following these first two digestions, however the processes was repeated a 
further 6 times with 15-minute digestion periods. After each digestion cycle the 7mls 
of buffer is added to 2mls of FCS, the mixture centrifuged at 10OOrpm (Universal 16, 
Heffion Ltd., Tattlingem, Germany) for 6 minutes, the supernatant discarded and the 
pellet pooled into 4mls of FCS. The pooled cells were then centrifuged and 
resuspended in 50mls plating media. The cell suspension was pre-plated for 30 
minutes in 90mm dishes (4 dishes with 12.5mls/dish) to remove fibroblast 
contamination. The media (containing <5% fibroblasts) was then retrieved and placed 
in 6-well gelatin-coated plates (2mls/well). These gelatin-coated plates were prepared 
from standard 6-well plates exposed to 1ml. of 1% gelatin (v/v, in PBS) two hours 
before use (the gelatin solution is aspirated immediately prior to myocyte plating). 
2.2 Culture 
Myocytes were cultured in plating medium for 24 hours following isolation at 37'C in 
room air containing 5%CO2- Media was then aspirated and, following a 
brief wash 
with PBS, cells placed in 2mls maintenance media. Cells were cultured 
in 
maintenance media at 37'C for at least 24 hours prior to use. 
2.3 DNA trans ction 
2.3.1 Adenoviral infection 
One day post-isolation, myocytes, grown in 6-well plates to 70-80% confluency, were 
incubated with Iml. of SFM containing adenovirus at 1X 
107 pfu (Mol =10) for 1 
hour at 37'C in room air containing 5%CO2. The cells were washed 
briefly in PBS 
and cultured in 2mls maintenance medium containing 
1% (v/v) FCS for an additional 
48 hours at 37'C in room air containing 
5%CO2. 
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2.3.2 Plasmid transfection 
Cardiocytes grown in 6-well plates at 70-80% confluency were transfected with 
pCAGGS expression plasmid by, unless otherwise stated, an integrin-targeting 
peptide-mediated transfection procedure described previously (279). The peptide used 
was P6, which has a polylysine DNA binding region (16 residues) and an OCvPj 
integrin-targeting head group (GACRRETAWACG). The peptide-Lipofectin 
complexes were prepared by mixing 40gl peptide (0.1%, w/v) and 0.75gl Lipofectin 
(Life Technologies Ltd., Paisley, UK). DNA (0.01%, w/v) in optimem was added to 
peptide-Lipofectin complex at a ratio of 2.5: 1 (v/v). DNA-peptide-Lipofectin 
complexes were allowed to stand for I hour at room temperature before use. IOORI of 
this mix was diluted to Iml in optimem and added to one well of a 6-well plate. Cells 
were then incubated overnight at 37'C in room air supplemented with 5%CO2- 
Thereafter complex/optimem was removed and replaced with maintenance medium 
containing 1% (v/v) FCS, and the cells were returned to the incubator. Cell extracts 
were assayed for protein 48 hours post-transfection. By using pCAGGS-GFP as a 
reporter, transfection efficiency was consistently between 20 and 30%. 
2.4 Principles of simulated ischaemia 
In 1994, David Hearse in his capacity as editor of Cardiovascular Research invited 33 
eminent cardiologists to write a simple definition of ischaemia (1). The response 
ranged from 3 words (supply-demand imbalance) to 404 words, proving that the term 
ischaemia was difficult to define without ambiguity. I would suggest that myocardial 
ischaemia is initiated by an inadequate blood supply to the heart. The consequence of 
the limited blood supply is that oxygen and nutrient availability is inadequate and 
tissue metabolites are insufficiently washed out. Thus, in the words of Dr Howard 
Morgan, "Ischaemia may be simulated in organ baths or tissue cultures by reducing 
oxygen and nutrient supply and adding metabolic products" (1). The model of 
simulated ischaemia used in the studies described within this thesis comprises 
hypoxia in a buffer lacking glucose but containing high potassium and lactate at low 
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pH. This therefore simulates oxygen and nutrient deprivation whilst mimicking the 
extracellular milieu of true ischaernia in vivo. 
2.5 Ischaemia simulation 
The cells were washed once with PBS before addition of Iml of ischaemia buffer (IB: 
118mM NaCl, 24mM NaHC03,, ImM NaH2PO4,2-5mM CaC12,1.2mMMgCI2, 
0.5mM sodium*EDTA'2H20,20mM sodium lactate, and l6mM KCI, pH 6.2), pre- 
gassed with 5%CO2,95% argon. On addition of ischaemia buffer spontaneous 
contraction within the monolayer ceased. Cells were then transferred to anaerobic 
GasPak pouches (Becton Dickinson, Maryland, USA) and incubated at 37'C for up to 
6 hours. The 02 content of the atmosphere inside the pouches was <1% for the 
duration of the experiment as measured by an anaerobic indicator. 
2.6 Principles of cell viability assays 
A number of endpoints can be used to assess cell death in cultured cells. We have 
chosen to use 3 separate endpoints that assess both membrane disruption and 
metabolic activity. One of the major forms of cell death during ischaemia and/or 
reperfusion is necrosis, during which the cell membrane integrity is lost and the cell 
constituents are leached to the extracellular milieu. Two enzymes, CK and LDH, can 
be detected in the buffer surrounding cells during ischaemia and quantified as a 
measure of membrane integrity or necrosis. Concomitant with necrosis, apoptosis has 
also been suggested to contribute to in ury during ischaemia/reperfusion (177). Unlike 
necrosis, the cell membrane remains intact during apoptosis, however the 
mitochondrial membrane potential is similarly dissipated. The tetrazolium component 
of 3-(4,5-dimethylthiaziazol-2-yl)2,5-diphenyI tetrazolium bromide (MTT) is 
reduced in metabolically active cells to a blue fon-nazan dye, hence the photometric 




2.7 Cell viability assays 
2.7.1 Measurement of enzyme release 
Materials and Methods 
On opening the anaerobic pouches (re-oxygenation) 200gl samples of the ischaemia 
buffer were gently collected for the determination of CK and LDH. The following day 
a spectrophotometric CK and LDH enzyme assay was performed with Boehringer 
Mannheim (MPR-1) and Sigma (TOX-7) assay kits respectively. 
2.7.2 MTT bioreduction assay 
After simulated ischaernia, cells were re-oxygenated in maintenance medium 
containing I% (v/v) FCS. After 2 hours, medium was aspirated and cells incubated in 
50%tl PBS containing 2.5mg MTT for 30 minutes at 37'C in room air containing 5% 
C02. Thereafter the reaction was terminated by addition of 50%Ll solubilisation 
solution (0.1 mol/I HCI, 10% (v/v) triton X- 100, in isopropranol) and the absorbance 
of the lysate was recorded at 570nm using a spectrophotometer, after initial 
standardization to a blank reading with DI H20 alone. 
3PROTEIN DETECTION AND QUANTITATION BY WESTERN BLOTTING 
3.1 Principles of SDS-Page and Western blotting 
During SDS-page, proteins are separated according to molecular mass by 
electrophoresis through Polyacrylamide gels. The relative distance that a protein 
migrates is dependent on: (i) the pore size of the polyacrylamide gel, where pore size 
decreases with increasing acrylamide concentration, (ii) the effective radius of the 
protein, which is determined by its quaternary structure, and (iii) the native charge of 
the protein. It is common to denature proteins with a reducing agent in the presence of 
excess SDS, which acts to unfold the protein and cause it to bind SDS, thus conferring 
an essentially identical negative charge on all proteins. This has the effect of reducing 
the importance of quaternary structure and native charge, leading to a separation that 
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is mainly dependent upon molecular size. Following separation, proteins are 
transferred to nitrocellulose by applying an electric field perpendicular to the plane of 
the gel. The proteins become immobilized within the nitrocellulose matrix, whilst 
epitopes still remain accessible to immunoglobulins allowing immunodetection. The 
nitrocellulose membrane containing the immobilized protein is blocked, to prevent 
non-specific antibody binding, before exposure to primary antibodies specific for the 
protein of interest. The subsequent addition of horseradish peroxidase-conjugated 
immunoglobulins, raised against the primary antibody species, localises horseradish 
peroxidase to the protein of interest. Luminol is then added to the membrane in the 
presence of hydrogen peroxide. The peroxidase activity with the membrane catalyses 
the oxidation of luminol, which immediately after oxidation is in an excited state and 
emits light whilst decaying to the ground state. This light emission can be recorded on 
photographic film. 
3.2 Preparation of protein samples 
3.2.1 Cell cultures 
Cells were washed twice in ice-cold PBS, before addition of 100ýtl of boiling two- 
times sample buffer (2xSB) per well of a 6-well plate. Cells were quickly removed 
into microcentrifuge tubes, 11 ýtl of 2-mercaptoethanol added and the samples boiled 
for 5-10 minutes. 1-2gl of bromophenol blue dye was added and the samples 
centrifuged for 2 minutes at 13,000rpm in a microfuge (to remove insoluble material) 
prior to loading on SDS gels. 
3.2.2 Isolated mouse hearts 
Hearts were crushed under liquid nitrogen using a micro-pestle and motor. 30mg of 
heart sample was then weighed, placed in 350gl of boiling 2XSB containing 10% 
(v/v) 2-mercaptoethanol and boiled for 5-10 minutes. 1-2gl of bromophenol blue dye 
was then added and the samples centrifuged for 2 minutes at 13,000rpm in a 
microfuge prior to loading on SDS gels. 
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3.3 Preparation of SDS-Page gels 
Materials and Methods 
Polyacrylamide gels were poured between glass plates separated by Imm. spacers. The 
gels were formed of a lower "resolving" gel and an upper "stacking" gel into which 
wells are set to allow sample loading. The lower gel (PH 8.8) was Prepared by mixing 
a 30% (v/v) acrylarnide solution, TRIS-buffered SDS solution (to PH 8.8), and DI 
H20 tOgive either a 10% or 12.5% acrylamide mixture. Prior to pouring, acrylamide 
polymerisation and cross-linking was induced by addition of ammonium persulphate 
(APS) and NNNN-tetraethylethalinediamine (TEMED). Water saturated butanol was 
overlaid whilst the gel polymerised to prevent drying. 
Once the lower gel had polymerised, the butanol was washed off and the stacking gel 
poured. The upper stacking gel (pH 6.8) was prepared by mixing a 30% (v/v) 
acrylamide solution, TRIS-buffered SDS solution (to pH 6.8), and DI H20 tOgive a 
5% acrylamide gel mixture. The gel was polymerised by addition of APS and 
TEMED and poured on top of the resolving gel. Toothed plastic combs were inserted 
and removed after polymerisation to leave rectangular indentations to load samples. 
The exact constituents of the gel can be found in Table 7-1 (Appendix, page 208). 
3.4 One-dimensional separation of proteins in SDS-page gels 
Samples were loaded into their respective wells and a voltage of 120V applied using a 
Powerpac 300 (Biorad, Herts, UK). The negatively charged proteins migrate towards 
the lower reservoir (anode). Once the proteins had left the stacking gel (=15 minutes) 
the voltage was increased to 150V until the dye front, the fastest migrating portion of 
samples, reached the bottom of the resolving gel. The resolving gel was then removed 
and used for either Western blotting or visualization of proteins by coomassie 
staining. 
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3.5 Coomassie staining of SDS-page gels 
Coomassie brilliant blue (BDH, Dorset, England) binds to proteins and can 
quantitatively detect protein levels between 0.5 and 15gg (280). The resolving gel 
was gently agitated in coomassie staining solution for I hour, after which it was 
transferred to destain solution and left shaking at room temperature overnight, to 
remove the non-specific background staining. 
3.6 Western blotting 
Proteins were transferred to nitrocellulose membranes (Hybond C, Amersham, Bucks, 
UK) by overlaying nitrocellulose on the resolving gel, taking care to exclude air 
bubbles. The membrane and gel were then sandwiched between filter papers inside a 
plastic cassette within a blotting tank (BioRad, Herts, England) containing transfer 
buffer (0.025M Tris, 0.5M Glycine, and 20% (v/v) methanol). A current of 150mA 
was applied, with the anode placed on the nitrocellulose side, for 2 hours to allow the 
transfer of negatively charged proteins onto the nitrocellulose membrane. Following 
transfer, resolving gels were stained with coomassie blue to confirm efficient protein 
transfer. 
Membranes were blocked against non-specific binding of antisera by incubation in 
blocking solution (5% (w/v) dried skimmed milk powder, 0.1% (v/v) Tween-20, in 
TBS) for I hour with gentle agitation at room temperature. Following a brief wash in 
TBS, containing 0.1% (v/v) Tween-20 and 0.1% (w/v) milk powder (TBST), 
membranes were incubated with the relevant primary antisera. For specific conditions 
of primary antibody incubations see the specific methods category of the relevant 
chapter (and Table 1-1; Appendix, page 212). Following antibody binding, 
membranes were washed in TBST for 10 minutes, four times. The membranes were 
then incubated with horseradish peroxidase conjugated secondary antibody. For 
specific conditions of secondary antibody incubations see the specific methods 
category of the relevant chapter. Following four further washes for 10 minutes in 
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TBST, membranes were developed using an enhanced chemiluminescence technique 
(Amersham, Bucks, England). 
4 LANGENDORFF PERFUSION OF ISOLATED MOUSE HEARTS 
4.1 Maintenance of the transgenic mouse colony 
4.1.1 Breeding 
Mice heterozygous for a disruption within the pkc-E alleles were initially mated to 
produce either wild type (+/+), heterozygous or knockout (-/-) offspring. 
Thereafter (+/+) x (+/+), (+/-) x (+/-), (-/-) x breeding pairs were used to 
generate all offspring. Female (-/-) mice were not fertile due to an apparent 
susceptibility to genital infections (Dan Pennington, personal communication). All 
mice used in Chapter 6 were generated from (-/-) male x (+/-) female breeding pairs. 
The genotypes were not determined until all physiological data had been collected, 
after which they were determined by polymerase chain reaction (PCR). 
4.1.2 Genotyping by polymerase chain reaction 
4.1.2.1 DNA isolation and purification 
lcm sections of tail were cut from mice (which were identified by ear clipping) and 
placed in tail buffer (50mM Tris (pH 8.0), lOOmM EDTA, 0.5% (w/v) SDS) 
containing 40gl of proteinase K (10mg/ml) overnight at 55'C in a compact 
thermomixer (Eppendorf, UK). The solution was then mixed, with shaking for 5 
minutes, with 700gl of phenol (equilibrated with Tris pH 8.0). The tubes were then 
microfuged and 60%tl of the aqueous phase transferred to fresh tubes containing 
200gl tail buffer. 7001il phenol: chloroform (1: 1) was added to each tube, which was 
subsequently shaken for 5 minutes and microcentrifuged for 5 minutes. Exactly 630gl 
was then removed from the aqueous phase and added to prepared tubes containing 
70[tl of 3M sodium acetate (pH 6.0 -a sodium acetate solution of pH lower than 6 
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will cause the EDTA to precipitate). The DNA was immediately precipitated by the 
addition of 700gl of 100% ethanol with shaking by inversion. The DNA pellet is 
recovered by centrifugation and aspiration of the supernatant. Addition of Iml of 70% 
(v/v) ethanol and further centrifugation removes the excess salt and the DNA pellet 
was air dried before resuspension in 80ýtl DI H20- 
4.1.2.2 Polymerase chain reaction 
The polymerase chain reaction (PCR) reaction mix was prepared by addition of all 
components shown in Table 2-1, except the DNA, to 200ýLl PCR tubes. Care was 
taken to keep all solutions on ice to prevent primer dimerisation. The DNA was 
quickly added to each tube and the solutions overlaid with mineral oil. The replication 
reaction was started by addition of 0.5gl Taq polymerase (Promega, 10OU/20gl) and 
the tubes placed in a thermocycler (Techne, UK) preset to 80'C. The machine was 
held at 80'C for 2 minutes 45 seconds before undergoing 32 cycles at 94'C (I 
minute), 60'C (30 seconds), and 72'C (30 seconds). The reaction mixture was then 
stored at 4'C prior to agarose gel electrophoresis to identify DNA products. 
Constituents Amount per tube (gl) 
Appropriate reaction buffer 5 
(as per manufacturer's instructions) 
M902 5 
dNTP's mix (10%, v/v) I 
primers 0.5 of each Q primers) 
DNA 2 
DI H20 35.5 
Table 2-1: PCR reaction mixture. 
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4.1.2.3 Agarose gel electrophoresis 
Materials and Methods 
25ýtl of PCR reaction mixture was then added to 5gl of 6x gel loading buffer prior to 
loading and electrophoresis on preformed 1% (w/v) agarose gels, stained with 
0.5gg/ml ethidium bromide. The gel was then visualised using a UV dual-intensity 
transilluminator (UVP, Genetic Research Instrumentation Ltd., Essex, UK) and 
photographed with a Polaroid DS34 instant camera with a EP H-7 hood (Polaroid UK 
Ltd., Hertfordshire, UK). 
4.2 The principles of retrograde perfusion 
The first preparation capable of maintaining the isolated heart was described by Oscar 
Langendorff (228). In the Langendorff preparation the ascending aorta is tied to a 
cannula through which perfusate enters the aortic root. As long as the aortic valve is 
intact and the pressure inside the left ventricle is less than that in the aortic root, the 
perfusate is forced through the right and left coronary arteries situated in the coronary 
sinuses. After passing through the coronary arteries and myocardial capillaries, 
perfusate drains into the right atrium and ventricle and exits through the pulmonary 
artery. Providing the perfusate contains essential substrates and the flow is sufficiently 
high to maintain supply and remove metabolites, the heart can remain viable and 
contract for many hours. 
4.3 Heart isolation and cannulation 
All male animals were anaesthetized with a ketamine/xylazine mixture (150mg/kg 
and 24mg/kg with IOOlU heparin, i. p. ). Hearts were rapidly excised from the thorax 
and placed in ice-cold modified Krebs-Henseleit (K-H) buffer. After removal of 
excess thymic and fatty tissue, the aorta was cannulated with a 23G blunt and grooved 
stainless steel needle. The heart was retrogradely perfused with K-H buffer at a 
constant pressure of 80mmHg (108cm H20). The K-H buffer was pre-filtered using a 
0.8gM micro-filter (Whatman, UK) and constantly gassed with 95% 02/5% C02- 
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4.4 Retrograde heart perfusion 
Following isolation the heart temperature was monitored continuously by a K-Type 
thermocouple, passed through the right ventricular wall into the right ventricle, and 
attached to a C9001 Thermometer (Comark, UK). The temperature was maintained at 
37.0±0.1'C by immersing the heart and cannula in K-H buffer kept at 37. OOC in a 
water-jacketed chamber. A fluid-filled balloon inserted into the left ventricle was used 
to assess contractile function. The balloon was attached to a pressure transducer, 
which was coupled to a 4S Powerlab (AD Instruments, UK). The frequency response 
characteristics of the isovolumic fluid-filled balloons, coupling tubing and transducer 
were flat to at least 3011z. The balloon was gradually inflated until the end-diastolic 
pressure reached between I and 5mmEg. Hearts were then paced at 580bpm by a 
0.075mm silver wire (Advent, UK) placed through the right ventricular wall into the 
right ventricular apex. The wire and aortic cannula were attached to an SD9 stimulator 























Figure 2-1: Langendorff perfusion apparatus used in studies described within this thesis. 
The heart is perfused by oxygenated K-H buffer maintained at 37C (by heat-exchange column), at a 
constant pressure of 80mmEg (determined by the height of the upper Kreb's reservoir). The 
temperature of the heart and inflow cannula is also maintained at 37C by submersion in the lower 
Kreb's reservoir. The heart temperature only varied ±0. I 'C, as measured by a thermocouple inserted 
into the right ventricle and attached to an electronic thermometer. The heart is paced at 580 bpm by 
electrodes attached to a stimulator. The contractile ftinction is monitored throughout via a fluid-filled 
balloon in the left ventricle attached, though fluid filled tubing, to an online pressure transducer. The 
output from the transducer is amplified in a bridge-amplifier, converted from analogue to digital and 
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Figure 2-2: Magnified image of a perfused mouse heart. 
The pacing electrodes are attached to the cannula (insulated from surrounding Kreb's) and right 
ventricle. The thermocouple is placed in the right ventricle and fluid-filled balloon in the left ventricle 
(through the mitral valve). K-H buffer is constantly perfused through the carmula into the aortic root, 












Figure 2-3: Image of digital readouts of left ventricular pressure and heart rate monitored 
throughout heart perfusion. 
4.5 Infarct size assessment 
4.5.1 TTC staining 
Following 1.5 hours reperfusion, hearts were perfused for I minute with 5mls 1% 
(w/v) triphenyl-tetrazolium chloride (TTC) in phosphate buffer (Na2HP04 45. ImM, 
NaH2PO4 3.3mM, pH 7.8). Hearts were then removed from the cannula and placed in 
an identical TTC solution at 37'C for 10 minutes. The atria were then removed, and 
the hearts blotted dry, weighed and stored at -20'C for up to I week. 
4.5.2 Sectioning andfixation of hearts 
Hearts were thawed, placed in 2.5% (v/v) glutaraldehyde for I minute and then set in 
5% (w/v) agarose solution. The agarose heart blocks were then sectioned from apex to 
base in 0.7mm slices using a vibratome (Series 1000, Agar Scientific, UK). Following 
sectioning, slices were placed overnight in 10% (v/v) formaldehyde at room 
temperature, before transferring into PBS for a further 2 days at 4'C. 
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4.5.3 Infarct size measurement 
Heart sections were compressed between Perspex plates (0.57mm apart) and imaged 
using a TK-1280E digital camera (JVC, Japan). A typical heart, stained and sectioned 
following ischaernia, is shown in Figure 2-4. Planimetry was carried out using image 
analysis software (Scion Image vl. 61, Scion corporation, http: //www. scioncorp. com) 
and surface area transformed to volume by multiplication by 0.57. 
Figure 2-4: Typical mouse heart, subjected to 45 minutes 
ischaemia, stained with triphenyl tetrazolium chloride (TTC) 
and sectioned using a vibratome before imaging. 
5 STATISTICAL METHODS 
All values are expressed as mean±SEM. All comparisons involving more than one 
group were assessed for significance using one-way analysis of variance (ANOVA), 
followed where appropriate by the Tukey-Kramer test for pair-wise comparisons. 
Comparisons between paired samples were performed using one-way analysis of co- 
variance (ANCOVA). Statistical tests were performed using commercially available 
software (Sigma Stat v2.03, SPSS Inc., USA). Unless otherwise stated, a statistical 
value of less than 0.05 was considered significant. 
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1 INTRODUCTION 
The binding of membrane phospholipids such as DAG and PS is an essential step in 
the activation of classical and novel PKCs. since it causes a conformational change 
that removes the inhibitory pseudosubstrate domain from the catalytic site, thus 
activating PKC (72) (Figure 1-3, page 40). Previous studies in our lab have exploited 
these features of PKC activation to engineer mutant PKC isoforms, rendered 
constitutively active by a deletion within their pseudosubstrate domain (Figure 3-1). 
Using this approach, we have shown that expression of an active PKC6 mutant is 
capable of protecting neonatal rat ventricular cardiocytes during simulated ischaemia 
(221). 
A 
CAf ý4 C4 
Figure 3-1: Representation of mutant PKC isoforms activated by a 
pseudosubstrate domain deletion. 
The N-terminal pseudosubstrate domain of PKC binds to the catalytic (C4) 
domain preventing activity in native PKC (Panel A). Upon activation, the 
pseudosubstrate is removed, which enables downstream substrate 
phosphorylation. A 9a. a. deletion within this pseudosubstrate domain (residues 
151-160) prevents its binding to the catalytic domain, thus enabling constitutive 
substrate activation (Panel B). 
The protection observed following PKC6 activation, although consistent with other 
studies (281), does not implicate this isoform in ischaemic preconditioning. Using 
isoforyn translocation as a surrogate for PKC activation however, other studies have 
associated preconditioning-induced protection with the activation of various PKC 
isofonns, including PKC6 (100,282-284). 
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A possible disadvantage of expressing an active PKC5 mutant is that, whilst 
endogenous PKC needs to be localised to the membrane for activation, mutant PKC 
does not, since it is active even in the absence of DAG and PS. This raises the 
question of whether 'constitutively active' PKC exhibits the same spatial localisation 
as physiologically activated PKC. On the other hand, in the active conformation 
mutant PKC has the RACK binding domain (within the C2 domain) exposed and 
therefore maybe constitutively present at the membrane even in the absence of 
stimulation. 
In an attempt to address the aforementioned issues and to corroborate the protection 
achieved by active PKC6 expression and ischaemic preconditioning, we wished to 
address the following two questions: 
9 Does ischaernic preconditioning translocate endogenous PKC8 in isolated 
neonatal cardiac myocytes? 
* Does the localisation of wild type and active PKC8 reflect to the localisation 
of PKC5 before and after preconditioning? 
2 SPECEPIC METHODS 
2.1 HEK 293 cell culture 
HEK 293 cells were cultured to confluency in 15mls FGM in a 75cm 
2 flask at 37C. 
Media was then aspirated, 2mls trypsin (5%, v/v, in versene) added and the flask 
returned to the incubator for 5 minutes, after which 10mls of FGM was added. 2mls 
of cell suspension was then added to each well of a 6-well plate and the cells cultured 
at 37'C for at least I day before use. 
2.2 Restriction digestion of plasmid DNA 
Restriction endonuclease enzymes cut DNA at specific codon sequences. These 
enzymes were used in restriction digests to verify the PKC isoforms 
inserted in the 
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expression plasmid pCAGGS. I [tg DNA, diluted to 17ýtl in DI H20, was added to I RI 
restriction enzyme and 2ýtl of appropriate lOx reaction buffer (as per manufacturers 
specifications). The mixture was then placed at 37'C for I hour, before addition of 
4ýtl of 6x gel loading buffer prior to electrophoresis on a I% agarose gel. 
2.3 Liposome-mediated transfection 
DC-chol: DOPE liposomes were prepared by Louisa Stewart at Imperial College of 
Science, Technology and Medicine. The liposomes (1.2gg/gl) were mixed with DNA 
in a 3: 1 ratio. The lipoplexes were complexed at 4'C for 30 minutes prior to addition 
of lml SFM. The media containing the complex was then added to HEK 293 cells 
grown to 80% confluency in a 6-well plate (lml media/well). The cells were then 
returned to the incubator for I hour before addition if Iml FGM, after which the cells 
were incubated for a further 48 hours before harvesting for Western blotting with anti- 
PKC8 antibodies to detect PKC levels. 
2.4 Experimental protocols 
The experimental protocols are shown below (Figure 3-2). The end of re-oxygenation 
was chosen to assay PKC localisation because PKC translocation has previously been 
documented at this time following preconditioning (284). 
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i Simulated Preconditioning i 
90 m in 
4 
B 
0 Simulated ischaemia 
0 Re-oxygenation 
Figure 3-2: Schematical representation of experimental protocols. 
Preconditioning was simulated by exposure to ischaemia buffer for 90 minutes followed by 
30 minutes re-oxygenation in standard maintenance media. The arrows indicate the time- 
points at which the cells were harvested and protein samples prepared. Panel A, PKC 
localisation was determined at the end of re-oxygenation. Panel B, MAPK activation was 
assessed at various time-points during re-oxygenation (0,2,5,10,15,20, and 30 minutes). 
2.5 Cell Fractionation 
Cells were briefly washed 3 times in ice-cold PBS, before addition of ice-cold lysis 
buffer (100ýtl/well) containing 0.05% (w/v) digitonin. The extract was incubated at 
4'C for 5 minutes with mixing by inversion. A sample was first taken (35ýtl), 
containing total cell protein, before the remainder was centrifuged for 2 minutes at 
15,000g and 4'C. The supernatant, containing the cytosolic protein, was removed and 
the pellet resuspended in lysis buffer (35pl) containing 1% (v/v) Triton X-100 and 
incubate for 5 minutes as before. Further centrifugation at 15,000g, in a microfuge for 
15 minutes at 4'C, enabled the separation of particulate (containing triton-soluble 
membrane proteins, nuclei and filaments) from insoluble material. An equal volume 
of boiling 2x SB, containing 20% (v/v) mercaptoethanol, was added to each sample 
before boiling for 5 minutes. 3-4pl of bromophenol blue was then added prior to SDS- 
PAGE and Western blotting. 
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2.6 Western blotting 
2.6.1 Antibody binding conditions 
Role of PKC isoforms during preconditioning 
All samples for Western blotting were run on 10% polyacrylamide gels, following 
coomassie staining of identically loaded gels to confirm uniform protein loading. All 
PKC antibodies were murine monoclonal antibodies (Transduction Laboratories, UK). 
For detection of MAPK activation, membranes were probed were murine monoclonal 
antibodies specific for ERK2 (Santa Cruz Biotechnology, Santa Cruz, USA), or rabbit 
polyclonal antibodies specific for p38, phospho-p38 or phospho-ERKI/2 (Cell 
Signalling, Hitchin, UK). All primary antibodies were incubated at 1: 1000 overnight 
at 4'C, prior to incubation with either peroxidase-conjugated rabbit anti-mouse IgG or 
peroxidase-conjugated swine anti-rabbit IgG secondary antibodies (DAKO A/S, 
Denmark) at 1: 2500 dilutions for 2 hours at room temperature. 
2.6.2 Quantification ofprotein levels 
Densitometry of protein bands were calculated using Scion Image vl. 61 (Scion 
corporation, http: //www. scioncorp. com). The density of each band was obtained from 
the average of three separate readings. The change in phosphorylation was calculated 
as a percentage of baseline control samples on the same membrane. 
3 RESULTS 
3.1 Translocation of endogenous PKC isoforms during preconditioning 
The PKC activator phorbol 12-myristate 13-acetate (PMA) activates PKC by binding 
to the Cl domain and anchoring PKC to the plasma membrane. PMA was therefore 
used as a positive control for PKC8 translocation, since it causes the relocalisation of 
all CI domain-containing isoforms (conventional and novel PKCs) from cytosol to 
particulate fraction. Myocytes were exposed to 80nm PMA for 10 minutes prior to 
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harvesting for fractionation and Western blotting. Figure 3-3 shows that, whilst in 
control myocytes PKC6 is situated in the cytosol and particulate fraction, after 
treatment with PMA, PKC6 is localised almost exclusively in the particulate fraction. 
T T C C P P 
+ - + - + 
Aw. PKC-8 
Figure 3-3: The effect of phorbol 12-myristate 13-acetate (PMA) on 
subcellular distribution of PKC5. 
80nm PMA was added to cell culture media for 10 minutes (+) before the cells 
were harvested. Constituent protein was then fractionated into cytosol (C) and 
particulate (P) fractions prior to Western blotting with anti-PKC6 antibodies. 
Compared to untreated controls (-), PMA caused a rapid translocation of 
PKC5 from the cytosol to the particulate fraction, although total PKC8 levels 
(T) remained unchanged. 
Having verified the viability of the subcellular fractionation protocol, the location of 
PKC8 was examined after simulated ischaemic preconditioning. Myocytes were 
preconditioned by 90 minutes simulated ischaemia and 30 minutes re-oxygenation, 
prior to harvesting protein for fractionation and Western blotting. Figure 3-4 shows 
that, similar to PMA treatment, preconditioning causes a redistribution of PKC6 from 
cytosol to the triton-soluble particulate fraction. 
"NOW 41gM 4-PKC-8 
Figure 3-4: The effect of preconditioning on the 
intracellular localisation of PKC8. 
Myocytes were preconditioned with 90 minutes simulated 
ischaernia and 30 minutes re-oxygenation (+) before total 
cell protein was fractionated into cytosolic (C) and 
particulate (P) fractions. Western blotting with anti-PKC8 
antibodies, in two independent experiments (Panels A and 
B), showed that PKC6 is preferentially localised to the 
particulate fraction following preconditioning 
103 
Chapter 3 Role of PKC isoforms during preconditioning 
If relocalisation of endogenous PKC5 is responsible for its activation and contributes 
to the subsequent protection, then ectopically expressed active PKC8, which confers a 
similar level of protection to preconditioning, should exhibit this preferential 
localisation in the absence of preconditioning. 
3.2 Verification of plasmid DNA by endonuclease restriction digest 
PKC mutants, donated as a kind gift from PJ Parker, are encoded within the multiple 
cloning site (MCS) of a high efficiency expression plasmid (pCAGGS) (285). Prior to 
use, the appropriate expression plasmids where checked for their respective PKC 
coding sequences by endonuclease restriction digest. PKC8 cDNA was inserted into 
the expression plasmid pCAGGS at an EcoRI restriction site within the MCS. 
pCAGGS expression vector alone, or containing wild type or active PKC6 were 
digested with EcoRI to check for presence of the insert. Whilst EcoRI produced 2 
fragments of 4.5 and 2.9Kb in wild type PKC6 (Figure 3-5, lane 2) and active PKC8 
(Figure 3-5, lane 4), only a single fragment of 4.5Kb was found with expression 
plasmid alone (lane 5). The 4.5Kb fragment is linearised pCAGGS plasmid, whereas 
the 2.9Kb fragment corresponds to the size of full length PKC6. To check the 
orientation of PKC8 cDNA, plasmids were digested with HindIII, which cuts 500 
base pairs 3' of the EcoRI site, in which PKC was inserted, and at base pair 1250 in 
PKC5. If the insertion were in the correct orientation a fragment of 1.7Kb would be 
excised, whereas a 2.2Kb fragment would indicate a reverse orientation. As shown in 
Figure 3-5, digestion with Hind1II gave a 1.7Kb band in both wild type (lane 1) and 








Figure 3-5: Endonuclease restriction digest of 
pCAGGS-PKC expression plasmids. 
pCAGGS vectors containing wild type PKC5 (lanes I and 
2), constitutively active PKC8 (lanes 3 and 4) or no insert 
(lane 5) were cut with either HindIII (lanes I and 3) or 
EcoRl (lanes 2,4 and 5). EcoRl excises the whole PKC6 
coding sequence (2.9Kb), whereas HindIII cuts outside 
the MCS and within the PKC8 sequence, thus excising a 
1.7Kb band when the PKC6 coding region is in the 
correct orientation. The 2.9Kb fragment in lanes 2 and 4 
indicates the presence of a PKC insert, whereas the 1.7Kb 
fragments in lanes I and 3 confirm the PKC insertion is in 
the Y-5' orientation. 
3.3 Verification of DNA transfection/protein expression 
3.3.1 In HEK 293 cells 
Expression of PKC isoforms was first confirmed in HEK 293 cells, since DNA uptake 
and/or protein expression is more efficient in this cell line than in neonatal cardiac 
myocytes. 48 hours post-transfection with cationic liposomes, cells were harvested 
and protein samples Western blotted with anti-PKC6 antibodies. Overexpression of 
PKC6 can be seen in both wild type and active PKC8 transfected cells compared to 
the endogenous level of PKC5, detected in both empty vector transfected and 
untransfected cells (Figure 3-6). 
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Figure 3-6: Expression of PKC8 plasmids in HEK 293 
cells. 
HEK 293 cells were harvested 48 hours after transfection 
with either wild type PKC8 (lane 1), active PKC6 (lane 
2), vector alone (3) or vehicle (4). Constituent protein was 
Western blotted with anti-PKC6 antibodies. A clear 
overexpression of PKC6 can bee seen following 
transfection with both wild type and active PKC8. 
3.3.2 In neonatal rat ventricular myocytes 
Expression of PKC isoforms in HEK 293 cells does not guarantee expression within 
neonatal cardiac myocytes, because of differences in transfection efficiency and 
promoter activity between the two cell types. Initial experiments using a GFP reporter 
encoded within the pCAGGS plasmid indicated that liposome-mediated transfection 
was poor, with transfection efficiencies less than 5% (Figure 3-7, Panel A). In 
contrast, integrin-targeting peptides were shown to efficiently infect rat neonatal 
myocytes, with efficiencies up to 30% (Figure 3-7, Panel B). The increased efficiency 
is probably because integrin peptides utilize a more specific receptor-mediated 
method of transfection, as opposed to the non-specific endocytosis relied upon by 
cationic liposomes. Recent evidence however casts doubt over the use of receptor- 
mediated endocytosis, suggesting instead that the peptide may aid intracellular 
processing and transport to the nucleus (286). Using the integrin-targeting peptides, 
overexpression of PKC isoforms could be clearly detected 48 hours post-infection 
with wild type or active PKC6 (Figure 3-7, Panel C). 
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Figure 3-7: Efficiency of transfection in neonatal cardiac myocytes. 
48 hours post-transfection with pCAGGS-GFP, myocytes were visualised under UV light 
to determine expression of the GFP reporter. At his point myocytes were approximately 
80% confluent. Liposome-mediated transfection was reproducibly less efficient (Panel A) 
than integrin-targeting peptides (Panel B), with efficiencies of approximately 5 and 30% 
respectively. 48 hours after infection using integrin-targeting peptides cells were 
harvested and constituent protein probed with anti-PKC8 antibodies (Panel C). PKC6 is 
overexpressed to a similar extent in wild type- and active-PKC8 transfected cells. 
3.4 Translocation of ectopically expressed PKCS 
Myocytes were infected with wild type PKC6 or active PKC8 and, 48 hours-post 
transfection, subjected to 90 minutes simulated ischaemia and 30 minutes re- 
oxygenation. Thereafter cells were harvested and fractionated as before and Western 
blotted with anti-PKC6 antibodies. Wild type PKC6 appears equally distributed 
between cytosol and particulate fraction prior to preconditioning, but is localised 
mainly in the particulate after preconditioning (Figure 3-8, Panel A). This agrees with 
the findings for endogenous PKC8 seen in untransfected cells (Figure 3-4). Active 
PKC6 however, shows a similar distribution before preconditioning as seen with wild 
type PKC8 after preconditioning (Figure 3-8, Panel B). This suggests that active 
PKC8 is similarly localised/activated as endogenous PKC6 following 
preconditioning, which may represent a key protective signalling event common with 
both these treatments. After preconditioning in active PKC5 expressing cells, there is 
a further decrease in cytosolic PKC6, possible caused by the translocation of 
endogenous PKC8. 
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Figure 3-8: Intracellular localisation of wild type and 
active PKC8, prior to and following simulated 
preconditioning. 
Myocytes, infected with wild type (Panel A) or constitutively 
active PKC5 (Panel B), were fractionated into cytosolic (C) 
and particulate (P) fractions, before (-) and after (+) 
preconditioning. Panel A, Western blotting with anti-PKC8 
antibodies shows that wild type, although equally distributed 
before preconditioning, is selectively localised in the 
particulate following preconditioning. Panel B, however 
shows that, unlike wild type, active PKC5 is preferentially 
localised in the particulate fraction even in the absence of 
preconditioning. 
If PKC activation during preconditioning is responsible for subsequent protection, the 
identification of its downstream substrate(s) may provide new therapeutic targets. One 
kinase family implicated in preconditioning is the mitogen- activated protein kinases 
(MAPKs) (126). We therefore sought to examine their activity during preconditioning 
in isolated neonatal cardiac myocytes. 
3.5 Phosphorylation of MAPKs during preconditioning 
MAPKs are activated via dual phosphorylation on a Thr-Xxx-Tyr motif (to pThr- 
Xxx-pTyr). Antibodies specifically raised against this phosphorylated motif allow the 
direct assessment of MAPK activation. Three members of the MAPK family, p38, c- 
Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs) 
were assayed for phosphorylation during an acute preconditioning stimulus in 
neonatal myocytes. Protein, from cells harvested at various time points during re- 
oxygenation following 90 minutes simulated ischaernia (as indicated in Figure 3-2), 
was Western blotted and probed with the appropriate antibodies. No JNK 
phosphorylation could be detected at any time during re-oxygenation, although 
antibody affinity was confirmed using a positive control of UV treated cells 
(results 
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not shown). Both p38 and ERKI/2 were transiently phosphorylated during re- 
oxygenation, reaching a maximum after 10 minutes (Figure 3-9). 
025 
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Figure 3-9: Activation of MAPKs during re-oxygenation following 90 minutes 
simulated ischaernia. 
Cells were harvested at various time points (minutes) during the re-oxygenation phase of 
preconditioning. Constituent protein was probed for phosphorylated ERKI/2 (Panel Ai), 
ERK2 (Panel Aii), phosphorylated p38 (Panel Bi) or p38 (Panel Bii). Both ERKI/2 and p38 
become rapidly phosphorylated during re-oxygenation, reaching a maximum at 10 minutes 
and returning to baseline by 30 minutes. Total p38 and ERKI/2 levels remain constant 
throughout re-oxygenation. 
Having established the time point for maximal MAPK phosphorylation, we harvested 
cells at 10 minutes re-oxygenation following 90 minutes simulated ischaernia and 
probed constituent protein for p38 and ERKI/2 phosphorylation to quantify 
activation. Figure 3-10 shows that p38, ERKI and ERK2 all exhibit at least a 3-fold 
activation during the re-oxygenation phase of simulated preconditioning. 
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Figure 3-10: Activation of p38-MAPK and ERKI/2 during re-oxygenation following 90 minutes 
simulated ischaernia. 
Myocyte cell lysates were prepared from naYve cells (C) and from myocytes after 90 minutes simulated 
ischaernia and 10 minutes re-oxygenation (IP). Each pair of samples is from a different cardiocyte 
preparation exposed independently to simulated ischaernia and re-oxygenation. Samples were probed 
with dual phospho-specific MAPK antibodies for ERKI/2 (Panel Ai) and p38 (Panel Bi), or antibodies 
detecting total ERK2 (Panel Aii) and total p38 (Panel Bii). Panels A and B show that both p38 and 
ERKI/2 are activated during preconditioning. Panel C, the mean activation of p38, ERKI and ERK2 
during preconditioning as a ratio of that seen in naive cells. * p<0.01 v nalve control, n=5. 
4 DisCUSSION 
These results demonstrate that PKC5 relocates from the cytosol to the triton-soluble 
fraction during preconditioning, which may represent activation of this endogenous 
isoform. Ectopically expressed PKC6, rendered constitutively active via a deletion 
within its pseudosubstrate domain, localises preferentially to the triton-soluble 
fraction under basal conditions. Since this mutant PKC isoform protects against 
ischaernia it is tempting to suggest that phosphorylation of a substrate(s) in this 
cellular fraction leads to protection, which may also contribute to protection in 
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response to preconditioning. The mitogen- activated protein kinases (MAPKs) p38 and 
ERKI/2, which are possible downstream targets for PKC, are activated transiently 
during re-oxygenation following 90 minutes simulated ischaemia. 
4.1 Measurement of PKC isoform activation 
PKC activation during preconditioning is essential for protection, since inhibitors, 
given during preconditioning alone, block the subsequent protection (Chapter 1, 
section 3.2.3.2.2). PKC is a Ser/Thr kinase that directly phosphorylates substrates; 
therefore, the identification of isoform unique substrates should allow the 
quantification of isoform- specific PKC activity in vitro. Demonstrating specific PKC 
isoform activation directly has proved difficult. Unfortunately, all currently available 
PKC substrates demonstrate only limited specificity. Even the most specific 
substrates, such as the PKC-epsilon pseudosubstrate or PKC-alpha pseudosubstrate 
domains, which are present in the full length PKC isoforms and bind to their 
respective catalytic sites, are still phosphorylated by other isozymes (287,288). 
PKC isoform. activity has been measured using immunoprecipitated PKC isoforms to 
phosphorylate substrates in vitro. Using this approach Ping and coworkers 
demonstrated activation of PKCF, during preconditioning, although the activity of 
other isoforms was not assessed (289). Similarly, Kitikaze et al. utilized the 
differential requirement for cofactors to implicate a role for conventional PKC 
isoforms in protection, since preconditioning caused an increase in PKC activity only 
when calcium was present in the phosphorylation reaction (96). Whilst these 
techniques can be used to assess changes in activity of individual isoforms, 
comparisons between isozymes are difficult due to differences in antibody affinity 
and isotype abundance. Moreover, since this can only be performed in vitro, cofactors 
such as DAG and PS have to be included in the phosphorylation reactions, making 
extrapolations to cellular levels of activity imperfect. These and other technical 
limitations in the direct intracellular measurement of PKC isoform. activity have 
prompted preconditioning investigators to use translocation as a surrogate for PKC 
activation (83). 
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4.2 Translocation of PKC isoforms during preconditioning 
Downey's group first postulated that, "PKC translocation during brief episodes of 
ischaernia underlies the protective effect of ischaemic preconditioning" (101). This 
hypothesis has since received substantial support from independent groups (96,100, 
282,290-292). The activation of PKC8 in neonatal cardiac myocytes is known to 
protect against simulated ischaemia and re-oxygenation (221). To determine whether 
endogenous PKC8 was activated during preconditioning in this model, the 
translocation of this isoform was assessed following simulated ischaernic 
preconditioning. 
4.3 The measurement of PKC localisation 
The majority of studies that document translocation of PKC isofonns during 
preconditioning use subcellular fractionation followed by Western blotting with 
isoform-specific PKC antibodies (96,282-284,293), although immunofluorescence 
microscopy of heart sections has been used (100,294). To measure translocation of 
PKC8 in neonatal cardiac myocytes, cells were first lysed with a mild detergent, 
digitonin, which is sufficient to disrupt the sarcolemmal membrane and release 
cytoplasmic proteins into the supernatant (cytosolic fraction). The remaining insoluble 
pellet is then washed with buffer containing I% (v/v) triton X- 100, which solubilises 
membrane- associated proteins, nuclei and filaments. When PKC is activated and 
associated with the membrane, through interactions with DAG and PS, it is only 
soluble in the presence of triton (particulate fraction). This is confirmed by PMA 
treatment, which causes the redistribution of cytosolic PKC8 to the particulate 
fraction (Figure 3-3). A similar translocation of PKC8 is detected following ischaemic 
preconditioning, suggesting this isoform is also activated following this treatment 
(Figure 3-4). 
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4.4 The localisation of mutant PKC isoforms 
A mutant PKC8, rendered constitutively active by a deletion within its 
pseudosubstrate domain, is able to protect myocytes against ischaemia (14). A 
problem levelled at this approach is the uncertain relevance to physiological PKC8 
activation. For example, a key step in the activation of endogenous PKC is the 
relocalisation to the membrane where, upon activation by pseudosubstrate domain 
removal, it is localised with common downstream substrates. Mutant PKC8 however, 
due to the absence of an inhibitory pseudosubstrate domain, does not require 
relocalisation for activation. It is questionable therefore whether mutant PKC6 
activates the same membrane-localised substrates. By examining the localisation of 
ectopically expressed PKC8, we observed a high level of "active" PKC8 in the 
membrane prior to preconditioning. This suggests that in the active conformation 
PKC8 still preferentially relocates from the cytosol to the membrane. This is 
consistent with the RACK theory for PKC activation proposed by Mochly-Rosen 
(295). This hypothesis proposes that receptors (termed RACKs), present on the inner 
surface of the membrane, preferential bind PKC in its active conformation. The 
selectivity for the active form originates from a RACK binding site in the C2 domain, 
which is concealed in the inactive closed conformation, but exposed by the 
conformational change that accompanies PKC activation (see Figure 1-3, page 40). It 
is likely that this site is already exposed in constitutively active PKC8, which 
promotes receptor interaction and membrane localisation in the absence of 
stimulation. 
4.5 Mitogen-activated protein kinase activation during preconditioning 
Activation of the mitogen-activated protein kinase (MAPK) family has been reported 
following preconditioning (124). Moreover, this MAPK phosphorylation has been 
attributed to prior activation of PKC (223,296). We therefore wanted to quantify the 
level of MAPK activation during preconditioning in isolated neonatal cardiac 
myocytes. No significant phosphorylation of any MAPK family members was seen 
during 90 minutes simulated ischaemia (results not shown), however transient 
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phosphorylation of both p38- and ERKI/2-MAPK was seen during the 30 minutes re- 
oxygenation following ischaemia (Figure 3-9). This activation, which was represented 
by at least a 3-fold increase in dual phosphorylation, was maximal for p38 and 
ERKI/2 after 10 minutes re-oxygenation (Figure 3-10). 
4.6 Critique of methods 
The fractionation method described within this chapter was modified from a protocol 
previously used to assess PKC translocation during preconditioning is isolated rabbit 
cardiomyocytes (293). Whilst sufficient for assessing translocation away from the 
cytosol, this method does not clearly define the exact intracellular location of PKC. 
PKC does not necessarily need to be localised at the sarcolemmal membrane for 
activation, since the lipid membranes of subcellular organelles, such as the 
mitochondria, will be sufficient to activate PKC. Using immunofluorescent 
microscopy with anti-PKC8 and -PKCF, antibodies, Mitchell et al. showed that PKC8 
translocates to the sarcolemmal membrane and PKCF- to the nuclei following brief 
ischaernia in the rat (100). Using a similar technique, and the same model, Wang et al. 
showed that PKC8 is localised to mitochondria and intercalated discs following 
diazoxide treatment, which protects against ischaemic injury presumably by the 
opening of KATP channels (292), a mechanism that has also been implicated in 
ischaernic preconditioning (155). A better understanding of PKC8 
compartmentalisation during preconditioning may aid the discovery of co-localised 
downstream substrates. Furthermore, it would be interesting to compare the exact 
location of constitutively active PKC8 with reference to physiologically activated 
PKC8 during preconditioning. 
As discussed earlier, it is believed that PKC translocation is required for PKC 
activation, this does not however imply that the translocation of PKC is synonymous 
with activation. PKC binds to a large number of proteins,, most of which display 
isoform specificity. These interactions probably significantly contribute to the 
differential effects of various PKC isozymes (297). Proteins that bind PKC are classed 
according to their preference for activation state. Whilst some of the binding proteins 
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have been shown to preferentially bind activated PKC (receptors for activated C- 
kinase or RACKs (104)), others specifically bind, and perhaps stabilise, inactive 
isoforms (receptors for inactive C-kinase or RICKs (105)), whilst yet other proteins, 
such as calveolin, interact with PKC and cause inhibition of activity (298). To add 
further complexity, although some binding proteins act as substrates (78), others serve 
to cluster signalling molecules by acting as scaffold proteins (78). Therefore, 
translocation cannot only be associated with activation, but also inactivation of PKC- 
Ideally, PKC8 should be immunoprecipitated from the particulate fraction following 
preconditioning and assayed for activity, although the necessary inclusion of DAG 
and PS in phosphorylation reactions further complicates the interpretation of activity 
assays. 
To unequivocally demonstrate PKC8 translocation following preconditioning, 
multiple western blots should be performed on independent samples and the band 
densities quantified by densitometry. This would give an indication of the level of 
PKC translocation and provide statistical data on PKC8 localisation. 
4.7 Conclusions 
Following ischaemic Preconditioning, and immediately prior to lethal ischaemia in 
isolated neonatal cardiac myocytes, PKC8 is preferentially localised to the particulate 
fraction, which may represent increased activity of this novel PKC isoform. It is 
tempting to suggest that this activation/translocation contributes to protection because 
expressing a constitutively active PKC8 mutant protects to a similar extent, and cause 
a similar translocation of PKC8, in the absence of preconditioning. Selective 
inhibition of this isoform during preconditioning would however be required to 
confirm its role during preconditioning in this model. 
Both p38- and ERKI/2-MAPK are activated during preconditioning in this model. 
The MAPK phosphorylation, seen during re-oxygenation following 90 minutes 
simulated ischaemiaý maybe a direct or indirect consequence of PKC activation. It 
would be interesting to determine the time-course of PKC translocation during 
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preconditioning to see if this correlates with the time of MAPK phosphorylation. 
Furthermore, subcellular fractionation of myocytes after 10 minutes re-oxygenation 
would reveal the proximity of phosphorylated MAPK to PKC. 
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1 INTRODUCTION 
In the previous chapter we demonstrated activation of PKC8, p38-MAPK and 
ERK1/2-MAPK during preconditioning in neonatal cardiocytes. Previous work in our 
laboratory has already demonstrated protection in response to PKC8 activation. 
Therefore the immediate questions to address were: 
e Does PKC8 activation protect through activation of MAPKs? 
9 Does the activation of PKC8 during preconditioning contribute to protection by 
MAPK activation? 
Therefore we examined the interplay between PKC and MAPKs during simulated 
preconditioning in neonatal cardiocytes 
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2 SPECIFIC METHODS 
2.1 Experimental protocols 
A 90 min 
Role of MAPKs during preconditioning 
Chelerythrine (10[tM) or Staurosporine (IýtM) 
B 
i Lethal Ischaemia I 
! NEW 
MKK6bE (48 hrs) 
SB 203580 (10ýtM) 
0 Simulated ischaemia 
0 Re-oxygenation 
A Protein samples taken 
CK and LDH MTT 
D 6 hours 
SB 203580 (IOgM) 
Figure 4-1: Schematical representation of experimental protocols. 
Panel A, cells were harvested 10 minutes into re-oxygenation following 90 minutes simulated 
ischaernia in the presence of chelerythrine (I OýM) or staurosporine (I ptM), to assess the contribution of 
PKC to MAPK activation during preconditioning. Panel B, cells were lysed and protein prepared at 
various time-points during ischaernia to assess MAPK activation. Panel C, the inhibition of p38 
activity by SB203580 was assayed in cells transfected with constitutively active MKK6b. Cells were 
incubated with 10ýiM SB203580 for I hour or left untreated, before harvesting and Western blotting of 
constituent protein with anti-phospho-HSP27 antibodies. Panel D, the role of p38 in ischaernic injury 
was determined by incubation with SB203580 (10ýM) throughout ischaernia. Enzyme release was 
measured immediately after lethal ischaernia and MTT bioreduction after a further 2 hours re- 
oxygenation. 
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2.2 Western blotting conditions 
All samples for Western blotting were run on 10% polyacrylamide gels, following 
coomassie staining of identically loaded gels to confirm unifonn protein loading. 
Blots were sequentially probed with either murine monoclonal antibodies specific for 
ERK2 (Santa Cruz Biotechnology, Santa Cruz, USA) and a peroxidase-conjugated 
rabbit anti-mouse IgG secondary antibody (DAKO A/S, Denmark), or rabbit 
polyclonal antibodies specific for p38, phospho-p38 or phospho-ERKI/2 (Cell 
Signalling, Hitchin, UK) and a peroxidase-conjugated swine anti-rabbit IgG 
secondary antibody (DAKO A/S, Denmark). Blots used to assay p38 inhibition with 
SB203580 were probed with murine monoclonal antibodies specific for phospho 
(ser82)-HSP27 at 1: 40 dilution (kindly donate as a gift from Dr RA Quinlan), before 
exposure to peroxidase-conjugated rabbit anti-mouse IgG secondary antibody (DAKO 
A/S, Denmark). Unless otherwise indicated, all primary antibodies were incubated at 
1: 1000 overnight at 4'C, prior to incubation with secondary antibodies at a 1: 2500 
dilution for 2 hours at room temperature. 
2.3 Statistical analysis 
All values are expressed as mean±SEM. Data for individual treatments were collected 
from no more than two wells from each experimental preparation. The "n" numbers 
under "results" relate to the number of wells from which data were obtained. For each 
treatment mean values were pooled to allow statistical comparisons. Statistical 
comparisons between groups were performed by one-way analysis of variance 
(ANOVA), followed where appropriate by the Tukey-Kramer test for pair-wise 
comparisons. All analyses were performed using Statview version 4.0 statistical 
package (Abacus Concepts Inc., Berkeley, CA). A probability value :! -ý 0.05 was 
considered significant. 
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3 RESULTS 
3.1 Is MAPK activation downstream of PKC? 
The specific phosphorylation of MAPKs observed during re-oxygenation (Figure 
3- 10) may be a consequence of PKC activation, since it has been reported previously 
that PKC is activated at the onset of reperfusion (291). If this were true in our model, 
and the isoform. involved is PKC6, then we should observe a comparable level of 
MAPK phosphorylation in cells overexpressing active PKC8, even in the absence of 
preconditioning ischaemia. Therefore to test this hypothesis we transfected myocytes 
with constitutively active PKC5, in an attempt to mimic the pattern of p38 and 
ERKI/2 phosphorylation seen following 90 minutes simulated ischaemia and 10 
minutes re-oxygenation. 
3.1.1 Effect of active PKC expression on MAPK activation 
Myocytes were transfected with the eukaryotic expression plasmid pCAGGS 
encoding either wild type or active PKC6. After 48 hours, myocytes were either 
harvested, to assess basal MAPK phosphorylation, or subjected to 90 minutes 
simulated ischaernia and 10 minutes re-oxygenation to examine preconditioning- 
induced MAPK activation. It is apparent from Figure 4-2 that overexpression of 
active PKC8 has no effect on basal ERKI/2 phosphorylation compared to untreated or 
empty vector transfected controls (Panel Ai). This suggests that PKC8 activation does 
not lead to ERKI/2 phosphorylation. To our surprise however, preconditioning- 
induced ERKI/2 phosphorylation is completely abolished in the presence of active 
PKC8. To test whether this was an effect on ERKI/2 expression levels or a selective 
effect on phosphorylation, identical samples were probed with an ERK2 antibody 
non-selective for active or inactive forms. The total levels of ERK2 between 
treatments remain unchanged, indicating the decreased activation is not due to a 
downregulation of MAPK, but rather an effect on its phosphorylation (Panel Aii). 
Looking at p38 activation in the same samples we observed a similar effect where, 
although p38 exhibits a higher basal activation in cells expressing active PKC8, once 
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again the increase in p38 phosphorylation associated with preconditioning is 
completely abolished (see Figure 4-2: Panel Bi). 
l= 
Q 
9. M 1 > N»w 
75 
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Figure 4-2: Activation of ERKI/2 and p38-MAPK after preconditioning in myocytes 
overexpressing PKC8. 
Western blots probed with anti-phospho-ERKI/2 (Panel Ai), anti-ERK2 (Panel Aii), anti- 
phospho-p38 (Panel Bi), or anti-p38 (Panel Bii) antibodies. Constituent proteins in both 
panels were derived from the same experimental groups. Naive cells (C) were compared to 
preconditioned (IP) in untreated cardiocytes, cells transfected with expression plasn-lid 
containing an empty multiple cloning site (null vector), encoding wild type PKC6 (WT- 
PKC5) or constitutively active PKC8 (Active-PKC6). Panel A, maximal ERKI/2-MAPK 
activation was assessed, in cell lysates harvested after 10 minutes re-oxygenation following 
90 minutes simulated ischaen-iia, using dual pho spho- specific ERKI/2 antibodies (i). Total 
ERK2 levels were detected using a monoclonal anti-ERK2 antibody (ii). Panel B, p38 
activation was detected using pho spho- specific p38 antibodies (i) and total p38 was detected 
using anti-p38 antibodies (ii). For both p38 and ERKI/2-MAPK, the increase in 
phosphorylation induced by preconditioning is abolished by active PKC8 expression. 
These results suggested that, rather than activating, PKC may actually inhibit MAPK 
activation during preconditioning, because increasing PKC6 activity lessens MAPK 
phosphorylation. To test whether this was an isoform- specific effect, the experiment 
was repeated using wild type or constitutively active PKCC, the other PKC isoform 
implicated in preconditioning (125). Active PKCF- decreased both p38 and ERKI/2 
activation during preconditioning to a similar extent as seen with PKC5 (Figure 4-3). 
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In summary, two PKC isoforms implicated in preconditioning are able to inhibit 
MAPK activation during simulated ischaemia and re-oxygenation. 
Control Vector alone WT-PKC-F, Act-PKC-F, 
C IP C IP C 
-IP 
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Figure 4-3: Activation of ERKI/2 and p38-NIAPK after preconditioning in myocytes 
overexpressing PKCF, 
The phosphorylation of ERKI/2 (Panel A) and p38 (Panel B) were assessed, before (C) and after (IP) 
ischaernic preconditioning, in untreated cells or cells transfected with expression vector alone, wild 
type PKCF- or constitutively active PKCF-. Panel A, ERK1/2 is phosphorylated during preconditioning, 
but not in the presence of active PKCF-. Panel B, p38 is phosphorylated during preconditioning, but this 
activation is less marked in cells expressing wild type or active PKCE. 
It is possible that the effect on MAPK is a consequence of PKC overexpression, 
which is not observed under physiological conditions. To test this possibility the 
activation of MAPK was examined during preconditioning in the presence of PKC 
inhibitors. If PKC were active endogenously during preconditioning then we would 
expect the activation of MAPK to be limited and thus increased by PKC inhibition. 
3.1.2 Effect of PKC inhibition on MAPK activation 
Two separate PKC inhibitors were used, chelerythrine and staurosporine (at 
previously reported concentrations (221)), since they act differently by binding to the 
regulatory or catalytic domains respectively (Sir P Cohen, personal communication). 
Inhibitors were given 15 minutes prior to, and throughout preconditioning, before 
cells were harvested after 10 minutes re-oxygenation and constituent protein subjected 
to Western blotting to analyse both p38 and ERKI/2 phosphorylation. In the presence 
of either inhibitor during preconditioning, p38 activation during re-oxygenation was 
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enhanced, although ERKI/2 phosphorylation was unchanged (Figure 4-4, Panels Ai 
and Bi). Blots probed with antibodies detecting total p38 or ERKI/2 verified this was 
a specific effect on phosphorylation, as total protein levels remain unchanged (Figure 
4-4, Panels Aii and Bii). These results confirmed that PKC is able to suppress the 
activation of p38-MAPK during preconditioning. 
Control Staur. Chel. 
c IP c IP c IP 
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Figure 4-4: ERKI/2 and p38-MAPK activation during preconditioning in the presence of PKC 
inhibitors. 
Myocytes were untreated (C) or preconditioned (IP) in the presence or absence of the PKC inhibitors 
chelerythrine (10[tM) and staurosporine (I[M). After 10 minutes re-oxygenation, ERKI/2 (Panel A) 
and p38 (Panel B) phosphorylation was assessed, as before using dual -pho spho- specific antibodies. 
Panel A, The phosphorylation (i) and total levels (ii) of ERKI/2 are unaltered by PKC inhibition. 
Panel B, p38 phosphorylation during preconditioning is enhanced in the presence of either 
chelerythrine (chel. ) or staurosporine (staur. ). 
These data did not support our original hypothesis that PKC8 protects by causing the 
same activation of MAPKs that occurs with preconditioning. In contrast, and 
paradoxically, these data suggest that PKC8 (and possibly other PKC isoforms, 
including PKCF-) inhibits MAPK activation in response to simulated ischaemia/re- 
oxygenation. It is possible that this unexpected negative regulation may be the 
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mechanism through with PKC8 protects against lethal ischaemia (221). This 
alternative hypothesis is consistent with reports examining the role of p38 during 
ischaemia in the absence of preconditioning, which show that inhibition is protective 
(131,133). However for PKC8 to protect via this mechanism the same inhibitory 
effect on MAPKs must occur during prolonged lethal ischaemia. Therefore we 
delineated the MAPK pathways that were activated by simulated ischaemia alone. 
3.2 MAPK activation during lethal simulated ischaemia 
To quantify the level of MAPK activation during ischaemia, cardiocytes were 
subjected to varying duration's of simulated ischaemia before cells were harvested 
and constituent proteins probed with anti-phospho-p38 and phospho-ERKI/2 
antibodies (see Figure 4-5). In agreement with other recent reports (131,299), we 
found that during ischaemia p38 exhibits a prolonged activation, which is maximal 
after 2.5 hours ischaemia (Panel B). In contrast, phospho-ERKI/2 is inhibited below 
basal levels for the entire duration of ischaemia (Panel A). 
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Ischaemic duration (hours) 
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Figure 4-5: Time course of ERK1/2 and p38-MAPK activation during prolonged simulated 
ischaernia in nalive cardiocytes. 
Cardiocytes were subjected to varying duration's of simulated ischaernia (0-4 hours) before cells were 
lysed for Western blot analysis. Constituent proteins were probed with dual -pho spho -specific ERKI/2 
antibodies to assess ERKI/2 activation (Panel Ai), or anti-ERK2 antibodies to examine total ERK2 
levels (Panel Aii). Identical samples were also probed with anti-dual-phospho-p38 antibodies to detect 
p38 activation (Panel Bi), or anti-p38 antibodies to assess total p38 levels (Panel Bii). Panel A, 
ERKI/2 become rapidly dephosphorylated during ischaen-tia with no change in total ERK levels. Panel 
B, p38 is phosphorylated 2 hours into ischaen-tia and remains activated for a further 2 hours. 
This suppression of ERKI/2 during ischaemia eliminates the possibility that PKC6 
protects through negative regulation of ERKI/2 phosphorylation. Therefore we 
wished to examine the result of PKC6 overexpression on the activation of p38 during 
simulated ischaemia. 
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3.3 Modulation of p38 activation in protected cells 
3.3.1 p38 activation during ischaemia in PKC8transfected cells 
Isolated myocytes were either cultured under normal conditions (untreated) or 
transfected with plasmids encoding wild type- or active-PKC8.48 hours post- 
transfection, cardiocytes were subjected to 2.5 hours simulated ischaernia and 
immediately harvested for Western blot analysis. Constituent proteins were probed 
with anti-p38 or anti-phospho-p38 antibodies to detect the effect of PKC6 
overexpression on either p38 induction or activation (see Figure 4-6). Overexpression 
of wild type PKC6 increased p38 phosphorylation during ischaernia, although 
comparable results with empty vector alone suggest this is not a consequence of 
PKC6 (results not shown). Interestingly however, transfection of active PKC6 
significantly attenuated the ischaernia-induced p38 activation, although there was no 





Figure 4-6: Effect of active PKC5 expression on p38 
phosphorylation during ischaernia. 
Untreated myocytes (Nalve cells) and cells transfected 
with wild type PKC5 (WT-PKC6) or active PKC5 (Act- 
PKC8) were subjected to 2.5 hours simulated ischaernia 
(+) and harvested for Western blot analysis to detect p38 
dual phosphorylation. p38 activation was greater during 
ischaernia in untreated or wild type PKC6 transfected 
cells, compared to myocytes expressing active-PKC6. 
Total p38 levels in the same cells were unchanged. 
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We have shown previously that cells expressing active PKC6 are protected against 
cell death during ischaernia (221) and, as we show here, PKC5 activation causes an 
inhibition of p38 phosphorylation. Since preconditioning also protects by activating 
PKC in this model, we sought to compare its effect on p38 activation by examining 
ischaernia-induced phosphorylation in naYve and preconditioned cells. 
3.3.2 p38 activation during ischaemia following preconditioning 
Preconditioned cardiocytes and untreated controls were subjected to 2.5 hours 
ischaernia to maximally activate p38. Thereafter p38 phosphorylation was assessed, as 
before, by immunoblotting with anti-phospho-p38 antibodies. Figure 4-7 shows that, 
akin to active PKC8 overexpression, preconditioning consistently inhibited p38 
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Figure 4-7: Effect of ischaernic preconditioning (IEP) on the activation of p38- 
MAPK during ischaernia. 
Panel Ai, Western blot probed with anti-phospho-p38 to detect p38 MAPK 
activation. Lysates were prepared from untreated cells or cells after 2.5 hours 
ischaen-tia with and without prior preconditioning. Panel Aii, total p38 levels were 
detected in the same cells with anti-p38 antibodies. Panel B, mean p38 activation 
compared to untreated controls (n=4). Simulated ischaemia causes a significant 
activation of p38, which is inhibited in cells preconditioned immediately prior to 
ischaemia. **p<0.01, p38 activation during ischaemia v non-ischaernic/untreated. 
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The negative regulation of p38 phosphorylation during ischaemia is therefore 
associated with the cardioprotective effects of both preconditioning and active PKC8 
overexpression. Following both these cardioprotective treatments however, as well as 
reduced p38 activation, ischaemia and its consequences are also diminished. 
Therefore, on the basis of these results alone, it is not possible to ascertain whether 
the inhibition is a cause, or simply a result, of protection. Therefore, to define the role 
of p38 on cell viability following ischaemia we used pharmacological inhibition of 
p38 in an attempt to mimic protection afforded by preconditioning/PKC activation. 
3.4 Consequence of p38 activation during ischaemia 
We wished to examine the role of p38 during ischaemia by inhibiting activity with 
SB203580, which reversibly binds to the ATP binding site (300). SB203580 therefore 
prevents downstream substrate phosphorylation and does not affect the dual- 
phosphorylation of p38 itself. To examine whether SB203580 does indeed block p38 
activity in our model we forced p38 phosphorylation, by expression of a constitutively 
active MKK6b mutant (an upstream activator of p38: see Chapter 5), in control and 
wild type p38(x transfected cells. 48 hours following transfection, cardiocytes were 
incubated with lOgM SB203580 or vehicle for I hour at 37'C. Protein was then 
harvested and Western blotted with anti-phospho-p38 or anti-phospho (ser82)-HSP27 
antibodies (Figure 4-8). HSP27 is phosphorylated on ser82 
by MAPKAPK-2, a 
downstream substrate of p38, therefore it can be used as an assay for p38 activity. 
Figure 4-8 shows that MKK6bE expression causes a strong phosphorylation of p38 
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Figure 4-8: An assay for SB203580-induced p38 inhibition. 
Cardiocytes, infected with MKK6bE +/- WTp38(x, were treated with 
SB203580 (1%tM) or vehicle for I hour. Cardiocytes were then harvested 
and Western blotted sequentially with anti-phospho-p38 and anti-phospho- 
HSP27 antibodies. Western blots demonstrate HSP27 phosphorylation only 
in the absence of SB203580. 
Since SB203580 completely inhibits p38 activity, we next sought to examine its effect 
on ischaemic injury. We therefore subjected cells to 6 hours simulated ischaemia in 
the presence and absence of I%tM SB203580. Using two separate endpoints of 
creatine kinase (CK) and lactate dehydrogenase release (LDH) release to assess cell 
injury, and by measuring cell viability with MTT bioreduction, significant protection 
is observed following p38 inhibition (Figure 4-9). Therefore, on the basis of these 
results alone, p38 activation during ischaemia is detrimental to myocyte survival. 
Hence the attenuation of p38-MAPK activation by PKC6 overexpression and 
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Figure 4-9: Cell viability after lethal ischaetnia in the presence of SB203580. 
Panel A, total CK and LDH released into ischaentia buffer during 6 hours of simulated ischaemia. 
Myocytes are injured less during ischaernia if p38 activation is inhibited. Panel B, cell viability was 
measured by MTT bioreduction within monolayers after 6 hours simulated ischaernia and 2 hours re- 
oxygenation. Myocytes are significantly more viable following ischaernia and re-oxygenation in the 
presence of S13203580. Injury in the presence of SB203580 is expressed as a percentage of injury in the 
absence of S13203580. Viability in cells treated with SB203580 alone for 6 hours (without ischaerrda) 
was equivalent to that observed in untreated cells (results not shown). All p values are for comparisons 
between ischaernia in the presence and absence of S13203580. *p<0.05, **p<0.001, n=20. 
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A better understanding of the mechanism by which PKC activation or preconditioning 
inhibit p38 activation may enable inhibition of p38, and resulting protection, without 
the need for PKC activation/preconditioning. We therefore attempted to delineate the 
basis for p38 inhibition by PKC8 and preconditioning. 
3.5 Cause of p38 inhibition in protected cells 
3.5.1 A roleforprotein kinase B 
Protein kinase B (PKB) has previously been shown to inhibit p38-MAPK activation in 
response to UV stimulation (301). Although no studies document PKB activation by 
PKC, its enhanced phosphorylation has been observed during preconditioning (302). 
We examined the activation of PKB in cells overexpressing active PKC5.48 hours 
after plasmid transfection, cells were harvested and Western blotted with anti- 
phospho-PKB antibodies. Immunoblots showed that, although a basal 
phosphorylation could be detected, this did not increase in the presence of wild type 
or active PKC8 (results not shown). 
3.5.2 MKP induction 
MAPK activation is eventually "turned off' by a group of proteins termed mitogen- 
activated protein kinase phosphatases (MKPs) (see Chapter 1, section 3.2.4.1.4). This 
negative regulatory mechanism is activated or induced by MAPK activation, which is 
thought to account for the transient nature of their activation. We have already shown 
that p38 becomes transiently phosphorylated during re-oxygenation following 90 
minutes simulated ischaemia (Figure 3-9). It is possible that this MAPK activation 
induces/activates a MAPK phosphatase. In this sense, the phosphatase would then be 
capable of limiting p38 activation during subsequent ischaernia. We therefore 
examined the levels of MKP-1 either after active PKC8 expression or 2.5 hours 
following preconditioning, to determine whether activating PKC6 or preconditioning 
were capable of upregulating MKP protein. Again these data proved negative as no 
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detectable MKP-I protein was seen in control or treated cells, although antibody 
affinity was confirmed with protein lysates for MKP-I transfected cells (Dr Richard 
Heads, unpublished observations). 
4 DisCUSSION 
The studies described within this chapter investigate the relationship between 
preconditioning, PKC and MAPKs in primary cultures of neonatal cardiocytes. The 
activation of p38- and ERKI/2-MAPK during preconditioning is not downstream of 
PKC. Paradoxically, MAPK phosphorylation during preconditioning is inhibited by 
PKC activation and potentiated by PKC inhibition. A similar relationship exists 
during lethal ischaernia in this model following preconditioning or PKC activation. 
More specifically, p38-MAPK undergoes a period of prolonged phosphorylation that 
is inhibited by preconditioning and the expression of active PKC8, both of which 
enhance myocyte survival. Inhibition of p38 activation with SB203580 also gives rise 
to protection. These findings suggest that p38-MAPK modulates cardiocyte survival 
during simulated ischaemia, which may represent a new and specific therapeutic 
target. 
4.1 The interplay between PKC and p38 during preconditioning and ischaemia 
Previous reports suggest that activation of p38 during preconditioning is responsible 
for the resulting protection (126,130,303). These conclusions were based on the 
ability of SB203580 to inhibit protection when given during preconditioning. Since 
PKC activation is also protective, we wished to examine whether this is associated 
with p38 activation. If p38 phosphorylation occurs downstream of PKC then we 
would expect overexpression of active PKC8, which we have shown protects 
myocytes during ischaemia (221), to activate the p38 pathway. Our findings do not 
support this hypothesis, since p38 activation was inhibited, rather than activated 
by 
active PKC8 (Figure 4-2). Moreover expression of active PKCc, another PKC isoform 
implicated in preconditioning (107), also inhibits p38 activation during simulated 
preconditioning (Figure 4-3). These results were confirmed by the inhibition of PKC 
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with chelerythrine and staurosporine, which conversely increased p38-MAPK 
activation, although no effect was seen on ERKI/2 phosphorylation (Figure 4-4). 
These inhibitor results should be interpreted cautiously however, because 
staurosporine is a relatively non-specific kinase inhibitor and chelerythrine has been 
shown to increase p38 activation independently of PKC inhibition (304). 
The inhibition of p38-MAPK by PKC has been reported in other models. In neuronal 
cells, PMA protects against apoptosis induced by serum withdrawal and prevents the 
activation of p38-MAPK. Moreover, Preventing p38 activity with SB203580 also 
protected these cells against apoptosis (305). Conversely, in human glioma cells, 
inhibition of p38 with calphostin C induces apoptosis and p38 activation (306). 
Perhaps the greatest analogies can be made with a study by Jun and co-workers, 
where p38 activation and apoptosis were induced in murine macrophages by the NO 
donor sodium nitroprusside (SNP). In this model, the stable expression of PKC8 was 
sufficient to reverse both apoptosis and p38 activation (307). 
Regardless of the mechanism of MAPK inhibition, these findings support a protective 
role for PKC activation during lethal simulated ischaemia, since all studies addressing 
the role of p38 during ischaemia, in the absence of preconditioning, demonstrate that 
activation is detrimental, with SB203580 decreasing infarct size and enhancing post- 
ischaemic functional recovery (131,133). 
4.2 MAPK activation during ischaemia in neonatal cardiac myocytes 
ERKI/2 and p38-MAPK were differentially activated during ischaemia, since 
ERKI/2 were inhibited below basal levels throughout lethal simulated ischaemia, 
whereas p38-MAPK exhibited a prolonged period of phosphorylation. This is in 
agreement with other studies in similar models (131,299). Also in agreement is the 
protection that accompanies p38 inhibition with SB203580. These data suggest that 
p38 activation at least contributes to injury during ischaernia. The mechanism by 
which p38 promotes injury is unknown, although its inhibition has been shown to 
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attenuate apoptosis (132) and tumour necrosis factor alpha (TNF(x) (308) release from 
cardiornyocytes. 
4.2.1 Induction of apoptosis 
Programmed cell death, or apoptosis, differs from necrosis in that it does not evoke an 
inflammatory response due to the maintenance of sarcolemmal integrity. Instead, the 
cells are removed by phagocytosis from either neighbouring cells or macrophages. 
Following myocardial infarction in humans a significant number of cells undergoing 
apoptosis were detected using immunohistochemical staining to define in detail the 
histology and cytology of the apoptotic areas (177). In fact, the large number of 
apoptotic bodies lying free in the extracellular space suggested that the phagocytic 
capacity was overwhelmed, which may result in a deviation from apoptosis to 
necrosis. If this is the case, it is difficult to accurately assess the extent of apoptosis 
because cells that appear necrotic may simply represent a late stage of apoptosis. 
Nevertheless, it is likely that apoptosis at least contributes to injury following and/or 
during ischaernia in cardiac myocytes (see Chapter 1, section 3.3.2). 
p38-MAPK activation has been shown to be promote apoptosis in a number of cell 
types (117,309-311), including cardiac myocytes (312). p38 activation has been 
linked to apoptosis through a number of signalling pathways, which will be discussed 
in detail below. 
4.2.1.1 p53 
p38 causes the phosphorylation of the pro-apoptotic gene p53 on serine 389 (313, 
314) and serine 33 (315), which stimulates the functional activity of this enzyme. In 
neonatal rat cardiac myocytes, p53 is activated by hypoxia, and artificially increasing 
activity by p53 overexpression promotes cardiomyocyte, but not fibroblast, apoptosis 
(316). Furthermore, in the isolated rat heart p53 protein is upregulated during 
reperfusion following regional ischaernia (317), although it should 
be noted that 
apoptosis following hypoxia or global ischaemia is unaltered in myocytes, and 
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Langendorff-perfused hearts, from p53 knockout mice (318). Therefore, there is no 
doubt that p53 activation promotes apoptosis, and it is possible that p53 activation 
occurs in the heart during ischaemia/reperfusion injury. The effect of ischaemic 
preconditioning on p53 activation has not been addressed in the heart, but the 
activation of p53 and its target genes during forebrain ischaemia in the rat is markedly 
inhibited by prior ischaemic preconditioning (319). This parallels the activation of 
p38 in our model, which is activated during ischaemia but inhibited by prior 
preconditioning. Therefore the role of p53 during ischaemia/reperfusion in the heart is 
controversial, however the possibility that p38 promotes injury through p53 activation 
warrants investigation. 
4.2.1.2 Signal transducers and activators of transcription (STATs) 
p38-MAPK activity is required for the serine phosphorylation of signal transducer and 
activator of transcription-I (STAT-1) in response to a variety of cytokines including 
interferon-(x, P, and y (EFN-(x/p/y) (320,321), and interleukin-2 and 12 (EL-2/12) 
(322). This serine phosphorylation leads to STAT-I activation and apoptosis in a 
variety of models (320,323), including rat neonatal cardiac myocytes (324). 
Moreover, this has physiological relevance to ischaemia, because overexpression of 
STAT-I or depletion of STAT-I with antisense oligonucleotides augments or 
attenuates ischaemia-induced cell death respectively (324). Although this study uses a 
similar model of prolonged simulated ischaemia in neonatal cardiac myocytes, the 
exact time of STAT-I phosphorylation was not addressed. Therefore, it would be 
interesting to assess STAT-I phosphorylation throughout prolonged ischaernia to 
ascertain whether it shadows p38 phosphorylation, and more importantly, whether it 
is inhibited by SB203580. 
4.2.1.3 Cytochrome C 
Ultraviolet B (UVB) radiation causes sustained activation of p38 and apoptosis in 
HaCaT cells (321). In this model, p38 promotes apoptosis by mediating the release of 
cytochrome C into the cytosol, because inhibition of p38 prevented apoptosis and 
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cytochrome C release from mitochondria. During ischaemia/hypoxia in adult 
ventricular myocytes, cytochrome C release has been detected in combination with 
apoptosis (325). Moreover, inhibition of cytochrome C release is associated with the 
anti-apoptotic action of ARC (an anti-apoptotic protein that is expressed 
predominantly in heart and skeletal muscle) in a heart derived cell line (H9c2), 
implying that cytochrome C release maybe a cause rather than a consequence of 
apoptosis (326). Again, the role of p38 in mediating the release of cytochrome C 
during ischaernia should be addressed. Interestingly, the fall in ATP levels during 
hypoxia has been linked to the translocation of Bax to the mitochondria and the 
subsequent release of cytochrome C (327). This is a potential mechanism for p38- 
mediated cytochrome C release, since p38 promotes Bax translocation to the 
mitochondria during nitric oxide-mediated apoptosis in neurons (328). 
4.2.2 Tumour necrosisfactor 
Tumour necrosis factor alpha (TNF(x) is released from the heart following ischaemia 
in animal models (329), and following cardiopulmonary bypass surgery in humans 
(330). Moreover, circulating levels of TNF(x are elevated after myocardial infarction, 
which correlates with the level of myocardial injury (331). The consequences of 
TNFoc on the heart include apoptosis, necrosis and contractile depression (332,333). 
Thus, the release of TNF(x during ischaemia and the corresponding detrimental effects 
on cardiac myocytes, suggests it at least contributes to myocardial injury following 
ischaemia and/or reperfusion. 
TNFoc is regulated at multiple levels by p38-MAPK. Firstlyl the release of TNF(x is 
regulated at the transcriptional and translational level by p38 (334,335). Secondly, 
some cellular responses to TNIF(x treatment are also dependent upon p38 activation 
(336,337). Thus, p38-MAPK is associated with both the release and action of TNF(x. 
The release of TNF(x in a human model of myocardial ischaemia in isolated 
trabeculae is dependent on p38 activity (135). Moreover, inhibition of p38 not only 
decreases TNF(x release but also enhances post-ischaemic myocardial function. 
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Furthermore, the protection against oxidant stress in isolated perfused rat hearts seen 
following p38 inhibition is also associated with a decrease in TNF(x production (308). 
Thus, the activation of p38 during prolonged simulated ischaemia in our model may 
cause injury by promoting the release of TNF(x from myocytes. If this is true, then the 
decreased TNF(x release during reperfusion in preconditioned rat hearts (338) maybe 
a result of decreased p38 activation during ischaernia. 
4.3 A role for other MAPKs in cell death? 
During ischaemia as well as p38 activation, we observe a strong suppression of 
ERKI/2-MAPK phosphorylation. It has been reported that a decrease in ERKI/2 
phosphorylation may be as important as increased p38 activation in triggering cell 
death (115). An observation supported by the fact that pharmacological inhibition of 
ERKI/2 with PD98059 causes apoptosis through activation of p38 in HeLa cells 
(301). In addition, ERKI/2 phosphorylation is reported to be both necessary (339) and 
sufficient (223) for protection in the whole heart. In our model however, 
preconditioning does not increase ERKI/2 activation during ischaemia (results not 
shown), which reinforces the importance of understanding cell death pathways 
independently of preconditioning since the manipulation of ERKI/2, in addition to 
p38, may further increase protection. Conversely preconditioning may activate 
deleterious pathways, the inhibition of which could potentiate protection. 
4.4 The effect of preconditioning on p38 signalling during ischaemia 
Regardless of the mechanism of p38-induced injury, it is clear that inhibiting its 
activity during ischaernia protects. It is also known that PKC activation prevents p38 
phosphorylation in this model, which may be the mechanism by which PKC 
activation protects against lethal ischaemia. Indeed we did observe a decreased 
activation of p38 during lethal ischaemia in cells expressing constitutively active 
PKC6- Preconditioning is also known to depend on the activation of PKC, therefore it 
may protect by similarly inhibiting p38 activation during ischaemia. As shown in 
Figure 4-7, preconditioning significantly inhibited p38 activation during ischaemia. 
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These data provide the first mechanistic link between ischaemic preconditioning and 
reduced p38 activation during ischaemia. Insights into the mechanism by which 
PKC/preconditioning inhibit p38 may reveal new therapeutic pathways. 
4.5 The mechanism of reduced p38 activation 
4.5.1 Mitogen-activated protein kinasephosphatases 
MAPK pathways relay, amplify and integrate signals from a diverse range of stimuli 
to elicit an appropriate physiological response. One critical determinant of 
physiological outcome is the duration and magnitude of MAPK activation, which may 
be regulated at multiple points within the MAPK pathway. Ultimately, the activity of 
MAPK reflects a balance between the activities of the upstream kinase and the protein 
phosphatases. Therefore, the phosphatases play an equally important, often 
overlooked, role in MAPK regulation. The best-characterised family of proteins 
capable of dephosphorylating MAPKs are the mitogen-activated protein kinase 
phosphatases (MKPs: Chapter 1, section 3.2.4.1.4). Many of the stimuli that activate 
MAPK, similarly increase MKP activity, which then act as a negative feedback loop 
by dephosphorylating MAPK and turning off the signal (340). 
MKP-1 induction can be stimulated by PKC activation (341). Therefore, perhaps 
MKP-1 induction is responsible for the suppressed MAPK activation in active 
PKC6/e expressing cells. Unfortunately, the levels of MKP-1 protein were 
undetectable 48 hours following active PKC6 transfection. MKP-1 expression is also 
hypoxia responsive, since it is induced by low oxygen conditions (342). Therefore, 
the sublethal ischaemia of preconditioning may upregulate MKP-1 protein. 
Furthermore, stimuli that activate MAPK are also thought to activate MKPs, and we 
have already shown that MAPKs are activated during preconditioning in this model. 
Using antibodies raised against MKP-1 protein, we observed no detectable increase in 
MKP-1 protein 3 hours following ischaemic preconditioning (at the time-point when 
p38 phosphorylation is attenuated). This does not discount the involvement of another 
phosphatase however. In fact, inhibition of tyrosine phosphatases with vanadate 
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prolongs p38 activation and increases susceptibility to simulated ischaemia in 
neonatal myocytes (134). 
If a phosphatase, capable of dephosphorylating MAPKs during ischaemia, is 
induced/activated following preconditioning, it maybe a consequence of MAPK 
activation during preconditioning. In this scenario, the protection would be dependent 
upon MAPK activation during preconditioning and MAPK inhibition during lethal 
ischaernia. For example, inhibition of MAPK during preconditioning would prevent 
phosphatase induction and therefore attenuate protection, whereas inhibition of p38 
during ischaernia would prevent injury and thus protect. Many reports in the literature 
suggest this exact dichotomy. Inhibition of p38 during preconditioning aborts 
protection (126,130,303), whereas p38 inhibitors during ischaemia protect (131, 
133). In fact the only study to address the role of p38 during both preconditioning and 
ischaemia found a similar dichotomy, with SB203580 preventing protection when 
given during preconditioning, but protecting when applied during ischaemia alone 
(299). 
Although MKP-1 induction was not observed following ischaemia during hypoxic 
preconditioning in our model, induction is observed following preconditioning in a 
similar model within our laboratory, which relies on metabolic inhibition with 2- 
deoxyglucose and dithionite, instead of hypoxia, to precondition. In this model a one- 
hour metabolic stress preconditions and causes a similar activation of p38 during re- 
oxygenation. p38 soon becomes dephosphorylated below basal levels within I hour of 
activation during re-oxygenation. This dephosphorylation is concomitant with the 
expression of MKP-1 protein. MKP-1 levels remain elevated for a further 6 hours, 
during which time p38 levels remain depressed. Moreover, preliminary experiments 
suggest that transfection of MKP-1 in this model inhibits p38 activation, although it's 




4.5.2 Protein kinase B 
Role of MAPKs during preconditioning 
It is not only phosphatases that can inhibit MAPK activity, because kinases can also 
prevent p38 activation. In HeLa cells the inhibition of ERK is sufficient to stimulate 
p38 activation and apoptosis, although addition of serum is sufficient to abolish this 
increased activity (301). In this model, inhibition of phosphatidylinositol 3-kinase (Pl- 
3 kinase) with wortmanin, or PKB inhibition with a dominant negative mutant, 
prevents the reversal of apoptosis/p38 activation with serum. This suggests that the 
PI-3 kinase/PKB pathway is able to negatively regulate p38. PKB activation does not 
appear to contribute to p38 inhibition in response to active PKC8 expression because 
no detectable PKB phosphorylation (Ser473 and Tyr308) was observed in active 
PKC6 expressing cells. The inhibition of p38 in response to simulated preconditioning 
maybe related to PKB, since PKB activation has been reported during preconditioning 
in this model (302). Unfortunately, studies in our laboratory suggest this is not the 
case since p38 activation during preconditioning is not modulated by PI-3 kinase 
inhibition with wortmanin (Dr James Mockridge, unpublished observations). 
4.5.3 14-3-3 
14-3-3 family members are dimeric phospho-serine binding proteins that participate in 
signal transduction pathways. In cultured fibroblasts, expression of dominant negative 
14-3-3-zeta increases the basal activation of p38 and JNK as well as promoting 
apoptosis (343). This induction of apoptosis was prevented by the inhibition of p38. 
More interestingly, targeted expression of dominant negative 14-3-3-zeta to murine 
postnatal cardiac tissue increased basal p38 activity and caused widespread apoptosis. 
The activation of 14-3-3 has not been assessed in relation to ischaemia, but is role as 
an anti-apoptotic signalling protein in the heart, coupled with its ability to inhibit p38, 
makes it a candidate binding protein for preconditioning in this model. 
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4.5.4 Differential p38 localisation 
For p38 to be phosphorylated it must be in close proximity to its upstream activator. 
During ischaernia, p38 may localise to active upstream kinase or the co-localised 
kinase may simply be phosphorylated. In either instance, changing p38 localisation 
may alter p38 phosphorylation. Therefore preconditioning may simply relocate p38 
away from its upstream activator, therefore preventing phosphorylation during 
subsequent ischaernia. Conversely, preconditioning may prevent the relocation of p38 
during ischaernia, thus inhibiting phosphorylation. To address these hypotheses, 
studies will be needed to examine the mechanism of p38 activation during ischaemia. 
This can then be compared to cells made ischaernic following preconditioning. 
Although the mechanisms listed above suggests that preconditioning may inhibit p38 
phosphorylation directly, it may simply inhibit/downregulate a kinase upstream of 
p38. To examine this possibility one can assess the activation of upstream kinases 
(MKK3/6) during ischaernia in control and preconditioned cells. 
4.6 Critique of methods 
The activation of p38 during simulated ischaemia can be quantified not simply by the 
level of phosphorylation (which is maximal after 2.5 hours ischaemia) but also by the 
duration. Therefore the duration of p38 activation is a critical determinant of cell 
outcome following ischaemia. Treatments that prolong p38 activation in similar 
models increase cell injury (134). Therefore, when assessing the modulation of p38 
activation by preconditioning/PKC activation, one should address the effect on the 
temporal pattern of p38 activation. It may be that a treatment decreases the maximal 
activation, but prolongs the total activation. Furthermore, preconditioning may simply 
delay the activation of p38 during ischaemia, thereby reducing the activation at 2.5 
hours, but having no effect on total activity. The abolition of p38 phosphorylation 
after 2.5 hours ischaemia suggests however, that total activation is at least decreased. 
Nevertheless, in the absence of time constraints, the time course of p38 
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phosphorylation during ischaemia should be quantified in control and preconditioned 
cells 
Increasing numbers of studies have questioned the specificity of the p38 inhibitor 
SB203580 used in these experiments. As well as inhibition of other MAPKs (344), 
SB203580 is also known to inhibit PDKI (345) and activate the serine/threonine 
kinase raf-1 (346). The concentrations required to elicit these effects however, are 
thought to be greater than IgM and parallel experiments within our laboratory have 
demonstrated protection against simulated ischaemia using I [tM SB203580 (Dr Roby 
Rakhit, unpublished observations). 
4.7 Conclusions 
Selective activation of PKC isoforms or ischaemic preconditioning attenuates the 
phosphorylation of p38 during ischaemia and protects. Ischaemic preconditioning 
requires the activation of PKC for protection, thus we hypothesise that PKC activation 
during preconditioning is also required for the reduction in p38 activity. It would be 
interesting to determine whether known inhibitors of preconditioning (i. e. GPCR 
antagonists and PKC inhibitors) prevent the reduction in p38 activation during 
ischaernia. 
We also know that p38 inhibition is protective in this model, therefore the reduction 
in ischaernia-induced p38 activation following preconditioning at least contributes to 
the resulting protection. The relative contribution of p38 inhibition to protection is 
unknown, although the levels of injury seen following p38 inhibition in these studies, 
and preconditioning in others studies within our group (221), are similar. 
The mechanism by which p38 phosphorylation is attenuated during ischaemia 
following preconditioning in this model remains unknown. The reduction in p38 
activation may be a consequence of attenuated activation or enhanced 
dephosphorylation. However, if the latter is the case then preconditioning should 
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diminish the activation of p38 following other known stimuli in the absence of 
ischaemia. 
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1 INTRODUCTION 
Like many other protein kinases, p38-MAPK comprises a family of structurally 
related proteins. To date, five separate mammalian p38 isoforms have been identified: 
p38(x (347,348), p38Pl/P2 (349,350), p38, y (351,352), and P388 (353,354). Recent 
reports suggest that these isoforms may differ significantly in function if not in 
structure. For example, the specific inhibition of p38(x and P in HeLa cells, by the 
pyridinyl imidazole SB202190, induces apoptosis (355). Expression of p38P 
attenuates this effect, whereas p38(x expression promotes cell death. A similar 'yin- 
yang' role for p38(x and P has been demonstrated by Wang and coworkers in neonatal 
cardiac myocytes. In this model, overexpression of a constitutively active mutant of 
the upstream p38 activator MKK3, in combination with p38(x, promoted apoptosis 
(116). Conversely, overexpression of constitutively active MKK6 in combination with 
p38P promoted hypertrophy. Moreover, these effects could be negated by the 
expression of dominant negative p38(x or P respectively. 
The dual-phosphorylation specific antibodies used to assay p38 activity recognize the 
TGY motif, and surrounding amino acids, present in p38 isoforms. Unfortunately, the 
sequence surrounding the TGY motif is conserved in all p38 isoforms, thus 
phosphorylation- specific isoform-selective antibodies are unavailable. Therefore, the 
measurement of total p38 activation, using phospho- specific antibodies has 
limitations. For example, an increase in p38(x activation with a comparable decrease 
in p38P phosphorylation may not alter total p38 activation as detected by phospho- 
specific antibodies. If the Wang hypothesis were correct however, we would expect 
such a change in the balance of active p38 isoforms to cause a large 
decrease in cell 
viability. Thus there is a possibility that this decrease in viability may not 
be correctly 
attributed to p38 activation using currently available antibodies. 
Furthermore, the 
differing effects of p38 activation on myocyte survival, such as the protection and 
injury caused by p38 phosphorylation during preconditioning (130) and 
ischaemia 
(131), may stem from the activation of different p38 isoforms. Therefore we wished 
to examine the isotype specific activation of p38 during 
ischaemia in our model. 
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2 SPECIFIC METHODS 
2.1 Experimental protocols 
A 
2.5 Hours 
Role of p38 isoforms during preconditioning 
90 2.5 Hou- 
90' minutes 
1/ 





DN-p38a or DN-p38p 
Figure 5-1: Schematical representation of experimental protocols used to assess the consequence 
and extent of p38 isoform activation during ischaemia. 
Panel Ai and ii, myocytes expressing wild type p3 8(x or p3 8P were preconditioned (ii) or left untreated 
(i) before exposure to simulated ischaernia for 2.5 hours. Panel AW, p38 isoform activation during 
preconditioning was assessed by subjecting wild type-p38CC or P-transfected cells to 90 minutes 
simulated ischaernia and 10 minutes re-oxygenation. Protein was harvested, as indicated by the arrows, 
for Western blot analysis with anti-p38 antibodies. Panel B, 24 hours after infection with dominant 
negative p38oc or p38p, cells were subjected to a 6-hour lethal ischaemic stress. At the end of ischaemia 
enzyme release was detennined, whereas cell viability was determined after a further 2 hours re- 
oxygenation. 
2.2 Immunoprecipitation of p38 isoforms 
At indicated time-points, myocytes were washed briefly in ice-cold PBS. The PBS 
was aspirated and 100ýtl cell fractionation buffer containing 1% (v/v) triton X-100 
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added to each well. The cell suspension from each well was scraped into a 
microcentrifuge tube and incubated with shaking at 4'C for 20 minutes, prior to 
centrifugation to remove insoluble material. The supernatant was centrifuged again in 
new tubes and added to fresh tubes containing 2.5gl of immobilised-phospho-p38 
mouse monoclonal antibodies (Cell Signalling, Hitchin, UK). The immobilised- 
antibodies were incubated with cellular protein for 1 hour at 4'C with rotation, before 
centrifugation. The immobilised-antibodies were then washed 3 times in ice-cold lysis 
buffer to remove unbound protein, prior to resuspension in 50ýLl 2xSB (containing 
10% (v/v) 2-mercaptoethanol and trace of bromophenol blue). The samples were then 
boiled for 10 minutes and centrifuged prior to loading on SDS polyacrylamide gels. 
2.3 Western blotting 
All samples for Western blotting were run on 10% polyacrylamide gels, following 
coomassie staining of identically loaded gels to confirm uniform protein loading. 
Blots were sequentially probed with rabbit polyclonal antibodies specific for p38 or 
phospho-p38 (Cell Signalling, Hitchin, UK) at 1: 1000 dilutions and a peroxidase- 
conjugated swine anti-rabbit IgG secondary antibody (DAKO A/S, Denmark). Blots 
of immunoprecipitates were sequentially probed with rabbit or goat polyclonal 
antibodies, specific for p38(x and P respectively (Santa Cruz Biotechnology, Santa 
Cruz, USA), and peroxidase-conjugated swine anti-rabbit or rabbit anti-goat IgG 
secondary antibodies (DAKO A/S, Denmark). Primary antibodies were incubated at 
either 1: 500 (p38(x) or 1: 5000 (p38p) overnight at 4'C, prior to incubation with 
secondary antibodies at a 1: 2500 dilution for 2 hours at room temperature. For 
translocation experiments, mouse monoclonal antibodies for phospho-MKK3/6 (Santa 
Cruz Biotechnology, Santa Cruz, USA) were used at 1: 1000 dilutions overnight prior 
to a 2-hour exposure to relevant secondary antibodies as above. 
2.4 Statistical analysis 
All values are expressed as mean±SEM. Data for individual treatments were collected 
from no more than two wells from each experimental preparation. The "n" numbers 
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under "results" rel. ate to the number of wells from which data were obtained. For each 
treatment mean values were pooled to allow statistical comparisons. Statistical 
comparisons between groups were performed by one-way analysis of variance 
(ANOVA), followed where appropriate by the Tukey-Kramer test for pair-wise 
comparisons. All analyses were performed using Statview version 4.0 statistical 
package (Abacus Concepts Inc., Berkeley, CA). A probability value !! ý 0.05 was 
considered significant. 
3 RESULTS 
3.1 p38 isoform activation during ischaemia 
3.1.1 Activation of ectopically expressed p38 a and 
As discussed earlier, phosphorylation- specific p38 antibodies do not selectively detect 
individual p38 isoforms. To look at the activation of individual isoforrns, we utilised 
recombinant adenoviruses as an efficient gene delivery vector to express various p38 
signalling molecules (116,356). Using a recombinant adenovirus expressing the green 
fluorescent protein (GFP) as a reporter, greater than 95% of myocytes express the 
transgene 48 hours post-transfection (results not shown). Cardiornyocytes were 
infected with vectors expressing FLAG-tagged wild type-p38(x and -p38P. 
Adenovirally-encoded p38P has a higher apparent Mw than p38(x, thus enabling us to 
easily distinguish between the isoforms using p38 antibodies (Figure 5-2, Panel A). At 
a multiplicity of infection of 10, adenoviral-directed p38(X and p38P expression was 
detected at comparable levels by Western blot analysis (Figure 5-2, Panel Aii). 
Using phospho- specific antibodies to examine activation, we noted that during 
ischaernia p38(x exhibits a strong phosphorylation (Figure 5-2, Panel Ai). In contrast 
transfected p38p, which exhibits a high level of basal phosphorylation, is inhibited 
during ischaemia (Figure 5-2, Panel Ai). This experiment was repeated at least four 
times, and band densities analysed with respect to basal phosphorylation of each 
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isoforrn in the control untreated cells. Thus activation (phosphorylation) during 
ischaernia is expressed as fold-increase over baseline. The results show that 
ectopically expressed p38(x and P are differentially regulated during ischaernia, with 
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Figure 5-2: Activation of ectopically expressed p38(x and p380 during ischaemia 
in neonatal cardiac myocytes. 
Cardiocytes were infected with adenoviral constructs encoding FLAG-tagged wild 
type p38oc or P. 48 hours post-infection, cardiocytes were subjected to 2.5 hours 
simulated ischaen-tia before cells were harvested and lysed for Western blots. Panel 
A, lysates were probed with dual -pho spho -specific p38 antibodies to detect isotype- 
specific p38 activation during ischaernia (i). The expression levels of p38(X and P 
were similar and remain unaltered between treatments (ii). Panel B, mean data 
shows that p38oc is activated during ischaernia, but p38P is significantly inhibited. 
*p<0.001, p38oc activation v p38P activation during ischaernia. **p<0.01, p38P 
activation during ischaernia v non-ischaerrk/untreated cells. 
3.1.2 Activation of endogenous p38 a and P 
Ischaernic phosphorylation of overexpressed p38 isoforms does not necessarily mimic 
the physiological activation of p38 isoforms. Therefore endogenous p38 isoform 
activation was assessed, by immunoprecipitation of phosphorylated p38 during 
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ischaernia, and Western blotting of the immunoprecipitates with the respective 
isoform- specific p38 antibodies. Cardiocytes were left untreated (control) or subjected 
to 2.5 hours simulated ischaernia (ischaemia). p38(x could only be detected in 
immunoprecipitates from ischaernic cells, indicating activation of this endogenous 
isoform (Figure 5-3). p38P activation however, could not be detected in either control 
or ischaernic samples (results not shown), confirming this isoform is not activated 
during ischaernia. The only difference between these data and those using ectopic p38 
expression is the lack of activation of endogenous p38P under control conditions. This 
suggests that the high level of p38P phosphorylation following transfection may 
simply be an artefact of overexpression. 
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Figure 5-3: Activation of endogenous p38(x during 
Ischaetnia in neonatal cardiac myocytes. 
Cardiocytes subjected to 2.5 hours ischaernia were 
immunoprecipitated with anti-dual-phospho-p3 8 
antibodies. Immunoprecipitates were then Western blotted 
with p38(x antibodies. There is a clear increase in dual- 
phospho-p38(x during ischaen-lia in both independent 
experiments. 
3.2 p38 isoform activation during ischaemia following preconditioning 
On the basis of the results above we can conclude that the endogenous p38 isoform 
activated during ischaernia is p38(x. We also know, from the data presented in the 
previous chapter, that p38 activation during ischaernia is attenuated in preconditioned 
cells. Therefore, we wished to examine the effect of preconditioning on ectopically 
expressed p38(x phosphorylation during ischaernia. 48 hours following adenoviral- 
infection of p38oc or p38P, expression levels are similar in all treatment groups 
(Figure 5-4, Panel Aii). Although p38oc is again phosphorylated during ischaernia, in 
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preconditioned cells this phosphorylation is markedly diminished (Figure 5-4, Panel 
Ai). Examining the mean data, we see the results for p38(x mirror those of endogenous 
p38, in that it is activated during ischaemia in control, but not preconditioned, cells 
(p<0.05). In contrast, transfected p38P exhibits a high level of basal phosphorylation 
and is inhibited during ischaemia (p<0.01) with no significant effect of 
preconditioning on this ischaemia-induced inhibition (Figure 5-4, Panel B). Thus 
preconditioning selectively inhibits the activation of p38(x. 
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Figure 5-4: Activation of p38 isotypes during ischaemia in untreated and preconditioned cells. 
Cardiocytes were infected with adenoviral constructs encoding FLAG-tagged wild type p38(x or P. 48 
hours post-infection, untreated and preconditioned cardiocytes were subjected to 2.5 hours simulated 
ischaernia before cells were harvested and lysed for Western blots. Panel A, lysates were probed with 
dual -pho spho- specific p38 antibodies to detect i sotype- specific p38 activation during ischaen-tia (i). The 
expression levels of p38ot and P were similar and remain unaltered between treatments (ii). Panel B, 
mean p38 activation during ischaernia compared to untreated controls in at least 4 independent 
experiments. The activation of p38(x during ischaernia is inhibited in preconditioned cells, similar to 
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3.3 p38 isoform activation during preconditioning 
p38 activation during preconditioning is reported to be beneficial, since inhibition 
with SB203580 blocks protection (126,130). This is in stark contrast to the protection 
that follows p38 inhibition during ischaernia. These dichotomous results maybe a 
consequence of differential activation of p38 isoforms. Since we already know that 
p38(x is activated during ischaemia in our model, we sought to examine which 
isoform is activated during preconditioning. 
Simulated preconditioning in this model maximally activates p38 after 90 minutes 
ischaernia and 10 minutes re-oxygenation. Therefore myocytes expressing either p38(X 
or p38P were subjected to 90 minutes simulated ischaernia and 10 minutes re- 
oxygenation before protein was harvested and Western blotted with anti-phospho-p38 
antibodies. Figure 5-5 shows that, similar to ischaernia, p38(X is activated above basal 
levels during preconditioning. p38P is again activated basally, but remains 
phosphorylated during preconditioning. Thus, the pattern of p38 activation appears 
similar to that seen during lethal ischaernia, except that p38P remains elevated during 
preconditioning. 
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Figure 5-5: Activation of ectopically expressed p38 isoforms during preconditioning. 
Cardiocytes were infected with adenoviral constructs encoding GFP, FLAG-tagged wild type p38(X or 
P. 48 hours post-infection, cells were harvested (C) or subjected to 90 minutes simulated ischaen-tia and 
10 minutes re-oxygenation (IP), before harvesting and Western blotting with anti-dual-phospho-p38 








3.4 The cause of differential p38 isoform activation during ischaemia 
It has been suggested that p38 isoforms are differentially activated by their upstream 
activators, MKK3 and MKK6, with MKK3 preferentially activating p38(x (357,358). 
If this selectivity is present in neonatal cardiac myocytes then ischaemia may activate 
only MKK3, which would result in selective p38(x phosphorylation. Therefore we 
wished to test for selectivity in myocytes, by transfecting with constitutively active 
MKK3bE and MKK6bE mutants (mutants of MKK3 and MKK6, which mimic an 
activating dual-phosphorylation; described previously (359)) in combination with 
p38(x or P. Firstly, the MKK3bE and MKK6bE were transfected alone into myocytes, 
which were harvested 48 hour later for Western blotting with anti-phospho-p38 
antibodies, to determine whether the constitutively active upstream kinases could 
phosphorylate endogenous p38. Expression of active MKK3bE or MKK6bE alone 
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Figure 5-6: Activation of endogenous p38 by constitutively 
active mitogen-activated protein kinase kinase (MKK) 
mutants. 
Myocytes were infected with adenoviral constructs encoding 
MKK3bE and MKK6bE, constitutively active mutants of MKK3b 
and 6b. 48 hours following transfection, cell were harvested and 
constituent protein probed with anti-phospho-p38 antibodies to 
detect p38 phosphorylation. p38 was strongly phosphorylated to a 
similar extent in both MKK3bE and MKK6bE expressing cells. 
To determine whether this p38 phosphorylation was isoform. selective, the experiment 
was repeated in the presence of wild type p38(x and P. Under these conditions, p38(X 
and P were strongly phosphorylated in the presence of either MKK3bE or 
MKK6bE 
(Figure 5-7), suggesting no isoform selectivity. 
155 
Chapter 5 Role of p38 isoforms during preconditioning 
ca 
n rn mý 1.0 
2 CLO cz CLO 
4 + 
rn 
mow Vw-4p38 Ap380 
Figure 5-7: Activation of ectopically expressed p38(x and p380 
by constitutively active MKK3 or MKK6. 
Myocytes were infected with adenoviral constructs encoding either 
MKK3bE or MKK6bE in combination with either p38(x or p38P. 
48 hours following transfection, cells were harvested and 
constituent protein probed with anti-phospho-p38 antibodies to 
detect p38 phosphorylation. Co-transfection with upstream MKKs 
caused a strong phosphorylation of p38(x or P above baseline. 
There was no selectivity in the phosphorylation of p38 isoforms 
with either MKK3 or MKK6. 
3.5 The activation of MKK3/6 during simulated ischaemia 
If MKK3/6 were responsible for p38 phosphorylation during ischaemia then we 
should see a corresponding increase in MKK3/6 dual-phosphorylation prior to p38 
phosphorylation during ischaernia. Myocytes were subjected to different durations of 
simulated ischaernia (1,2,3, or 4 hours) prior to harvesting. Constituent protein was 
then fractionated into soluble and insoluble fractions (using the protocol described 
previously; see Chapter 3 section 2.5). The high sequence homology around the 
phosphorylation site of MKK3 and 6 prevents the development of isoform-specific 
phospho- specific antibodies, therefore fractionated protein was Western blotted for 
phospho-MKK3/6. Figure 5-8 shows that MKK3/6 are phosphorylated between 2 and 
3 hours ischaernia, which is identical to the time of p38 phosphorylation in this model 
(Figure 4-5, page 126). Interestingly, while phosphorylated MKK3/6 is exclusively in 
the soluble fraction prior to ischaernia, it is localised to the insoluble fraction after 2 
hours simulated ischaemia. This may represent translocation of MKK3/6, or an 
upstream activator, during ischaemia. 
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Figure 5-8: Phosphorylation of endogenous MKK3/6 during 
ischaemia in neonatal cardiac myocytes. 
Myocytes subjected to different durations of simulated ischaen-lia (0,1, 
2,3, and 4 hours) were harvested and protein separated into soluble (S) 
and insoluble fractions (1). Samples were then Western blotted with 
anti-phospho-MKK3/6 antibodies. MKK3/6 becomes phosphorylated 
exclusively in the insoluble fraction after 2 hours simulated ischaemia. 
3.6 Effect of dominant negative p38 isoforms on cell viability following ischaernia 
As shown in Figure 4-9 and by others (131,133), inhibition of p38 during ischaemia 
using SB203580 protects against cell death. Since we demonstrate a selective 
activation of p38(x over p38P during ischaemia, we would expect that protection 
ensues as a result of p38(x inhibition with SB203580. To test this hypothesis we 
transfected cells with a dominant negative p38(x mutant (residues 180-182; TGY to 
AGF; described previously (359)). As shown in Figure 5-9,48 hours after transfection 
of either wild type or dominant negative p38(x (DN-pMa), comparable 
overexpression of p38 can be detected (Panel B). Following 2.5 hours ischaemia, 
which is the time of maximal p38 activation, cells expressing DN-p38(x showed no 
significant p38 activation, whereas cells expressing wild type p38(X show increased 
p3 8 activation (Figure 5-9, Panel A). 
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Figure 5-9: Modulation of ischaemic p38 activation with dominant 
negative-p38cc. 
Cardiocytes were infected with adenoviral constructs encoding FLAG-tagged 
dominant negative-p38(x (DN-p38(x) or wild type-p38(x (WT-p38(x). 48 hours 
post-infection, cells were subjected to 2.5 hours simulated ischaernia (+) or left 
untreated (-). Myocytes were then harvested and lysed for Western blot analysis. 
Panel A, activation of p38 was assessed using pho spho- specific p38 antibodies. 
Ischaernia caused a marked activation of p38 in wild type-p38(x transfected 
cells, whereas p38 activation decreased during ischaen-da in cells expressing 
dominant negative p38(x. Panel B, the total p38 levels were assessed with anti- 
p38 antibodies. Adenoviral infection causes a consistent level of expression of 
either WT- or DN-p38(x, which is unaltered during ischaen-lia. 
Parallel cells, infected identically, were subjected to 6 hours simulated ischaemia and 
2 hours reperfusion to examine the effect of dominant negative p38(X (DN-p380c) on 
cell viability following ischaemia/re- oxygenation. The cells expressing DN-p38(x 
were protected against simulated ischaemia compared to empty vector-transfected 
cells (CK release = 82.9±3.9% and MTT bioreduction = 130.2±6.5%, n=8, p<0.05; 
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Figure 5-10: Effect of p38cc activation on cell survival during ischaetnia. 
Myocytes, transfected as in Figure 5-9, were exposed to simulated ischaernia for 6 hours and the 
supernatant collected to assay CK leakage. Panel A, therefore represents cell injury during ischaernia 
alone. Panel B, cell viability was measured by MTT bioreduction within monolayers after 6 hours 
simulated ischaernia and 2 hours re-oxygenation. Injury in the presence of DN-p38(x is expressed as a 
percentage of injury in the presence of an empty vector. Viability in cells treated with DN-p38(x alone 
for 6 hours (without ischaernia) was equivalent to that observed in untreated cells (results not shown). 
Specific inhibition of p38(x during ischaen-tia decreased cell injury and enhanced survival. All p values 
are for comparisons between ischaemia in the presence of DN-pHoc v empty vector. *p<0.05, n=8. 
4 DisCUSSION 
These studies demonstrate that p38(x is the endogenous p38 isoform activated during 
simulated ischaernia in neonatal rat cardiac myocytes. In contrast, p38P is inhibited 
below basal levels during ischaemia. Since, as shown in the previous chapter, p38(x 
and P inhibition with SB203580 protects against ischaemia, this can be attributed to 
159 
Chapter 5 Role of p38 isoforms during preconditioning 
the specific inhibition of p38(x activity. This was confirmed using dominant negative 
p38(x, which protected against simulated ischaemia to a similar extent as SB203580 
treatment. 
4.1 The need to address individual p38 isoforms 
The limitations of the work in the previous chapter became apparent when 
considering reports of various p38 isotypes, two of which (p38(x and P) are highly 
expressed in the heart. The likelihood that these isotypes carry out different, perhaps 
even opposite, intracellular functions casts doubt over the use of non-selective 
inhibitors (SB203580) and antibodies to infer the function of p38. Neglecting 
isoform- specific effects could lead to contradictory results. For example, a treatment 
such as preconditioning may switch the balance of activation from one isoform to 
another which, if they have opposing roles, may have a dramatic effect on cell fate. 
However the detection of p38 phosphorylation using antibodies would be insensitive 
to this switch, and thus not show a significant change in overall activation. Moreover, 
inhibition of p38, when the major isoform activated is (X may have significantly 
different results to inhibition when P is predominantly phosphorylated. This may 
explain the controversial findings in rabbit cardiomyocytes were SB203580 given 
during ischaemia actually accelerates injury (128). Therefore a greater insight into the 
differential activation of p38 isoforms allows a more complete appraisal of their 
effects on cell viability. 
4.2 A differential role for p38 isoforms 
To examine isoform- specific activation we used adenoviral-mediated expression of 
wild type p38(x and P. Assessment of isotype activation after 2.5 hours ischaemia 
showed that p38(x was activated, whereas p38P was significantly inhibited (Figure 
5-2). These results were also confirmed in untransfected cells, using 
immunoprecipitated phospho-p38 (Figure 5-3). According to Wang and co-workers, 
p38(x activation in neonatal cardiac myocytes is sufficient to cause apoptosis and cell 
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death, whereas increasing p380 phosphorylation promotes hypertrophy and survival 
(116). If this were true in our model, then the hypothesis would fit with a mechanism 
whereby p38(x is the specific detrimental MAPK isoform activated by ischaemia. It is 
also possible that the inhibition of p38P contributes to injury, since activation of this 
isoform has been shown to promote survival (116). 
Whilst p38 activation during ischaemia in this model is detrimental, others have 
shown that activation during preconditioning is beneficial, with SB203580 inhibiting 
protection (126,130). Since p38 activation in these studies was simply measured 
using phospho-specific antibodies, it is unknown which isoform(s) is/are activated. It 
may be that the predominant isoform activated during preconditioning is p38P. If this 
were true, then this would provide an explanation for the opposite results to 
ischaernia, when alpha is predominantly phosphorylated. To examine this in our 
model we examined the phosphorylation of p38(x and P during preconditioning. We 
observed a similar activation of p38(x during preconditioning, although interestingly 
p38P remained phosphorylated. This does not account for the apparent dichotomous 
effects of preconditioning and lethal ischaemia, although the maintenance of p38P 
phosphorylation during preconditioning, as opposed to the inhibition seen during 
ischaemia, may contribute to these discrepancies. 
4.3 The basis of differential activation of p38 isoforms 
Understanding the cause of differential p38 isoform activation would aid the design of 
therapeutic strategies to protect the heart by preventing p38(X activation during 
ischaernia. Theoretically, p38 isoforms could be activated by different upstream 
activators (or at least display differing selectivity), which may lead to specific isoform 
activation during ischaemia. Therefore we attempted to examine the activation of 
p38ot and P by the known upstream activators MKK3 and 6. Specific activation of 
MKK3b and 6b was achieved by the adenoviral-mediated expression of constitutively 
active mutants, rendered constitutively active by a mutation of a Serine and 
Threonine 
residue to Glutamate (MKK3bE and MKK6bE). The acidic side chain on 
Glutamate 
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mimics the phosphorylation of these residues that occurs when they are activated 
endogenously. Co-transfection of these mutants with p38(x or P showed that, under 
these conditions, either kinase was capable of phosphorylating both p38 isofonns. 
These data were in disagreement with earlier studies from Davis' group examining the 
selectivity of MKK3 and 6 for p38(x and P, which showed that whilst MKK6 was 
non-selective, MKK3 only phosphorylated p38(x (357). Initially we presumed the 
discrepancy was due to a lack of selectivity following overexpression. Since this 
study (357) however, the Davis group have further characterised the interaction 
between MKK3/6 and pHodp. They found that whilst MKK3 is unable to 
phosphorylate p38P, its splice variant MKK3b can (358). By constructing chimeric 
MKKs they mapped a p38-docking site to the N-terminal region of MKK3b, MKK6, 
and MKK6b, which is absent in MKK3. Therefore it is still possible that MKK3 is 
selectively activated during ischaemia in this model, which causes preferential 
activation of p38(x. 
4.4 Activation of MKKs during simulated ischaemia 
Examining endogenous MKK3/6, we noted a strong phosphorylation after 2 hours 
simulated ischaernia (Figure 5-8), which suggests this causes the subsequent p38 
activation during ischaernia. Unfortunately, the phospho- specific antibody was unable 
to distinguish between MKK3 and MKK6. It would be interesting to 
immunoprecipitate the active MKK3/6 and probe with the respective MKK3 or 
MKK6 antibodies, to determine whether ischaemia does selectively activate a 
particular MKK isoform. 
Another feature oil ischaemic MKK3/6 activation was the striking redistribution of 
phosphorylated MKK3/6 from soluble to insoluble fraction. It is unknown, from these 
results alone, whether this represents a relocalisation of total MKK3/6 or 
phosphorylated MKK3/6. In fact, it may simply be representative of a translocation of 
the upstream MKK3/6 activator from cytosol under basal conditions to insoluble 
fraction during ischaernia. Regardless of the mechanism for translocation, the 
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different localisation of upstream activators of p38 in control or ischaemic samples 
provides an intriguing possibility for isoform selectivity. If p38 isoforms ((x and P) are 
present in different cellular fractions then isoform- selective activation could be 
induced by translocation of common upstream activators (i. e. MKK3/6). For example, 
if p38P is cytosolic and p38(x in the insoluble fraction, then the localisation of 
MKK3/6 that we observe (i. e. soluble in controls and insoluble during ischaemia) may 
cause p38P phosphorylation basally, but p38(x phosphorylation during ischaemia. 
Future studies examining the localisation of p38(x and P should be designed to address 
this hypothesis. 
4.5 The effect of preconditioning on isoform activation during ischaemia 
In the previous chapter we showed that in preconditioned myocytes p38 
phosphorylation during ischaernia was significantly diminished. Presumably, this is 
due to inhibition of endogenous p38(x activation, since this is the isoform activated 
during ischaemia. Therefore, to verify this we examined the effect of preconditioning 
on ectopically expressed p38(x and P. We observed a specific reduction in ischaemia- 
induced p38ot phosphorylation following preconditioning, although p38P activation 
was unaltered. This selectivity for p38(x inhibition may however, simply be a 
reflection of the lack of p38P phosphorylation during ischaemia. 
4.6 The effect of p38-isoform activation? 
The data presented within the previous chapter regarding protection following p38 
inhibition during ischaemia relies on the use of the pharmacological inhibitor 
SB203580. Whilst SB203580 does inhibit p38 (Figure 4-8), it is also known to affect 
a range of other kinases. For example, it inhibits JNK (344), and PDKI activity (345), 
whilst it activates Raf-I (346). These non-specific effects of SB203580 complicate the 
interpretation of data for these and other (131-133) studies. Therefore we adopted a 
complementary approach by expressing a dominant negative p38(X mutant 
in 
myocytes prior to ischaemia. The p38(x was rendered dominant negative 
by 
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substitution of the Tyrosine and Threonine residues to non-phosphorylatable amino 
acids (residues 180-182; TGY to AGF). The effect of this dominant negative was to 
reduce p38 phosphorylation during ischaemia and protect. These data confirm the 
SB203580 results from the previous chapter and indicate that p38(x activation alone is 
detrimental to myocyte survival during ischaernia. 
4.7 Critique of methods 
When examining the selectivity of MKK3/6 for p38uJp, constitutively active 
MKK3bE and MKK6bE mutants were used. Since completion of these studies it has 
become clear that MKK3b does not preferentially phosphorylate p38(X, but MKK3 
does (see section 4.3). Therefore, the experiment should be repeated with MKK3E 
mutants in combination with p38(x or p38P to determine their selectivity in this 
model. In relation to ischaemia, although total MKK3/6 activation is increased, 
MKK3 and MKK6 phosphorylation should be quantified independently to determine 
whether a particular isoform is activated which may selectively phosphorylate p38a. 
While inhibition of p38(x protected cells during ischaemia, it would be advantageous 
to determine whether there is a reciprocal decrease in viability following p38(x 
activation during ischaemia. Constitutively active MKK3 could be co-expressed with 
p38(x prior to ischaemia, although the activation of p38(x for hours prior to ischaemia 
would complicate data interpretation. Similarly, the effect of p38P activation during 
ischaernia was not determined in this model. 
4.8 Conclusions 
The phosphorylation of p38 isoforms during simulated ischaemia in this model is 
isoform selective, with p38(x being activated. Moreover, p38P phosphorylation is 
suppressed below basal levels during ischaemia. Ischaemic preconditioning, which 
inhibits endogenous p38 activation, also specifically inhibits p38(x phosphorylation 
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during ischaemia. This inhibition probably contributes to protection, since specific 
p38(x inhibition with a dominant negative mutant confers a similar level of protection. 
The cause of differential p38 activation is unknown, although it may be related to the 
activation of MKK3/6 seen during ischaemia. MKK3/6 is activated in the insoluble 
fraction during ischaemia, compared to its phosphorylation in the soluble fraction 
under basal conditions. Thus, MKK3/6 may co-localise with specific p38 isoforms 
under different physiological conditions. Alternatively, MKK3 and MKK6 may be 
differentially phosphorylated during ischaemia, which could dictate the pattern of p38 
isoform activation. 
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Preconditioning in PKC-epsilon knockout mice 
The activation of either PKC8 (281) or PKCF_ (109) has been shown to protect the 
whole heart. However, PKCF_ activation may be more directly relevant to ischaemic 
preconditioning, since isoform- specific inhibitory peptides are able to abolish 
"preconditioning-like" protection in isolated neonatal rat (107) and adult rabbit (108) 
cardiornyocytes (108). These peptides function by preventing the binding of specific 
PKC isoforms to their respective receptors for activated C-kinase (RACKs). The 
rationale is that they prevent a specific PKC isoform from localising with its 
substrate(s), thus causing a loss of function. The difficulty in measuring isofonn 
activation makes evaluation of the selectivity and efficacy of these peptides complex. 
Moreover, the simulated ischaemia in isolated cell models is only a substitute for 
ischaemia in the whole heart. Therefore, ischaemic preconditioning in the whole heart 
may depend on the activation of other PKC isoforms. There is therefore a need to 
further clarify the role of individual isoforms during ischaemic preconditioning in the 
whole heart. The lack of suitable pharmacological inhibitors, and the low efficiency of 
transfection in vivo, limits the models available to address isoform- specific PKC 
activation. 
The ability to manipulate the mouse genome in a targeted and predictable fashion has 
enabled scientists to generate mutant mouse strains, which have been used to provide 
new and critical insights into the molecular mechanisms governing normal and 
disrupted biological processes. By using gene targeting via homologous 
recombination in murine embryonic stem cells, a specific gene can be either ablated or 
modified, and the mouse carrying the targeted locus can be generated for subsequent 
studies. To utilise these molecular genetic approaches in the field of cardiac 
physiology, models to assess whole organ function would be needed to analyse 
important aspects of any resultant phenotypes. Thus, techniques were developed in 
which the well-characterised isolated perfused heart apparatus was miniaturized such 
that parameters of myocardial contractility could be reproducibly assessed by using 
either a Langendorff or left-sided working heart preparation (360). 
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The Langendorff model involves retrograde perfusion of the heart with buffer, which 
enters the coronary arteries via the coronary sinuses at the base of the aortic root. This 
enables the heart to contract and remain viable for many hours. Ischaemia can be 
mimicked by clamping the aortic inflow tubing, thus preventing buffer-perfusion. 
Ischaernia/reperfusion injury has been characterised using this isolated mouse heart 
model (361), and preconditioning can be mimicked by brief cycles of 
ischaernia/reperfusion prior to lethal global ischaemia (29,232). 
We obtained mice lacking PKCc protein due to a targeted disruption of the pkc-E 
alleles. We therefore sought to use these mice to investigate ischaemic 
preconditioning, in an attempt to delineate the role of this PKC isoform in protection 
following preconditioning in the mouse. 
2 SPECIFIC METHODS 
2.1 Principles of transgenic mice 
The generation of transgenic mice is a multi-stage procedure that requires the 
generation, amplification and purification of a suitable transgene cassette inserted into 
a plasmid vector. The expression of the transgene is confirmed in vitro by transfection 
into eukaryotic cells. The transgene is then introduced into the embryonic stem (ES) 
cell either by vector transfection and selection or by direct microinjection of plasmid- 
free transgene fragments into embryonic pronuclei. Manipulated embryos can then be 
placed in the reproductive tract of a pseudo-pregnant recipient or introduced into the 
embryo of another mouse strain by injection into the blastocyst stage embryo. The 
genomic DNA of live-born pups is then analysed for the presence of the transgene 
DNA sequence. Littermates, heterozygous for the transgene, can then be mated to 
produce homozygous offspring. Below is an example of a targeting strategy 
involving 
pronuclear microinj ection (Figure 6- 1). 
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Figure 6-1: Sequence of events in the generation of a transgenic animal by pronuclear 
microinjection. 
Panel A, the double-stranded DNA components of the transgene are combined enzymatically 
to yield a transgene expression cassette. Panel B, transgene cassettes are inserted into plasmid 
vectors and cloned. Panel C, transgene-bearing plasrnids are transfected into cultured 
eukaryotic cells to evaluate expression of the transgene. Panel D, plasmid-free transgene 
fragments are introduced directly into embryonic pronuclei. Panel E, manipulated embryos 
are placed in the reproductive tract of a pseudo-pregnant recipient. Panel F, the genornic 
DNA of live-born pups is analysed for the presence of the transgene DNA sequence. 
2.2 Generation of PKC epsilon deficient mice 
Dr Daniel Pennington at the Imperial Cancer Research Fund, London, carried out the 
targeting of the pkc-E allele and the generation of pkc-E homozygous mutant mice. In 
brief, a 9.3Kb EcoRl fragment containing the first exon of the pkc-. E gene was isolated 
from a murine 129/Sv genomic DNA library (gift from T. Rabbits, LMB, Cambridge). 
To generate a targeting vector, a positive selectable cassette was introduced into the 
Pstl site of exon 1. This cassette contains stop codons in all three frames, an 
independent ribosomal entry site (IRES) followed by the LacZ gene with an SV40 
polyadenylation sequence, and a neomycin phosphotransferase gene (MCINeo 
poly(A); gift from A. Smith, Centre for Genome Research, Edinburgh). Correctly 
targeted GK129 ES cells were selected and then injected into C57BL/6 blastocysts. 
Chimeric mice were bred to C57BL/6 mice in specific pathogen free (SPF) conditions 
and offspring crossed to generate pkc-E homozygous mutant animals. PKCF- deficient 
mice were shown to be negative for PKCF- protein by Western Blotting. 
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2.3 Experimental protocols 







Figure 6-2: Schematical representation of mouse heart perfusion protocols. 
Two different durations of ischaernia were used, 30 minutes (Panel A) and 45 minutes (Panel B). 
Preconditioning was simulated with 4 cycles of 4 minutes ischaemia and 6 minutes reperfusion before 
45 minutes index ischaernia (Panel C). A 90 minute duration of reperfusion was used since this was 
sufficient to allow maximal contractile recovery and washout of dehydrogenases, NADH and other co- 
factors from the necrotic tissue that may cause false positive tetrazolium staining of dead cells. 
2.4 Western blot analysis 
Samples were obtained from the liver or whole heart by homogenisation in 2xSB. 
Western blotting was then carried out, as described previously, to assess PKC isoform 
abundance in mice wild type (+/+), heterozygous (+/-), and homozygous (-/-) for a 
disruption within the pkc-. c alleles. All PKC antibodies were murine monoclonal 
antibodies (Transduction Laboratories, UK), which were detected using a peroxidase- 
conjugated rabbit anti-mouse IgG secondary antibody (DAKO A/S, Denmark). 
2.5 Statistical analysis 
Data for functional recovery at the end of reperfusion were analysed by one-way 
ANOVA, followed were appropriate by the Tukey-Kramer test for pair-wise 
comparisons. Linear regression was carried out using SigmaStat statistical package. 
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Comparisons of infarct size with respect to total myocardial volume between groups 
were made by analysis of covariance (ANCOVA) using an Excel plug-in (Ferris State 
University). A probability value of !ý0.05 was considered significant. 
3 RESULTS 
3.1 Frequency-response characteristics of isovolumic fluid-filled balloons 
The frequency response of the fluid-filled balloon, tubing and pressure transducer 
should be flat to at least IOHz, to avoid false pressure readings at mouse heart rates of 
580bpm used in these studies. The frequency response characteristics of the balloon, 















Figure 6-3: Typical frequency-response trace for a fluid-filled balloon and coupling tubing. 
3.2 Preliminary studies on global ischaemia and reperfusion 
Preconditioning has been proposed to delay the onset and rate of necrosis 
during 
index ischaemia. We chose 45 minutes as the duration of lethal ischaemia since 
in a 
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standard inbred strain (T/O mice, B&K Universal Ltd, England) infarction was 
significantly larger than after 30 minutes (26.3±3.7% v 8.0-+2.7%, p<0.05, and see 
Figure 6-4). Since we were able to detect this difference, and preconditioning is 
thought to delay infarction by 10-15 minutes, we reasoned that preconditioning prior 














Figure 6-4: The effect of ischaemic duration on infarct size. 
Panels A and B, typical mouse hearts sectioned after triphenyl-tetrazolium chloride JTQ 
staining to demarcate infarction (pale tissue) after 45 minutes (Panel A) or 30 minutes (Panel 
B) of global no-flow ischaernia and 90 minutes reperfusion. Actual infarct volumes as a 
percentage of heart volume are 24.2% and 4.1% respectively. Panel C, mean infarct size 
following 45 or 30 minutes ischaemia and 90 minutes reperfusion. *p<0.05. 
Yellon's group have previously shown that 4 cycles of 5 minutes ischaen-ýia/5 minutes 
reperfusion preconditions the isolated mouse heart (232). Initial experiments in our 
model showed that 5 minutes ischaemia caused a slight elevation in end diastolic 
pressure and predisposed hearts to dysrhythmias during subsequent reperfusions. We 
therefore used 4x4 minutes ischaemia/6 minutes reperfusion, which caused no 
observable detrimental effects (results not shown). Moreover, extending reperfusion 
to 2.5 hours after this preconditioning stimulus caused no perturbation in left 
ventricular developed pressure (LVDP) compared to aerobically perfused controls. 
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TTC, which is reduced from a yellow to a red pigment in living cells, was used to 
demarcate the infarct zone. Insufficient washout of dehydrogenases, NADH and other 
co-factors from the necrotic tissue may cause false positive staining of dead cells. In 
keeping with previous studies (26), pilot experiments showed that increasing the 
duration of reperfusion from 1.5 to 2.5 hours had no significant effect on TTC- 
determined infarct size (results not shown). Moreover, functional recovery plateaued 
between I and 1.5 hours reperfusion, therefore 1.5 hours was used as the duration of 
reperfusion in all subsequent studies. 
3.3 Preconditioning studies in a standard inbred mouse strain 
A total of 33 male T/O mice were randomised to either control (no preconditioning) 
or ischaernic preconditioning (4 x4 minutes ischaemia/6 minutes reperfusion) groups. 
Four hearts were excluded during the stabilisation period due to high aortic flows (2), 
low developed pressure (1), or persistent dysrhythmias (1). There were no significant 
differences in baseline parameters between groups (Table 6-1). 
Experimental Groups Control (n=15) IP (n= 14) 
Body Weight (g) 35.0±0.8 35.8±0.6 
Wet Heart Weight (mg) 132.3±5.5 133.1±5.2 
Heart Volume (MM) 95.6±4.2 97.6±3.6 
Coronary Flow (ml/min) 2.5±0.1 2.4±0.1 
Isolation Time (sec) 154±6 152±5 
LVDP (mmHg) 70.3±1.6 69.2±1.9 
Table 6-1: Morphometric characteristics and baseline parameters of isolated buffer-perfused 
hearts from T/O mice. 
Values are mean-+SEM. There were no statistically significant differences between the groups for any 
parameters. Coronary flow and LVDP were recorded after 30 minutes stabilisation. Isolation time 
refers to the time interval between thoracotomy and retrograde perfusion. 
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Preconditioning prior to the index ischaemia reduced mean infarct size and improved 
contractile recovery following subsequent reperfusion (Figure 6-5). These data 
demonstrate that infarct size is halved in preconditioned hearts and contractile 
















Figure 6-5: Effect of ischaemic preconditioning (]UP) on infarct size in buffer perfused hearts 
from T/O mice. 
Panel A, mean data for infarct volume as a percentage of total heart volume in control (0, n= 15) and 
IIP (0, n=14) groups (*p<0.05). In the control group infarction was 26.3±3.7%, whereas infarction in 
the IP group is 12.2±1.7%. Panel B, contractile recovery in control and IP hearts expressed as a 
percentage of baseline left ventricular developed pressure (**p<0.001). Data shows that 
preconditioning significantly decreases infarct size and improves functional recovery. 
There was however, a large variability in infarct size within the controls, ranging from 
5-50% (Figure 6-5, Panel A). The net effect of this variability is the need for large 
experimental numbers to reach statistical significance. When the infarct volumes are 
expressed against the respective heart volumes we see a close positive correlation 
(Figure 6-6, r=0.96 and 0.92 for control and preconditioned groups respectively). 
When analysed (using analysis of covariance [ANCOVA]) with respect to total 
myocardial volume, the reduction in infarction in preconditioned hearts reached a 
higher level of significance (p<0.001, see Figure 6-6). 
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Figure 6-6: Infarct volumes expressed against heart volumes in control and 
preconditioned hearts. 
Infarct volume in control (0) and IP (0) hearts expressed with respect to total 
heart volume. Linear regression for control (r=0.96) and IP (r=0.92) groups both 
reached statistical significance (p<0.001). Data shows that, for a given heart 
volume, the infarct volume is less in ischaernically preconditioned hearts. 
**p<0.001, by ANCOVA. 
3.4 Verification of transgenic genotype 
Offspring of heterozygous (+/-) x knockout (-/-) breeding pairs were randomised to 
either preconditioning or control groups. Since the genotype of the progeny would be 
predicted to be 50% heterozygous and 50% knockout, tail clips were simply retained 
at -20'C for genotyping after all the physiological data had been collected. Purified 
DNA from the tail clips was subjected to PCR with oligonucleotide primers specific 
for sequences both 3' and 5' of the inserted cassette. Thus, in mice homozygous for a 
disruption within the PKCE alleles (-/-), the PCR product was a large 700bp fragment 
containing the cassette. In wild type (+/+) mice a smaller 350bp fragment was 
obtained, whereas heterozygous mice (+/-) yielded both fragments (Figure 6-7). 
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700bp 
350bp 
Figure 6-7: Polymerase chain reaction (PCR) used to 
identify genotype in transgenic mice. 
Wild type (+/+) mice yield a fragment encoding 350bp, 
whereas knockout (-/-) mice generate a larger 700bp 
fragment, and heterozygous (+/-) mice produce both 
fragments. 
3.5 Analysis of PKC isoform expression levels in transgenic mice 
Mouse hearts were homogenised and constituent protein subjected to Western blot 
analysis with anti-PKC antibodies. PKCc protein was detected in both wild type and 
heterozygous mice, although PKCe was absent in knockout mice (Figure 6-8). A 
major concern of knockout technologies is the possibility of developmental 
upregulation of closely related isoforms to compensate for the lack of a particular 
gene. Therefore, heart protein was probed with antibodies for PKC6 and (x, two other 
PKC isoforms implicated in myocardial protection. As shown in Figure 6-8 the levels 
of PKC6 and a remain unaltered between groups. 
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Figure 6-8: Analysis of PKC isoform expression in hearts from mice wild 
type 
heterozygous (+/-), and homozygous (-/-) for a disruption within the pkc- E alleles. 
Panel A, Hearts from (-/-) mice have no detectable expression of PKCE protein, whereas 
hearts from 
(+/+) and (+/-) mice show similar levels of PKCF- protein expression. 
PKCE genotype has no significant 
effect on expression of PKC8 or PKC(x, two other 
PKC isoforms implicated in IP. Equal protein 
loading was confirmed by coomassie staining of 
identically loaded gels. There was no difference in 
actin levels between groups. 
3.6 Preconditioning studies in PKC epsilon deficient mice 
Having characterised the protein expression 
in transgenic mice, we then sought to 
examine the effect of ischaernic preconditioning 
in these mice. A total of 48 male 
mice entered the study, but five 
hearts were excluded during stabilisation 
due to high 
aortic flows (2), low developed pressure 
(1), or persistent dysrhythmia (2). There 
were no significant differences 
in baseline parameters between groups (Table 
6-2). 
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Experimental Groups Control (+/-) IP (+/-) Control (-/-) IP (-/-) 
(n=10) (n=12) (n=8) (n=13) 
Body Weight (g) 41.4±1.9 40.7±1.7 38.0±1.4 41.9±1.2 
Wet Heart Weight (mg) 167.4±9.0 170.7±5.6 152.3±5.9 154.1±4.8 
Heart Volume (MM) 123.9±5.5 125.8±5.9 115.2±4.7 120.8±2.9 
Coronary Flow 2.39±0.18 2.35±0.06 2.36±0.10 2.34±0.10 
(mVmin) 
Isolation Time (sec) 137±8 144±15 158±12 130±10 
LVDP(mmHg) 69.6±1.9 67.6±0.9 71.9±2.2 67.4±1.4 
Age (days) 121±3 122±3 119±2 123±2 
Table 6-2: Morphometric characteristics and baseline parameters of isolated buffer-perfused 
hearts from mice heterozygous (+/-) and homozygous (-/-) for a disruption within the pkc-, c 
alleles. 
Values are mean-+SEM. There were no statistically significant differences between the groups for any 
parameters. Coronary flow and LVDP were recorded after 30 minutes stabilisation. Isolation time 
refers to the time interval between thoracotomy and retrograde perfusion. 
In heterozygous (+/-) mice, which contain the full complement of PKCE protein, 
preconditioning resulted in a significant reduction in infarct size (Figure 6-9, Panel A; 
p<0.05), although again this reached higher significance when expressed against heart 
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Figure 6-9: The effect of ischaemic preconditioning (IP) in isolated buffer-perfused 
hearts from mice heterozygous (+/-) for a disruption within the pkc- E alleles. 
Panel A, mean infarct volume, expressed as a percentage of total myocardial volume, 
was significantly lower in preconditioned hearts compared to controls (24.3±4.5% v 
41.3±4.7%, *p<0.05 [ANOVA]). Panel B, infarct volume in control (40) and IP (0) 
hearts from (+/-) mice expressed against total heart volume. Preconditioning prior to 
ischaernia significantly reduced infarct volume compared to controls (**p<0.001 
[ANCOVA]). 
In knockout (-/-) hearts that lack the pkc-E gene and PKCF- protein, there was no 
statistical difference in infarct size between ischaemic preconditioning and control 
hearts, when analysed as a percentage of (Figure 6-10, Panel A), or with respect to 
(Figure 6- 10, Panel B), myocardial volume - 
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Figure 6-10: The effect of ischaemic preconditioning (]UP) in isolated buffer-perfused 
hearts from mice homozygous (-/-) for a disruption within the pkc-, c alleles. 
Panel A, mean infarct volume, expressed as a percentage of total myocardial volume, was 
unaltered in preconditioned hearts compared to controls (36.4±2.9% v 38.8±4.5%). Panel B, 
infarct volume in control (A) and IF (A) hearts from (-/-) mice expressed against total heart 
volume. Preconditioning prior to ischaernia had no effect on infarct volume when assessed by 
ANCOVA. 
By superimposing the infarct data from these two studies we can see that the 
relationship between myocardial volume and infarct size was identical in 
heterozygous (+/-) and knockout (4-) control hearts, indicating that the lack of PKCF- 
per se had no effect on infarct size following ischaernialreperfusion (Figure 6-11). 
However., the lack of PKCF- did prevent any effect of preconditioning on infarct size, 
since the only significantly different group is the preconditioned heterozygotes. 
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Figure 6-11: Infarct volume in control (filled) and IP (open) hearts from heterozygous (circles) 
and knockout (triangles) mice expressed against total heart volume. 
There is no difference in infarct size in control (+/-), control (-/-), and IP (-/-) groups. The IP 
hearts had significantly less infarction than all other groups (*p<0.005, by ANCOVA). 
Although there was no benefit of preconditioning on infarct size in hearts from (-/-) 
mice, surprisingly contractile recovery was preserved in this group to a level similar 
to that seen in preconditioned (+/-) hearts (Figure 6-12). 
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Figure 6-12: The effect of ischaemic preconditioning (]UP) on contractile recovery in 
isolated buffer-perfused hearts from mice heterozygous (+/-) and homozygous for a 
disrupted pkc- E allele. 
Mean data for contractile recovery in control (0) and IP (0) hearts from (+/-) and mice. 
IP significantly improved recovery in hearts from both (+/-) and (-/-) mice. *p<0.05. 
4 DisCUSSION 
Using Langendorff-perfusion of hearts from a standard in-bred mouse strain we have 
shown that preconditioning with 4x4 minutes ischaemia/6 minutes reperfusion prior 
to 45 minutes global ischaemia improves contractile recovery and reduces infarct size. 
However the percentage of the heart volume that undergoes infarction is highly 
variable. The most significant factor contributing to this variability is heart size, with 
smaller hearts exhibiting disproportionately small infarct volumes. This effect can be 
unmasked by analysing the covariance between infarction volume and heart volume. 
In common with a standard inbred mouse strain, preconditioning reduces infarction in 
mice with a single disrupted pkc-E allele that retains a significant cardiac PKCF_ 
complement. However in their littermates, with a similar genetic background but with 
both pkc-E alleles disrupted and no cardiac PKCF_ protein, preconditioning fails to 
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reduce infarction. Paradoxically however, despite these dichotomous effects on 
infarction, preconditioning improves post-ischaemic contractile recovery in both the 
presence and the absence of cardiac PKCF-protein. These data show that PKCF, is 
essential for the reduction in infarct size but not for the increase in contractile 
recovery that follows preconditioning. This suggests that distinct intracellular 
mechanisms may underlie the different manifestations of preconditioning, cautioning 
extrapolation between models with diverse endpoints. 
4.1 Relationship between heart volume and infarct volume 
In this model, infarction volume is related to heart volume and weight. Thus when 
heart volume is less than 80mm. 3 (=I 1 Omg) we found little or no infarction after 45 
minutes global ischaernia. Superficially this seems surprising and counter-intuitive. 
However, identical relationships between volume at risk of infarction and final 
infarction volume are documented in better characterised small animal models of 
myocardial infarction (17,55,362). Arguably the best-characterised small animal 
model is regional myocardial ischaernia in the rabbit. In this model a number of 
studies have shown that infarction following 30 minutes of regional ischaemia is 
absent when the risk zone volume is less than 300MM3 (55,362). In an identical 
manner to our study, these studies have also reported statistically significant effects of 
interventions based on comparisons of mean infarctionxisk zone ratios. However 
these comparisons must be viewed as relatively crude since they ignore a critical 
determinant of infarction volume and assume a zero intercept. Previous reports of 
murine models of infarction have also ignored this contribution to the variance in 
infarction: risk zone ratios. It is possible therefore that the ANCOVA analysis reported 
in this manuscript would have allowed statistical significance to be achieved in these 
previous studies with fewer observations. This potential saving in resources underlies 
the importance of the observation. Table 6-3 displays the infarct size and heart weight 
derived from manuscripts that use an isolated mouse heart perfusion model and 
document both infarct size and heart weight data. 
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Sumeray et al., 1998a (361) 20 190 10 
Xi et al., 1999a (363) 20 230 20 
Xi et al., 1998 (29) 20 244 24 
Xi et A, 1999b (364) 20 254 27 
Yoshida et al., 1996 (365) 30 140 8 
Yoshida et al., 1997 (366) 30 140 7 
Sumeray et A, 1998a (361. ) 30 1.70 30 
Sumeray et al., 1998b (232) 30 200 55 
Saurin et A, 2000 45 128 26 
Greaves et al., 2000 45 138 31 
Saurin et al., 2000 45 158 42 
Table 6-3: Infarct size and heart weight of isolated mouse hearts subjected to varying durations 
of ischaernia in published studies 
Data for Saurin et al. are derived from studies contained within this thesis. Greaves et al. are 
unpublished observations from our group. 
These data indicate that for a given ischaemic duration infarct size increase with 
increasing heart size. Furthermore, when heart size decreases (bold values), the length 
of ischaemia must be increased to maintain the same level of infarction. These data 
suggest a disproportionately relationship between heart size and infarct size in 
isolated perfused mouse hearts. 
The mechanism(s) by which risk zone volume influences susceptibility to infarction is 
unknown. Our presumed explanation for this effect is superfusion of nutrients and 
metabolites between heart and surrounding Krebs-Henseleit buffer in our experiments 
or between risk zone and normally perfused myocardium in the rabbit. Thus the value 
of the intercept, which provides the volume below which infarction is absent, reflects 
the surface area to volume ratio of the risk zone that is large enough to provide 
adequate superfusion to maintain myocyte viability during 45 minutes ischaemia. 
This 
could explain why this constant is lower in our studies where the risk zone 
is spherical 
compared to that in the rabbit where small risks zones are serpiginous. 
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4.2 Ischaemic preconditioning in isolated buffer-perfused mouse hearts 
To our knowledge there have been only 2 previous reports of preconditioning in the 
isolated mouse heart (29,232). Using one of these protocols, which consisted of 4 
cycles of 5 minutes ischaemia and 5 minutes reperfusion, we found hearts were 
disposed to dysrhythmias and elevated diastolic pressures during preconditioning. It is 
possible that this duration of ischaemia was too severe, although viability assays were 
not performed following this preconditioning protocol. Instead the ischaemic duration 
was shortened to 4 minutes, and reperfusion increased to 6 minutes. This protocol 
prevented the adverse effects during preconditioning. We therefore characterised our 
own protocol for preconditioning with 4 cycles of 4 minutes ischaemia with 6 minutes 
of intervening reperfusions before 45 minutes global ischaemia. The endpoints used to 
assess myocardial injury were contractile recovery and infarct size, which were 
enhanced and attenuated respectively by ischaemic preconditioning. 
4.3 The role of PKC isoforms in preconditioning 
The difficulty in measuring the activity of individual PKC isoforms has lead to 
contradictory reports implicating different isofon-n(s) in ischaemic preconditioning. 
Using translocation as a surrogate for activation, it has been suggested that PKCoc, 8, 
F-, and il are all activated following a preconditioning stimulus (284,291). Until 
recently this was simply associative data, but the design of isoform specific peptides 
that inhibit PKC translocation has provided the strongest evidence in favour of PKCF, 
in early ischaemic preconditioning. These studies, in isolated neonatal cardiac 
myocytes (107) and adult cardiomyocytes (108), show that preconditioning requires 
the translocation of PKCe for protection against simulated ischaemia. Moreover, 
peptides, that function by promoting the translocation of PKC6 
have also been shown 
to protect both neonatal cardiac myocytes and the mouse 
heart against ischaernia 
(109). Furthermore, Ping et al. have showed that overexpression of PKCF- protects 
adult cardiomyocytes against simulated ischaemia 
(223). A major concern in all these 
studies is the inability to accurately assess 
isoform activation. This is because 
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isoform- specific substrates are currently unknown and differing antibody affinities, 
isotype abundance, and in-vitro activation, complicates the interpretation of PKC 
activity after immunoprecipitation of individual isoforms. The requirement for some 
measure of activity is highlighted in the activatorlinhibitor peptide studies, since these 
selective strategies rely on the premise that PKC translocation is synonymous with 
activation. This premise may not be correct with the possibility of non-translocation 
dependent activation (63), and even translocation dependent inhibition (298). The use 
of deficient mouse-lines is resistant to such advances in our understanding of PKC 
biology. 
The other advantage of using specific PKC isoform deficient mouse lines is the ability 
to investigate the role of PKC isoforms in more physiological models of 
preconditioning. The difficulty in efficiently transfecting the whole heart has so far 
limited genetic approaches to cell-based models of simulated ischaemia. Furthermore, 
even in these models, other uncertainties exist since our group (221) has previously 
suggested that specific activation of PKC5 in rat myocytes protects against simulated 
ischaernia. In fact the downstream signalling pathways activated by PKC6 and 6, 
which are thought to lead to protection, have many similarities (18,367). For these 
reasons we sought to examine ischaemic preconditioning in hearts from mice 
deficient in PKCF-. 
4.4 Ischaemic preconditioning in isolated hearts from pkc-, c knockout mice 
For controls, we chose to use mice heterozygous (+/-) for a disrupted pkc-E allele, 
rather than wild type (+/+) mice. This decision was reached after ensuring that mice 
with these genotypes had a similar complement of PKCE within their hearts 
(Figure 
6-8). Thus all male offspring of (+/-) x (-/-) matings could be randomised before 
genotyping. This reduced colony maintenance costs and eliminated 
bias since 
genotypes were not determined until all physiological data 
had been collected. A 
further advantage of this approach is that mice share the same genetic background, 
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thus reducing the effect of modifier genes and thereby increasing the probability that 
the effects observed are due to the gene of interest. 
We have shown that protection is present in heterozygous (+/-) mice, whereas the 
knockout (-/-) littermates lacking PKCF- show no reduction in infarct size following 
ischaemic preconditioning. This demonstrates that preconditioning, at least in the 
mouse, protects against infarct size via a signalling pathway that involves the specific 
activation of PKCF-. It is possible that selective activation of other PKC isoforms may 
be sufficient to protect in this model, but this does not detract from the fact that 
ischaernic preconditioning relies on the activation of the endogenous PKC-epsilon 
isofon-n. Future studies in this mouse line should address whether activation of PKC 
with PMA is sufficient to protect knockout hearts, thus determining whether the 
dependence on PKCF- during preconditioning is a unique ability of this isoform. to 
protect, or whether preconditioning only activates this endogenous isoform. If the 
latter is true, then future studies should not disregard the other PKC isoforms, since 
specific activation of these pharmacologically may offer an equal therapeutic benefit. 
4.5 The dichotomy of contractile recovery and infarct size 
In hearts lacking PKCF-, although infarct size is unaltered by preconditioning, 
contractile recovery is still preserved. We are not able to provide a definite 
explanation for this dichotomy. However one can speculate that it is related to the 
mutually exclusive processes of stunning and infarction. For example, antioxidants 
given at the onset of reperfusion have been shown to improve contractile recovery 
with no effect on necrosis. Puett et al. (368) showed in dogs that oxypurinol, which 
inhibits xanthine oxidase and decreases free radical production, improved regional 
ventricular function when given during reperfusion following 60 minutes ischaemia, 
but failed to reduce infarct size. The authors suggested oxygen radicals contribute to 
stunning of reversibly damaged myocardium but not to the final extent of necrosis. 
Ischaemic preconditioning has also been shown to reduce oxygen radical production 
during reperfusion following ischaemia (262), it is therefore possible that this 
reduction in oxidant stress and consequential stunning is independent of 
PKCF- 
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activation in the mouse heart. This would explain the improvement in functional 
recovery, but not infarction, in PKCc deficient hearts following preconditioning. 
Other evidence suggesting these processes differ in murine myocardium is that the 
attenuation of stunning following ischaemic preconditioning requires a greater 
ischaemic trigger than that for infarct size reduction. For example, using 
preconditioning cycles of 2x2.5 minutes ischaemia/2.5 minutes reperfusion, Xi et al. 
showed that ischaemic preconditioning reduces infarction but has no effect on 
contractile recovery in the isolated mouse heart (29). The fundamental question to 
answer however is whether contractile function is a marker of cell viability or whether 
it is a more indicative marker of contractile function within the viable population of 
cells. The fact that contractile function and infarction can be dissociated in these 
studies, and by others (262), argues in favour of the latter. 
4.6 Critique of methods 
A major concern of knockout technologies is the possibility that closely related genes 
may be developmentally upregulated to counteract the knockout phenotype. In this 
respect, although no significant changes in PKC(x or PKC6 protein levels could be 
detected, it is still possible that these isoforms may counteract the knockout effect by 
binding to and activating PKC&specific substrates. Furthermore, although PKCE 
displays a 10-fold greater affinity for its intracellular RACK (RACK1), this RACK is 
still capable of binding other isoforms (Dr Daria Mochly-Rosen, personal 
communication). Therefore, in the absence of PKCF,, another isoform may translocate 
and bind to the PKCF_ RACK and stimulate "epsilon-like" responses. To further 
characterise these effects, PKC isoform. localisation should be compared between 
heterozygous and knockout mice. Nevertheless, these concerns are, to an extent, 
alleviated by the lack of preconditioning in knockout mice. 
Using heterozygous and knockout mice offers the advantage of a more homogenous 
genetic background, however it is still possible that PKCF- protein levels are reduced 
in heterozygotes. Although this does not abolish preconditioning in our model, it may 
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limit the protection. For this reason, the level of protection seen in these hearts should 
be compared to protection in hearts from wild type mice. Alternatively, the levels of 
PKCc protein in heterozygous and wild type mice should be quantified by slot 
blotting. 
Most isolated heart perfusion studies assess cell injury by enzyme (creatine kinase) 
leakage. This proved technically difficult in our model since the low coronary flow 
through mouse hearts necessitates that the heart and cannula are submersed in 37'C 
Krebs throughout the experiment. This prevents the easy collection of coronary 
effluent, although this could have been achieved by cannulation of the pulmonary 
artery. 
4.7 Conclusions 
We have used sibling mice of a single sex to demonstrate that disruption of both, but 
not one, pkc-E alleles leads to the loss of cardiac PKCF, protein and ischaemic 
preconditioning against infarction. The similarity of genetic background suggests the 
association between PKCF- and preconditioning is causal. In murine myocardium, 
PKCF, is necessary for the infarct size reduction that accompanies preconditioning. 
For selective activation of PKC to become a feasible clinical target, future work must 
focus on the design of isoform- specific PKC activators. 
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Chapter 7 General Discussion and Conclusions 
1 ]RATIONALE FOR EXPERIMENTAL METHODS 
Figure 7-1 shows a schematical representation of a signalling pathway that is initiated 
at a cell surface receptor and culminates in an intracellular effect. 





Figure 7-1: Schematical representation of an intracellular signalling pathway. 
This over-simplified schematic highlights both the advantages and difficulties of 
investigating cell signalling pathways. If it were therapeutically desirable to 
pharmacologically agonise the above effect (i. e. ischaemic preconditioning), then 
agents that target distal molecules in the signalling pathway would be more specific. 
Thus, understanding the complete pathway may enable the design of pharmacological 
agents with fewer side effects. The technical difficulties in investigating these 
signalling pathways stem from the large number of structurally related proteins that 
constitute the intracellular protein kinases. Thus, unlike the relatively specific 
agonists/antagonists of cell surface receptors, the pharmacological tools available to 
manipulate signalling proteins are limited and often less specific. 
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To overcome these difficulties, one can adopt a genetic manipulation based approach, 
were the structure of a particular gene (i. e. kinase) is altered to produce an inhibitory 
or activating effect. To modify the gene of interest, DNA must be introduced into 
cells (by transfection) to allow the synthesis of a modified protein. Unfortunately, the 
poor transfection efficiencies in the whole heart, necessitates the use of surrogate, 
cell-based models of preconditioning. An alternative approach is the modification of a 
whole animal genome so a particular protein is either ablated or overexpressed. This 
involves the genetic manipulation of the embryonic stem cell, implantation into a 
female recipient, and breeding of the resulting offspring to generate an animal 
homozygous for the modified gene (the animal is commonly a mouse, due to low 
maintenance costs and rapid gestation periods). 
The studies described within this thesis use both a cell based and genome-targeting 
mouse approach to help overcome the difficulties in examining the signalling 
pathways responsible for ischaemic preconditioning. 
2SUMMARY OF RESULTS 
This thesis examines the role of protein kinases implicated in the intracellular 
signalling pathway responsible for protection following ischaemic preconditioning. 
Previous studies have demonstrated the requirement for G-protein coupled receptor 
activation, which stimulates phospholipase C via the activation of the G-protein (X- 
subunits, Gi/(Gq). One of the effects of phospholipase C activation is the production of 
diacylglycerol, which activates protein kinase C (PKC). 
The PKC family is composed of at least 10 different isoforms. Non-isoform- selective 
PKC inhibitors abolish preconditioning, demonstrating the importance of this kinase 
family, however the particular isoform(s) responsible for protection is/are unknown. 
We used hearts from mice deficient in PKCF- protein to study the role of this 
PKC 
isoform in preconditioning. Evidence is presented to suggest that PKCE is essential 
193 
Chapter 7 General Discussion and Conclusions 
for the reduction in infarct size seen following IP, but is not associated with the 
improvement in contractile recovery. 
Mitogen-activated protein kinase (MAPK) activation has been implicated in 
protection downstream of PKC. Therefore., we examined the interplay between these 
kinases in a characterised model of ischaemic preconditioning in cultured rat neonatal 
ventricular cardiocytes. Of all the MAPK isoforms, only p38 was activated during 
simulated ischaernia in neonatal rat cardiac myocytes. Surprisingly, rather than 
enhancing, preconditioning/PKC activation diminished p38 activity during ischaemia. 
This inhibition of p38 contributes to protection, since pharmacological inhibition also 
protects against simulated ischaemia. 
To assess the relative contributions of different p38 isoforms we used ectopic 
expression of p38(x and p38P. Data is presented that suggests p38(x is the isoform 
activated during ischaemia and inhibited by preconditioning, whereas p38P is 
inhibited during ischaernia. The detrimental effects of p38(x activation are confirmed 
using a dominant negative p38(x mutant, which protects myocytes against simulated 
ischaernia. 
In conclusion, preconditioning protects myocytes by selective activation of PKCF-. 
One of the downstream pathways that contribute to this protection is the inhibition of 










Figure 7-2: Summary of conclusions, based on the results presented within this thesis. 
3 DESIGN OF FUTURE STUDIES 
3.1 Protein kinase C 
Since the discovery that PKC activation is essential for preconditioning, the search for 
its downstream targets have been exclusively hypothesis driven. These hypotheses are 
based on whether known effectors of preconditioning are PKC substrates. For 
example, the activation of the ATP-sensitive potassium (KATP) channel downstream of 
the adenosine receptor was originally reported as the "end-effector" of 
preconditioning (155). Since adenosine receptors couple to PKC via G-proteins, it 
was logical to assume that PKC activation may be necessary for the activation of KATp 
channels. Thus, perhaps not surprisingly, PKC activation was soon shown to be 
critical to KATP channel opening and protection (224,225). However, this early 
interpretation may prove incorrect since the most recent evidence suggests this 
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channel acts as a redox trigger of signalling during preconditioning (369). Similarly, 
tyrosine kinase (130), mitogen-activated protein kinase (223), and stress -activated 
protein kinase (299,370) activation are all implicated in preconditioning and have 
been linked pharmacologically to protein kinase C. The problem with this approach is 
that interpretation of results is dependent on the question being asked. The final 
picture is of a confused field with experimental support for mutually exclusive 
hypotheses (125). 
In attempt to escape these preconceptions, one could adopt a proteomic approach to 
screen for target proteins downstream of PKCF_. This could be achieved by examining 
phosphorylation events associated with preconditioning in isolated mouse hearts using 
two-dimensional gel electrophoresis. These two-dimensional protein phosphorylation 
maps can be repeated in PKCF_ deficient mice, which will not exhibit preconditioning 
despite exposure to identical patterns of ischaemia. By examining the differences in 
phosphorylation patterns in the presence and absence of PKCE it may be possible to 
identify new downstream candidate proteins. This approach can also be employed by 
comparing preconditioned and control hearts, but the lack of ischaemia in the controls 
would be expected to cause large changes in protein phosphorylation patterns that are 
unrelated to protection. The advantage of the knockout approach, is the only 
difference between groups, as well as the ability to precondition, is the presence of 
PKCF-. 
The findings presented in this thesis support the need to design experiments to 
examine MAPK activation following preconditioning in the PKCF- deficient mice. If, 
as suggested in Chapter 1, the decrease in p38 activation is a result of PKC activation, 
which contributes to protection, then this decrease should be absent following 
preconditioning in PKCF- knockout hearts. 
Although PKCF, is responsible for preconditioning in this model, it is unknown 
whether this is a unique ability of this isofonn to protect, or whether preconditioning 
only activates this PKC isoform. To address this question, experiments should be 
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designed to test whether PKC activators can protect mouse hearts in the absence of 
PKCF-. 
A recent study has suggested that mitochondrial KATPchannel opening can trigger the 
preconditioned state by the generation of free radicals, which presumably activate 
intracellular kinases (369). This has raised doubts as to whether mitochondrial KATP 
channel function as a trigger, or effector, of preconditioning (175). Experiments in the 
PKCF, knockout mouse model could help to determine the position of KATPchannels 
in relation to PKCc, by the administration of a KATP channel opener (diazoxide) in 
heterozygous and knockout mice. 
3.2 Mitogen-activated protein kinases 
At the present time, much controversy surrounds the role of p38-MAPK during both 
preconditioning and ischaemia. Most preconditioning investigators believe that 
activation of p38-MAPK contributes to protection. Thus, activation of PKC increases 
p38 activity, which causes MAPKAPK-2 phosphorylation and protection (presumably 
by phosphorylating a protective downstream substrate such as HSP27). During 
ischaemia however, most studies, including those described within this thesis, show a 
detrimental role for p38-MAPK activation. We believe a contributory factor to these 
disparities is the reliance on the p38-MAPK inhibitor, SB203580, as the key 
manipulation to differentiate benefit from harm. This inhibitor is non-specific and 
known to inhibit and activate kinases other than p38. Furthen-nore, the disregard to 
the possible opposing effects of p38 isoforms may also contribute to the confusion. 
In attempt to overcome these uncertainties, future studies should be designed to 
delineate the cause and consequence of differential p38 isoform activation in the 
whole heart. To do this, the studies assessing isoform activation in neonatal cardiac 
myocytes can be repeated in the whole heart by immunoprecipitation of 
phosphorylated p38 during ischaemia followed by Western blotting with anti-p3kc 
and p38P antibodies. To address whether MKK3 activation is responsible for p380C 
activation during ischaemia, we have recently obtained mice deficient in MKK3 
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protein. Preliminary studies to ascertain whether p38 activation during ischaemia is 
abolished in these mice are currently being undertaken. If p38 phosphorylation were 
inhibited, this would provide an ideal opportunity to assess the consequence of p38(x 
activation during ischaemia in the whole heart. 
In regard to preconditioning, we have acquired mice deficient in the downstream p38 
substrate, MAPKAPK-2. If the protective p38 hypothesis is correct, then these mice 
should lack the ability to precondition. Studies are due to start that will investigate 
whether these mice precondition in vivo. 
A final possibility that deserves investigation is whether transient p38 activation 
during preconditioning modulates the sustained p38 phosphorylation during 
ischaernia. This hypothesis could unify the findings that p38 is both good and bad, 
because transient p38 activation during preconditioning may protect by inhibiting the 
detrimental sustained activation during ischaemia. To address this hypothesis one 
could examine the activation of p38-MAPK during ischaemia following 
preconditioning in the presence or absence of p38 inhibitors during preconditioning. 
4 IMPLICATIONS OF THE WORK DESCRIBED 
The field of myocardial protection has been an area of intense research activity for the 
past 3 decades. The attraction lies in the fact that myocardial infarction is the major 
cause of death in the Western World, and that manoeuvres that slow or prevent 
ischaemic cell death are likely to have important clinical implications. Ischaemic 
preconditioning is second only to reperfusion as an efficient means of protecting the 
heart against ischaemia. The studies presented within this thesis highlight two related 
intracellular mechanisms involved in protection, namely PKCF_ activation and p38(x 
inhibition. These findings may represent viable clinical targets, but should at least 
form the basis of future studies designed to dissect the signalling pathways initiated or 






General laboratory chemicals were of analytical grade, solid chemicals were dissolved 
in DI H20 (resistivity >18mQ/cm 3) unless otherwise stated, and adjusted to the 
required pH with either HCI or NaOH. 
1.1 Tissue culture 
1. LI Full growth media 
Dulbecco's Modified Eagles Medium (DMEM) 500mls 
Foetal Calf Serum 50mls 
Penicillin/Streptomycin (100units/ml) 5mls 
1.1.2 Serumfree media 
DMEM 500mls 
Penicillin/Streptomycin (100units/ml) 5mls 
1.1.3 Phosphate-buffered saline 
This was made from pre-formed tablets (GibcoBRL, UK) consisting of: 
NaCl 4. Og 
KCI O. lg 
Na2PO4 0.72g 
KH2PO4 0.12g 
Dissolved in 500mls DI H20- 
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1.2 Neonatal myocyte isolation and culture 
1.2.1 ADS buffer (10x) 
This was used (after diluting 1: 10 in DI H20) to buffer the neonatal cardiac myocytes 
during isolation. The stock solution consisted of 120mM NaCl, 18mM HEPES, ImM 






MgS04 O. Ig 
The pH was adjusted to 7.35 with IN NaOH and the solution brought up to 1 litre 
with DI H20. The solution was then filtered into aI litre autoclaved Duran, using a 
0.22gg Nalgene bottle-top filter, and stored at 4'C. 
1.2.2 Digestion buffer 
INADS buffer (as above) 10MIS 
Collagenase Type-2 (317units/mg) 30mg 
Pancreatin (0.125g/ml) 500gl 
Made up to I 00mls in sterile DI H20and bubbled with 
100% 02 for 60 minutes 
before filter sterilisation. 
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1.2.3 Plating media 
This was used for primary cultures of neonatal myocytes during the first 24 hours 
following isolation. 
DMEM 
Medium 199 (with hanks' salts) 
Horse serum 







1.2.4 Maintenance media 
24 hours following isolation, neonatal myocytes were cultured in maintenance media, 
containing low serum, prior to experimentation. 
DMEM 
m 199 






1.3 Ischaemia studies in neonatal myocytes 
1.3.1 Simulated ischaemia buffer 
Ischaernia is simulated by exposure to Iml of ischaernia buffer containing: 118mM 
NaCl, 24mM NaHC03,, ImM NaH2PO4,2.5mM CaC12,, 1.2mMMgCI2,0.5mM 
sodium, EDTA'2H20,, 20mM sodium lactate, and 16mM KCI, pH 6.2. 






KCI (1 60mM) 10MIS 
NaH2PO4 OOOMM) imi 
CaC12 (250mM) imi 
M9CI2 (120mM) Iml 
sodium, EDTA, 2H20(5OmM) imi 
sodium lactate (60%,, w/v) 175gl 
DI H20 60mls 
pH to 6.2 with IM HCI and made up to 100mls in DI H20- 
1.3.2 Cell viability assay 
1.3.2.1 MTT solution 
An MTT solution (5mg/ml, w/v) is used to assess cell viability, since it is reduced 
from a yellow to a blue dye in living cells. 
MTT 50mg 
PBS 10MIS 
1.3.2.2 Solubilisation solution 
The MTT reaction is stopped by the addition of solubilisation solution containing 
OAM HCI and 10% (v/v) Triton X-100 in isopropranol. 
HCI (IM) 10MIS 




1.4 Viral Production 
1.4.1 Caesium chlotide solutions 
Caesium chloride is commonly used to separate DNA and adenovirus from cellular 
debris, RNA and empty (defective) capsids by ultracentrifugation on buoyant density 
gradients. For separation of recombinant adenovirus from defective virions three 
different buoyant density gradients were used: 
1.25g/ml buoyant density CsCl 
1.35g/ml buoyant density CsCl 




100mls of PBS was added to the caesium chloride and stored at room temperature. 
For separation of DNA from RNA and cellular protein a 65% (w/v) solution of 
caesium chloride was used. 
cscl 65g 
Made up to 100mls with DI H20- 
1.4.2 Dialysis buffer 
This buffer was used to dilute residual caesium chloride from recombinant adenoviral 
preparations. It comprises of 10% (v/v) glycerol, IMM M902, lOmM TRIS at pH 
7.4. 
Glycerol 400mls 
IM M902 stock solution 4mls 
IM TRIS (pH 7-4) 40mls 
Made up to 4 litres with DI H20- 
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1.4.3 Virus storage medium 
This solution was used for storing and diluting aliquots of recombinant adenovirus. Its 
composition is the same as the dialysis buffer above, except the solutions is filtered 
through a 0.45[tm filter prior to use. Aliquots were then stored at -70'C. 
1.5 DNA preparation 
1.5.1 Solution I (GET) 
Consists of 50mM glucose, lOmM EDTA and 25mM Tris pH 8.0. 
Glucose 0.9g 
0. IM EDTA 10MIS 
OAM Tris. HCI (pH 8.0) 25mls 
Made up to 100mls with DI H20- 
1.5.2 Solution 2 (SSDS) 
Consists of 0.2M NaOH and 1% (w/v) SDS. 
IM NaOH 20mls 
10% SDS 10MIS 
Made up to 100mls with DI 
H20- 
1.5.3 Solution 3 
Consists of 3M potassium acetate and 11.5% (v/v) glacial acetic acid. 
5M K. acetate 60mls 
Glacial acetic acid 11.5mls 
DI H20 28.5mls 
204 
Appendices 
1.5.4 Luria-Bertani medium 
Luria-Bertani (LB) medium was used for the small and large-scale growth of bacteria. 
Selection antibiotic (ampicillin) was added to the media prior to use, at either room 
temperature or approximately 40'C for LB-agar. 
To 950mls DI H20 add: 
Bacto-tryptone log 
Bacto-yeast extract 5g 
NaCI log 
The pH was then adjusted to 7.0 with addition of NaOH, and the volume of solution 
brought to I litre with DI H20 and sterilised by autoclaving. To make LB-agar for 
plating bacteria, l5gll of agarose was simply added to the media before autoclaving. 
1.6 Agarose gel solutions 
Agarose gels were used to separate and visualise DNA. They were composed of: 
Agarose 0.6g 
TBE (5x) 12mls 
DI H20 48mls 
Ethidium bromide (10mg/ml) 3gl 
The mixture was heated in a 90OW microwave (Sanyo Electric Co. Ltd., UK) to 
dissolve the agarose and poured into gel casts containing well-forming combs. The 
gel was then left to set for I hour at room temperature prior to use. 
TBE stock (x5) consisted of: 
Tris 54g 
Boric acid 28g 
EDTA (0.5M, pH 8.0) 20ml 
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Made up to I litre with DI H20. 
1.7 Protein harvesting solutions 
1.7.1 Sample buffer (2x) 
Unless otherwise indicated, protein was harvested in boiling two-times sample buffer 




Made up to 100mls with DI H20- 
1.7.2 Cellfractionation lysis buffer 
The buffer used while fractionating samples contained either digitonin (0.05%, w/v) 
for cytosolic fractions or triton X-100 (1%, v/v) for particulate fractions, added to a 
lysis buffer containing 50mM TrisHCl (pH 7.5), 5mM EGTA, 2mM EDTA, I OOMM 
NaF, 20pM Leupeptin, 10[tM E-64,120[tM Pepstatin A, 200[tM PMSF, and 5mM 
DTT. 
TrisHCI (pH 7.5,1 M) 500gl 
EGTA (0.05M) Iml 
EDTA (0.5M) 40ýtl 
NaF (I M) Iml 
Leupeptin (I mg/ml) 100ý11 
E-64 (IOmM) IORI 
Pepstatin A (1.4mg/ml) 60%tl 
PMSF (I OOmM) 20gl 
DTT (I M) 50gl 




1.8 SDS-PAGE gel solutions 
1.8.1 Polyacrylamide gel solutions 
1.8.1.1 Resolving gel 
Contains 1.5M Tris, 0.4% (w/v) SDS to pH 8.8 with HCI. 
SDS 2g 
Tris 90.9g 
Add DI H20to 500mls. 
1.8.1.2 Stacking gel 
Contains 0.5M Tris, 0.4% (w/v) SDS to pH 6.8 with HCI. 
SDS 
Tris 
Add DI H20 to 500mls 
2g 
30.25g 
Polyacrylamide gels were made, depending on concentration, according to Table 7-1. 
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Stack Base (Running) Gel 
Acrylamide 5% 5% 7% 10% 12.5% 15% 18% 
Concentration 
Solution Added: 
Acrylamide (30%) 2ml 6ml 8.4ml 12ml 15ml 18ml 22.5ml 
Resolving gel 9ml 9ml 9ml 9ml 9ml 9ml 
Stacking gel 3ml - 
DI H20 7ml 21 ml 18.6ml 15ml 12ml 5.4ml 4.5ml 
APS (10%) 10ORI 338gl 225gl 180gl 147gl 113gl 103gl 
TEMED 10gl 15ýtl 15gl 15gl 15gl 15ýtl 15gl 
Table 7-1: Solutions used to make polyacrylamide gels for SDS-PAGE. 
1.8.2 Coomassie blue solution 
Protein can be visualised in polyacrylamide gels by exposure to coomassie blue 
solution followed by destaining to remove background staining. 
Coomassie brilliant blue R250 0.25g 
Methanol 45mls 
H20 45mls 
Glacial acetic acid 10MIS 
1.8.3 Destain solution 
Methanol 400mls 
Glacial acetic acid 70mls 
H20 530mls 
1.8.4 Gel running buffer (JOx) 
Proteins were electrophoresed in running buffer containing 25mM Tris, 
0.5M 




Glycine 72. lg 
SDS 5g 
Made up to 500mls with DI H20- 
Before use the above buffer was diluted 1: 10 in DI H20- 
1.8.5 Gel transfer buffer (IOx) 
Proteins were transferred electrophoretically from SDS-PAGE gels onto nitrocellulose 
membranes in buffer containing 25mM Tris, 0.5M Glycine, and 20% (v/v) methanol. 
Tris 
Glycine 
Made up to 500mls with DI H20. 
15.2g 
72. lg 
Prior to use, 200mls of the above solution is added to 400mls methanol and 1400mls 
DI H20- 
1.8.6 Western blot washing solution 
Unless otherwise indicated, this solution was used to wash nitrocellulose membranes, 
between incubation of antibodies, to prevent non-specific binding. 
PBS 500mls 
Tween-20 50%tl 




1.9.1 Anaesthetic solution 
Mice were anaesthetised by an intraperitoneal injection of ketamine (I 50mg/kg), 
xylazine (24mg/kg), and heparin (I OOIU) (adapted from Marber et al. (26)). 
This was achieved by injecting the following solution at volumes dependent on mouse 
weight, as indicated in Table 7-2. 
Ketamine (100 mg/ml) 2mls 
Xylazine (20 mg/ml) 1.6mls 
PBS 1.4mls 
Heparin 4mls 
Mouse weight (g) Anaesthetic (gl) Mouse weight (g) Anaesthetic 
25 203 36 242 
26 211 37 250 
27 218 38 258 
28 227 39 266 
29 235 40 274 
30 243 41 285 
31 251 42 293 
32 259 43 301 
33 267 44 309 
34 275 45 318 
35 283 46 326 
Table 7-2: Dose of anaesthetic administered to mice. 
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1.9.2 Krebs-Henseleit Buffer 
Krebs-Henseleit (K-H) buffer consisted of 118.5mM NaCl, 25. OmM NaHC03, 








DI H20 4.5 litres 
The solution is bubbled with 95%02/5%CO2 for 10 minutes to lower the pH. Then 
1.04g CaCl2was added and the solution brought up to 5 litres. The buffer was filtered 
through a 0.8gM cellulose nitrate micro-filter (Whatman, Maidstone, UK), and stored 
at 4'C for no longer than I day. 
1.9.3 Ttiphenyl tetrazolium chloride staining solution 
AI% (w/v) triphenyl tetrazolium chloride (TTC) was used to demarcate the infarct 
zone in isolated mouse hearts. 
Na2HP04 (8% solution, w/v) 0.8mls 
NaH2PO4 (20% solution, w/v) 0.2mls 
TTC O. Ig 
DI H20 9MIS 
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1.9.4 Mouse heartfixative 
Following sectioning, the heart slices were fixed for 24 hours, prior to visualisation in 
a 10% (v/v) formaldehyde solution. 
Formaldehyde (40%, v/v) 
DI H20 
2 TABLE OF ANTIBODIES 
12.5mls 
37.5mls 
Antibody Dilution Type Source 
PKC-delta 1: 1000 Mouse mAb Transduction Labs 
PKC-epsilon 1: 1000 Mouse mAb Transduction Labs 
PKC-alpha 1: 1000 Mouse mAb Transduction Labs 
ERK2 1: 1000 Mouse mAb Santa Cruz Biotech. 
PhosphoThr2O2/Tyr2O4 
-ERK1/2 1: 1000 Rabbit pAb Cell Signalling 
p38 1: 1000 Rabbit pAb Cell Signalling 
Phospho Thrl8O/'ryrlg2 -p38 1: 1000 Rabbit pAb Cell Signalling 
Immobilised-phosphoThrl8O/Tyrl82 -p38 1: 50 Mouse mAb Cell Signalling 
PhosphoThr183fryrI85 
-JNK1/2 1: 1000 Mouse mAb 
Cell Signalling 
Phospho Ser82 -HSP27 1: 40 Mouse mAb 
Dr RA Quinlan 
PhosphoSer473_p" 1: 1000 Rabbit pAb Cell Signalling 
PhosphoTyr308_p" 1: 1000 Rabbit pAb Cell Signalling 
MKP-I 1: 1000 Rabbit pAb Santa Cruz Biotech. 
p38-alpha 1: 500 Rabbit pAb Santa 
Cruz Biotech. 
p38-beta 1: 5000 Goat pAb Santa 
Cruz Biotech. 
Phospho-MKK3/6 1: 1000 Mouse mAb Santa Cruz Biotech. 
Table 7-3: Description of antibodies used throughout this thesis. 
Polyclonal (pAb) or monoclonal (mAb) antibodies were used at different dilutions as 
indicated. For phosphorylation-specific antibodies, the phosphorylation site(s) 
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ABSTRACT Activation of protein kinase C (PKC) 
and more recently mitogen-activated protein kinases 
(MAPKs) have been associated with the cardiopro- 
tective effect of ischemic preconditioning. We exam- 
ined the interplay between these kinases in a charac- 
terized model of ischemic preconditioning in 
cultured rat neonatal ventricular cardiocytes where 
ectopic expression of active PKC-6 results in protec- 
tion. Two members of the MAPK family, p38 and 
p42/44, were activated transiently during precondi- 
tioning by brief simulated ischemia/reoxygenation. 
Overexpression of active PKC-8, rather than aug- 
menting, completely abolished this activation. We 
therefore determined whether a similar process oc- 
curred during lethal prolonged simulated ischemia. 
In contrast to ischemia, brief, lethal-simulated isch- 
emia activated only p38 (2.8--i: 0.45 vs. basal, 
P<0.01), which was attenuated by expression of 
active PKC-8 or by preconditioning (0.48: L-0-1 vs. 
ischemia, P<0.01). To determine whether reduced 
p38 activation was the cause or an effect of protec- 
tion, we used SB2035809 a p38 inhibitor. SB203580 
reduced ischemic injury (CK release 38.0--t3.1% 
LDH release 77.3. ±: 4.0%, and MTT bioreduction 
127.1. -t: 4.8% of control, n=20, P<0.05). To deter- 
mine whether p38 activation was isoform selectiveg 
myocytes were infected with adenoviruses encoding 
wild-type p38ot or p38P. Transfected p38ot and P 
show differential activation (P<0.001) during sus- 
tained simulated ischemia, with p38ot remaining ac- 
tivated (1.48--tO. 36 vs. basal) but p380 deactivated 
(0.36--tO. l vs. basalý P<0.01). Prior preconditioning 
prevented the activation of p38ot (0.65: tO. ll vs. 
ischemia, P<0.05). Moreover, cells expressing a 
dominant negative p38ot, which prevented ischemic 
p38 activation, were resistant to lethal simulated 
ischemia (CK release 82-9: t 3.9 % and MTT bioreduc- 
tion 130.2: t6.5% of control, n=8, P<0.05). Thusq 
inhibition of p38ot activation during ischemia re- 
duces injury and may contribute to preconditioning- 
induced cardioprotection in this model. -Saurin, 
A. T., Martin, J. L., Heads, R. J., Foley, C., Mock- 
ridge, J. W., Wright, M. J., Wang, Y., Marber, M. S. 
The role of differential activation of p38-mitogen- 
activated protein kinase in preconditioned ventricu- 
lar myocytes. FASEBJ 14,2237-2246 (2000) 
Key Words: myocardial ischemia - cardioprotection - ischemic 
preconditioning - cytoprotection 
THE TERM ISCHEMIC preconditioning was first coined 
by Murry and colleagues to describe a phenomenon 
where brief periods of sublethal ischemia protected 
or 'preconditioned' the heart against infarction 
caused by a subsequent more prolonged period of 
coronary artery occlusion (1). Since this initial dis- 
covery, preconditioning has become recognized as 
the most powerful form of cardioprotection other 
than reperfusion (2). Unfortunately, the protection 
afforded by a brief period of ischemia is short-lived 
(3) and cannot be renewed (4). In an attempt to 
overcome these deficiencies, the signaling pathways 
responsible for triggering and maintaining this pow- 
erful form of cardioprotection have become the 
focus of many investigators. 
Early pharmacological studies delineated the me- 
diator(s) responsible for adaptation in response to 
brief ischemia. These investigations in whole heart, 
and later in cell-based models (5), showed that 
protection was dependent on the activation of a wide 
variety of heptahelical transmembrane receptors in- 
cluding adenosine type I and 3 (6,7), bradykinin 
(8), (xl-adrenergic (9), endothelin (10), angiotensin 
11 (11), and delta-1 opioid receptors (12,13). Al- 
though structurally diverse, these receptors have a 
common feature of coupling to protein 
kinase C 
(PKQ via GTP binding proteins. The importance of 
protein kinase C to ischemic preconditioning 
has 
been shown in a variety of studies in whole 
heart and 
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in isolated ventricular cardiocytes (8,11,14-16). 
Although it is widely accepted that PKC plays a 
pivotal role in ischemic preconditioning, the rele- 
vant downstream signaling molecules remain a topic 
of intense investigation and controversy. 
Apart from PKC, the only other well-accepted 
component of the preconditioning signaling path- 
way is the ATP-dependent potassium channel. It is 
uncertain, however, whether this channel lies up- 
stream or downstream of PKC (17-19). Similarly, in 
preconditioned myocardium an increase in the acti- 
vation of p38 and p42/44 mitogen-activated protein kinases (MAPK) has been linked to protection (20, 
21). However, this is not consistent with the reduc- 
tion in ischemic injury that accompanies p38-MAPK 
inhibition in similar models (22-24). These incon- 
sistencies only serve to further fuel the investigation 
of signals distal to PKC. 
Neonatal rat ventricular cardiac myocytes have 
been used as an archetypal model to interrogate the 
signal transduction cascades underlying cardiac hy- 
pertrophy (25). Hypertrophy and preconditioning 
have features in common, including agonists, which 
trigger (endothelin, norepinephrine, angiotensin 
11), and PKCs, which mediate the final response 
(25). These similarities have caused others (26-28) 
and us (29) to characterize models of ischemic 
preconditioning in this cell type (5). These and 
other cell-based models (13,30-37) have the advan- 
tages of the in vivo features of ischemic precondi- 
tioning without the disadvantages of multiple cell 
types, low transfection. efficiency and spatial hetero- 
geneity in depth of ischemia and quality of reperfu- 
sion (5). Using such a model, we previously demon- 
strated that preconditioning is PKC dependent and 
can be mimicked by expression of constitutively 
active PKC-8 (29). Our aim was to use this character- 
ized model to investigate the interplay between 
preconditioning, PKC, and MAPKs- 
MATERLUS AND METHODS 
Isolation and culture of rat ventricular cardiomyocytes 
Neonatal rat ventricular myocytes were prepared from 1- to 
2-day-old Sprague-Dawley rats as described previously (29, 
38). Briefly, cells from neonatal rat ventricles were dispersed 
in a series of incubations at 37'C in HEPES-buffered salt 
solution containing 0.5 mg/mI colliagenase and 0.6 mg/ml 
pancreatin. Dispersed cells were then preplated for at least 30 
min to minimize fibroblast contamination, and the unat- 
tached cells were replated on 6-well gelatin-coated plates at a 
density of -I million cells/well. Fibroblast contamination was 
less than 5%. The cardiac myocytes were cultured in 4: 1, 
Dulbecco's modified Eagle's medium: M199, supplemented 
with 10% horse serum, 5% fetal calf serum (FCS), and 100 
units/ml penicillin/streptomycin at 370C in room air with 5% 
C02 for the first 24 h. Thereafter, cells were maintained in an 
identical medium with a reduced serum concentration of 1% 
FCS- Under these conditions, in excess of 80% of cells beat spontaneously for up to I wk in culture. Experiments were performed after 2-4 days in culture. 
cDNA constructs 
The high efficiency eukaryotic expression plasmid pCAGGS was used for all PKC transfections (39). This plasmid contains the cytomegalovirus immediate early enhancer and chicken P-actin promoter with the first intron upstream of a multiple 
cloning site. It has been shown previously that this heterolo- 
gous promoter is transcriptionally active in cardiac myocytes (40). PKC mutants were constructed as described previously (29). Two PKC isotypes were studied: 1) wild-type PKC-8; 2) PKC-8 with a limited deletion of the inhibitory pseudosub- 
strate subdomain (residues 151-160). This mutant PKC iso- 
type has been shown to code for a constitutively active functional protein (41,42). All plasmids were purified by 
alkaline lysis of the bacterial host (DH5ot), followed by 
polyethylene glycol precipitation. 
Recombinant adenovirus vectors 
Recombinant adenoviruses encoding wild-type p38(x, wild- 
type p38P, or dominant negative p38ot driven by a cytomeg- 
alovirus promoter were generated as described previously 
(43,44). The dominant negative p38(x has a mutated phos- 
phorylation site (TGy180-I82 to AGF), rendering it resistant to 
phosphorylation (45). Recombinant adenoviruses were tested 
for transgene expression in cardiac myocytes by reverse 
transcriptase-polym. erase chain reaction, Western blot, or 
kinase assays. The concentrated recombinant adenoviruses 
were prepared and titered as described (44). 
Transfection of neonatal cardiomyocytes 
Cardiocytes at 70-80% confluency were transfected with 
pCAGGS expression plasmid by an integrin targeting peptide- 
mediated transfection procedure described previously (46). 
The peptide-Lipofectin complexes were prepared by mixing 
40 RI peptide (0.1% w/v) and 0.75 ýd Lipofectin (Life 
Technologies Ltd., Paisley, U. K. ). DNA (0.01% w/v) in opti- 
mem was added to peptide-Lipofectin complex at a ratio of 
2.5: 1 (v/v). DNA-peptide-Lipofectin complexes were al- 
lowed to stand for Ih at room temperature before use; 100 RI 
of this mix was diluted to 1 ml in optimem and added to one 
well of a 6-well plate. Cells were then incubated overnight at 
37'C in room air supplemented with 5% C02. Thereafter, 
complex/optimem was removed and replaced with mainte- 
nance medium containing I% FCS and the cells were re- 
turned to the incubator. Cell extracts were assayed for protein 
48-72 h post-transfection. By using pCAGGS-GFP as a re- 
porter, transfection efficiency was consistently between 20 
and 30%. 
Cells maintained in serum-free medium were infected with 
adenoviruses at a multiplicity of infection of 10 plaque- 
forming units/cell for Ih at 37'C in room air containing 5% 
C02. Cells were then cultured in maintenance medium 
containing 1% FCS for an additional 48-72 h before bio- 
chemical analysis. 
Ischemia model 
The cells were washed once with phosphate-buffered saline 
(PBS) before addition of 1 ml of ischemia buffer (118 mM 
NaCl, 24 mM NaHC03, I mM NaH2PO4,2.5 mM CaC12,1.2 
MM MgC'2,0.5 mM sodium-EDTA-2H20,20 mM sodium 
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lactate, and 16 mM KCI, pH 6-2) pregassed with 5% C02ý 95% 
argon. On addition of ischernia buffer, spontaneous contrac- 
tion within the monolayer ceased. Cells were then transferred 
to anaerobic GasPak pouches (Becton Dickinson, Sparks, 
Md. ) and incubated at 370C for up to 6 h. The 02 content of 
the atmosphere inside the pouches was <I% for the duration 
of the experiment as measured by an anaerobic indicator. 
Measurement of enzyme release 
Upon opening the ischernia chamber (reoxygenation), 200 
ýLl samples of the ischernia buffer were gently collected for 
the determination of creatine kinase (CK) and lactate dehy- 
drogenase (LDH). The next day a spectrophotometric CK 
and LDH enzyme assay was performed with Boehringer 
Mannheim (Mannheim, Germany; MPR-1) and Sigma (St. 
Louis, Mo.; TOX-7) assay kits, respectively. 
Evaluation of cell viability 
After simulated ischemia, cells were reoxygenated in mainte- 
nance medium containing 1% FCS. After 2 h, medium was 
aspirated and cells incubated in 500 [LI PBS containing 2.5 mg 
3-(4,5-dimethylthiaziazol-2-yl)2,5-diphenyI tetrazolium bro- 
mide (NfrT) for 30 min at 37'C in room air containing 5% 
C02. During this incubation the tetrazolium component of 
the dye is reduced, in metabolically active cells, to a formazan 
dye. Thereafter the reaction was terminated by addition of 
500 ýLl solubilization solution (0.1 mol/I HCI, 10% triton 
XIOO, in isopropanol) and the absorbance of the lysate was 
recorded at 570 nm using an ELISA reader. 
Western blot analysis 
Cells from parallel plates were washed three times in ice-cold 
PBS and harvested in 1 ml of hot electrophoresis sample 
buffer (250 mM Tris-HCl, 4% sodium dodecyl sulfate, 10% 
glycerol, and 2% P-mercaptoethanol, pH 6.8), then boiled for 
an additional 5 min. The cell extracts were then centrifuged 
for 5 min to remove insoluble material; 0.003% bromphenol 
blue was added and the samples were loaded on a 10% 
polyacrylamide gel. After I-dimensional separation the pro- 
tein was electrophoretically transferred to nitrocellulose 
membranes (Hybond C, Amersham, UK). Coomassie stain- 
ing of identically loaded gels confirmed uniform protein 
loading. 
Blots were sequentially probed with either munne mono- 
clonal antibodies specific for ERK2 (Santa Cruz Biotechnol- 
ogy, Santa Cruz, Calif. ) and a peroxidase-conjugated rabbit 
anti-mouse IgG secondary antibody (DAKO A/S, Glostrup, 
Denmark) or rabbit polyclonal antibodies specific for p38, 
phospho-p38, or phospho-p42/44 (New England BioLabs, 
Hitchin, U. K) and a peroxidase-conjugated swine anti-rabbit 
IgG secondary antibody (DAKO A/S). Secondary antibodies 
were then detected by incubation of the nitrocellulose with 
enhanced chemiluminescence (ECL, Amersham, Little Chal- 
font, U. K) for 60 s prior to exposure to autoradiography film. 
The densities of all Western blot bands were analyzed using 
NIH Image version 1.61. 
Statistical analysis 
All values are expressed as mean ±SE. Data for individual 
treatments were collected from no more than two wells 
from 
each experimental preparation. 
The 'n' numbers under 
tresults' relate to the number of wells 
from which data were 
obtained. For each treatment, mean values were pooled to 
ISCHEMIC PRECONDITIONING 
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allow statistical comparisons. Statistical comparisons between 
groups were performed by one-way analysis of variance. All post hoc comparisons were by the Fischer protected least 
significant difference method. All analyses were performed 
using Statview version 4.0 statistical package (Abacus Con- 
cepts Inc., Berkeley, Calif. ). A probability value :50.05 was 
considered significant. 
RESULTS 
Activation of MAPKs during preconditioning in 
isolated neonatal cardiac myocytes 
Preconditioning with 90 min ischemia and 30 min 
reoxygenation has been shown to delay cell death in 
response to subsequent prolonged ischemia in our 
model (29). p38-MAPK activation has been reported 
during preconditioning-like ischemia in the intact 
heart (47). It has been proposed that this activation 
is associated with subsequent protection against le- 
thal ischemia (20). Therefore, we wished to investi- 
gate whether similar activation occurred during pre- 
conditioning with simulated ischemia in our model. 
Cardiocytes were harvested at various time points 
during an acute preconditioning stimulus of 90 min 
ischemia and 30 min reoxygenation. Cell lysates were 
probed with phospho-specific antibodies for p38, 
p42/44, or p46/54 to quantify MAPK activation. 
These preliminary experiments demonstrated that 
although no p46/54 phosphorylation could be de- 
tected, p38 and p42/44 were transiently activated 
during reoxygenation after sublethal ischemia (re- 
sults not shown) and that at 10 min reoxygenation 
both p38 and p42/44 displayed maximal activation 
(see Fig. 1). 
The specific phosphorylation of MAPKs during 
reoxygenation may be a consequence of PKC activa- 
tion, since it had been reported previously that PKC 
is activated at the onset of reperfusion (48). If this is 
true in our model then we should observe a compa- 
rable level of MAPK phosphorylation in cells overex- 
pressing active PKC-8 even in the absence of precon- 
ditioning ischemia. Therefore, to test this hypothesis 
we transfected myocytes with constitutively active 
PKC-8 in an attempt to mimic the pattern of p38 and 
p42/44 phosphorylation seen after 90 min simulated 
ischemia and 10 min reoxygenation. 
Effect of PKC-8 on MAPK activation in cardiac 
myocytes 
To determine whether PKC-8 could activate MAPKs, 
myocytes were transfected with the eukaryotic ex- 
pression plasmid pCAGGS encoding either wild-type 
PKC-8, active PKC-8, or vector alone. After 
48-72 h, 
myocytes were either harvested, to assess 
basal MAPK 
phosphorylation, or sub"ected to 
90 min ischemia 
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Figure 1. Activation of p38 and p42/44 NIAPK during reoxy- 
genation after 90 min simulated ischemia. Myocyte cell lysates 
were prepared from naive cells (control) and from wells after 
90 min SI and 10 min reoxygenation (ischemia). Each pair of 
samples is from a different cardiocyte preparation exposed 
independently to simulated ischemia and reoxygenation. 
Samples are probed with dual phospho-specific NLAPK anti- 
bodies for p42/44 (Ai) and p38 (Bi) or antibodies detecting 
total p42 (Aii) and total p38 (Bii). Panel C represents the 
mean activation of p38, p42 and p44 during simulated 
ischemia/reoxygenation expressed as a ratio of that seen in 
naive cells in 5 independent experiments. *P<0.01 vs. naive 
control, n=5. 
ing-induced NLAPK activation. It is apparent from 
Fig. 2 that overexpression of active PKC-8 has no 
effect on basal p42/44 phosphorylation compared to 
controls (Fig. M). Surprisingly, however, the in- 
crease in p42/44 phosphorylation observed during 
preconditioning was completely abolished in the 
presence of active PKC-8; this is not due to a down- 
regulation of NIAPK, as the total amounts of p42 
remain constant between treatments (Fig. 2 Ail). In 
contrast, p38 exhibits a higher basal activation in 
cells expressing active PKC-8; however, once again 
the preconditioning-induced increase in p38 phos- 
phorylation is completely abolished (see Fig. 2Bi). 
These data did not support our original hypothesis 
that PKC-8 protects by causing the same activation of 
MAPKs that occurs with preconditioning. In contrast 
and paradoxically, these data suggest that PKC-8 
inhibits MAPK activation in response to ischemia/ 
reoxygenation. It is possible that this unexpected 
negative regulation may be the mechanism through 
with PKC-8 protects against lethal ischemia (29). 
This alternative hypothesis is consistent with reports 
examining the role of p38 during ischemia in the 
absence of preconditioning, which show that inhibi- 
tion is protective (22-24). However, for PKC-8 to 
protect via this mechanism, the same inhibitory 
effect on "Ks must occur during prolonged lethal 
ischernia. Therefore, we delineated the NLAPK path- 
ways that were activated by simulated ischernia alone. 
Activation of NL4, PKs during prolonged simulated ischemia 
To quantify the level of MAPK activation during ischemia, cardiocytes were subjected to varying du- 
ration's of simulated ischemia before cells were harvested and constituent proteins probed with anti- 
phospho-p38 and -p42/44 antibodies (see Fig. 3). In 
agreement with other recent reports (22,49), we found that during ischemia p38 exhibits a prolonged 
activation, which is maximal after 2.5 h ischemia 
(Fig. 3B). In contrast, phospho-p42/44 MLAPK is inhibited below basal levels for the entire duration of ischemia (Fig. 3A). This suppression of p42/44 dur- 
ing ischemia eliminates the possibility that PKC-8 
protects through negative regulation of p42/44 
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Figure 2. Activation of p38 and p42/44 MAPK after precon- 
ditioning in myocytes overexpressing PKC-8. A) Western blot 
probed with anti-phospho-p42/44 (i) or anti-p42 (ii). B) 
Western blot probed with anti-phospho-p38 (i) or anti-p38 
(ii). Constituent proteins in both panels were derived from 
the same experimental groups. Naive cells (-) were com- 
pared to preconditioned (+) in untreated cardiocytes, cells 
transfected with expression plasmid containing an empty 
multiple cloning site, encoding wild-type PKC-8, or constitu- 
tively active PKC-8 (see Materials and Methods). A) Maximal 
p42/44 MAPK activation was assessed in cell lysates harvested 
after 10 min reoxygenation after 90 min simulated ischemia, 
using dual phospho-specific p42/44 antibodies (i). Total p42 
levels were detected using a monoclonal anti-p42 antibody 
(ii). B) p38 activation was detected using phospho specific 
p38 antibodies (i) and total p38 was detected using anti-p38 
antibodies (ii). 
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Figure 3. Time course of p38 and p42/44 MAPK activation 
during prolonged simulated ischernia in naive cardiocytes. 
Cardiocytes were subjected to varying duration's of simulated 
ischemia (0-6 h) before cells were lysed for Western blot 
analysis. A) Constituent proteins were probed with dualphos- 
pho-specific p42/44 antibodies to assess p42/44 NLAPK acti- 
vation or anti-p42 antibodies to examine p42 levels. B) 
Samples identical to panel A were probed with anti-dualphos- 
pho-p38 antibodies to detect p38 activation or anti-p38 anti- 
bodies to assess total p38 levels. 
the result of PKC-8 overexpression on the activation 
of p38 during simulated ischemia. 
Effect of active PKC-8 on p38 phosphorylation 
during lethal simulated ischemia 
Isolated myocytes were either cultured under normal 
conditions (untreated) or transfected with plasmids 
encoding wild-type or active PKC-8; 48-72 h post- 
transfection, cardiocytes were subjected to 2.5 h 
simulated ischemia and immediately harvested for 
Western blot analysis. Lysates were probed with 
anti-p38 or anti-phospho-p38 antibodies to detect 
the effect of PKC-8 overexpression on either p38 
induction or activation (see Fig. 4). Overexpression 
of wild-type PKC-8 increased p38 phosphorylation 
during ischemia (Fig. 4i), although comparable re- 
sults with empty vector alone suggest this is not a 
consequence of PKC-8 (results not shown). However, 
transfection of active PKG8 significantly attenuated 
the ischemia-induced p38 activation (Fig. 4i), al- 
though there was no effect on total p38 levels (Fig. 
4ii). 
We have shown previously that specific activation 
ISCHEMIC PRECONDITIONING AND p38-MAPK 
of PKC-8 during ischemia protects myocytes against 
cell death (29) and, as we show here, PKC-8 activa- 
tion causes an inhibition of p38 phosphorylation. Since preconditioning also protects by activating PKC, we sought to compare its effect on p38 activa- 
tion by examining ischemia-induced phosphoryla- 
tion in naive and preconditioned cells. 
Activation of p38 during simulated ischemia after 
preconditioning 
Cardiocytes were preconditioned with 90 min simu- 
lated ischemia and 30 min reoxygenation. These and 
untreated myocytes were then subjected to 2.5 h 
ischemia to maximally activate p38. Thereafter p38 
phosphorylation was assessed, as before, by immuno- 
blotting with phospho-p38 antibodies. Figure 5 
shows that, akin to active PKC-8 overexpression, 
preconditioning consistently inhibited p38 activa- 
tion during ischemia (P<0.01). 
The negative regulation of p38 activation during 
ischemia is therefore associated with the cardiopro- 
tective effects of both preconditioning and active 
PKC-8 overexpression. However, on the basis of 
these results alone, it is not possible to ascertain 
whether the inhibition is a cause of protection or 
simply a consequence of the attenuation of ischemic 
injury. Therefore, to define the role of p38 on cell 
viability after ischemia, we used pharmacological 
inhibition of p38 in an attempt to mimic protection 
afforded by preconditioning/ PKC - 
Consequence of p38 activation on myocyte viability 
after ledial ischemia 
We wished to examine the role of p38 during 
ischemia by inhibiting activity with SB203580, which 
reversibly binds to the ATP binding site (50). Using 
two separate end points of CK and LDH release to 
assess cell injury and by measuring cell viability with 
MTT bioreduction, we can clearly see that inhibition 
of p38 during ischemia significantly protects myo- 
cytes against cell death (see Fig. 6). Therefore, 
during ischemia p38 activation is detrimental to 
myocyte survival, because specific inhibition of this 
Figure 4. Effect of active PKG8 
expression on p38 phosphorylation 
during ischemia. 48-72 h post- 
transfection, myocytes were sub- 
jected to 2.5 h simulated ischemia 
and harvested for Western blot 
analysis to detect p38 dual phos- 
phorylation. Using dual phospho- 
specific p38 antibodies, ischemia- 
induced p38 activation was 
detected in untreated cells or cells 
transfected with wild-type or active PKC-8 (i). Total p38 levels 
in the same cells were assessed with anti-p38 (ii). 
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Figure 5. The consequence of 
preconditioning on subse- 
quent p38 activation during 
simulated ischernia. Ai) West- 
ern blot probed with anti- 
phospho-p38 to detect p38 
MAPK activation. Lysates were 
prepared from untreated cells 
or cells after 2.5 h ischernia in 
preconditioned and control 
cells. Aii) Total p38 levels were 
detected in the same cells with 
anti-p38. B) Mean p38 activa- 
tion compared to untreated 
controls (n=4). *P<0.01, p38 
activation during ischernia vs. 
nonischernic /untreated. 
§P<0.01, p38 activation during 








pathway is sufficient to protect myocytes. Hence, the 
attenuation of p38-NLAPK activation by PKC-8 over- 
expression and preconditioning contributes to the 
protective effect of both these treatments. 
The measurement of total p38 activation through 
the use of dual phospho-specific antibodies has limita- 
tions. In light of recent reports characterizing new p38 
isoforins that share the same TGY motif recognized by 
commercially available antibodies, it has become ap- 
parent that isotypes may differ significantly in function, 
if not in structure. In fact, Wang and co-workers have 
proposed opposing roles for p38ot and p38P on myo- 
cyte survival, postulating that p38u- may be responsible 
for cell death and apoptosis, and p38P for hypertrophy 
and survival (51). Therefore, an increase in p38(X 
activation with a comparable decrease in p38P phos- 
phorylation may not alter total p38 activation as de- 
tected by phospho-specific antibodies. But if the Wang 
hypothesis were correct, we would expect such a 
change in the balance of active p38 isoforms to cause a 
large decrease in cell viability. Thus, there is a possibil- 
ity that this decrease in viability may not be correctly 
attributed to p38 activation using currently available 
antibodies, so we wanted to examine the isotype spe- 
cific activation of p38 during ischemia in our model. 
Activation of p38 isotypes during simulated 
ischemia 
To look at the activation of individual isotypes, we 
used recombinant adenoviruses as an efficient gene 
delivery vector to express various p38 signaling mol- 
ecules (51,52). Using a recombinant adenovirus, 
expressing the green fluorescent protein (GFP) as a 
reporter, greater than 95% of myocytes express the 
transgene 48-72 h post-transfection. Cardiomyocytes 
were infected with vectors expressing FLAG-tagged 
wild-type p38a_ and p38P. Adenovirally encoded 
p38P has a higher apparent MW than p38(x, thus 
enabling us to easily distinguish between the iso- forms using p38 antibodies (Fig. 7). At a multiplicity 
of infection of 10, adenoviral-directed p38a_ and 
p38P expression was detected at comparable levels by Western blot analysis (Fig. 7A). 
Using phospho-specific antibodies to examine ac- 
tivation, we noted that during ischemia p38ot exhib- its a strong phosphorylation similar to that seen with 
endogenous p38 in untransfected controls (see Fig. 7B). Preconditioning, which decreases endogenous 
p38 activation during ischemia, also significantly 
attenuates ectopically expressed p38ot phosphoryla- 
tion (P<0.05). In contrast, transfected p38p, which 
exhibits a high level of basal phosphorylation, is 
inhibited during ischemia (P<0.01) and this inhibi- 
tion is moderately enhanced in preconditioned cells 
(Fig. 7 Q. 
Effect of p38 isotype activation during simulated 
ischemia 
As shown in Fig. 6 and elsewhere (22-24,53), inhibi- 
tion of p38 during ischemia using SB203580 protects 
against cell death. Since we demonstrate a selective 
activation of p38ot over p38P during ischemia, we 
would expect that protection ensues as a result of p38a. 
inhibition with SB203580. To test this hypothesis, we 
transfected cells with a dominant negative p38u- mu- 
tant (TW80-182 to AGF: see Materials and Methods). 
As shown in Fig. 8A, 48 h after transfection of either 
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Figure 6. Cell viability after 6h of simulated ischemia in the 
presence of SB203580. A) Total CK and LDH released into 
ischernia buffer during 6h of simulated ischemia. Panel A 
therefore represents cell injury during ischemia alone. B) Cell 
viability was measured by MTT bioreduction within monolay- 
ers after 6h simulated ischemia and 2h reoxygenation. 
Injury 
in the presence of SB203580 (M) is expressed as a percentage 
of injury in the absence of SB203580 ([1). 
Viability in cells 
treated with SB203580 alone for 6h (without ischemia) was 
equivalent to that observed in untreated cells 
(results not 
shown). All P values are for comparisons between 
ischemia in 
the presence and absence of SB203580. *P<0.05, 
**P<0.001, 
n=20. 
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Figure 7. Activation of p38 isotypes during iSchemia in un- 
treated and preconditioned cells. Cardiocytes were infected with 
adenoviral constructs encoding FLAG-tagged wild-type p38-a or 
-P. 48-72 h postinfection untreated and preconditioned cardio- 
cytes were subjected to 2.5 h ischernia before cells were har- 
vested and lysed for Westem blots. A) The relative expression of 
p38 signaling molecules in infected cells were compared with 
untreated cells using anti-p38 antibodies. B) Identical lysates 
were probed with dualphospho-specific p38 antibodies to detect 
isotype-specific p38 activation during iSchemia. Q Mean p38 
activation during ischemia compared to untreated controls in at 
least 4 independent experiments. ýP<0.001, p38a. activation vs. 
p38P activation during ischernia. *P<0.05, p38ot activation dur- 
ing ischernia with vs. without preconditioning (EP). "P<0.01, 
p38P activation during ischernia vs. nonischemic/untreated 
cells. 
activation in our system is a decrease in myocyte 
survival. Constitutively active PKG8, which renders 
myocytes resistant to ischemia, inhibits ischemia- 
induced p38o- activation. An identical effect occurs 
in untransfected cells preconditioned by brief simu- lated ischemia. Similar inhibition of p38o- with a dominant negative mutant also protects against isch- 
emia. These data suggest that the protection con- ferred by preconditioning may, at least in part, be 




We have investigated the relationship between pre- 
conditioning, protein kinase C and mitogen-acti- 
vated protein kinase in primary cultures of neonatal 
cardiocytes. Our data show that during lethal simu- 
lated ischemia, p38ot-MAPK exhibits a period of 
prolonged phosphorylation that reduces myocyte 
survival. In addition, preconditioning and the ex- 
pression of active PKC-8 inhibit p38ot activation 
during lethal ischemia and enhance myocyte sur- 
vival. Inhibition of p38ot activation with SB203580 or 
dominant negative p38o- (p38otDN) also gives rise to 
protection. These findings suggest that p38o--NLAPK 
modulates cardiocyte survival during simulated isch- 
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wild-type or dominant negative p38u- (p38a_DN), com- 
parable overexpression of p38 can be detected. After 
2.5 h ischemia, which is the time of maximal p38 
activation, cells expressing p38a_DN showed no signifi- 
cant p38 activation whereas cells expressing wild-type 
p38a_ showed increased p38 activation (Fig. 8B). More- 
over, the cells expressing p38u-DN were protected 
against simulated ischemia compared to empty vector 
transfected cells (CK release=82.9-+-3.9% and MTT 
bioreduction=130.2-+-6.5%, n=8, P<0.05, see Fig. 9). 
Expression of wild-type p38u- had no effect on cell 
injury (Fig. 9). 
In summary, our data suggest that simulated 
isch- 
emia selectively activates ectopically expressed p38ot 
over p38P (P<0.001). One consequence of this 
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Figure 8. Modulation of ischemic p38 activation with 
p38(xDN. Cardiocytes were infected with adenoviral con- 
structs encoding FLAG-tagged dominant negative or wild-type 
p38ot. 48 h postinfection, cells were subjected to 2.5 h 
simulated ischernia or left untreated. Myocytes were then 
harvested and lysed for Western blot analysis. A) The total p38 
levels were assessed with anti-p38 antibodies. Adenoviral 
infection causes a consistent level of expression of either 
wild-type or dominant negative p38ot that is unaltered 
during 
ischemia. B) Activation of p38 was assessed using phospho- 
specific p38 antibodies. Ischemia caused a marked activation 
of p38 in wild-type-p38ot transfected cells, whereas p38 activa- 
tion decreased during ischernia in cells expressing dominant 
negative p38ct. 
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Figure 9. Effect of p38ot activation on cell survival during 
ischemia. Myocytes transfected as in Fig. 8 were exposed to 
simulated ischemia for 6 h. Panel A therefore represents cell injury during ischemia alone. B) Cell viability was measured by MTT bioreduction within monolayers after 6h simulated ischemia and 2h reoxygenation. In ury in the presence of j 
p38otDN (0) is expressed as a percentage of injury in the 
presence of an empty vector (0). Viability in cells treated with 
p38otDN alone for 6h (without ischemia) was equivalent to 
that observed in untreated cells (results not shown). All P 
values are for comparisons between ischemia in the presence 
of p38aDN vs. empty vector. *P<0.05, n=8. 
emia, which may represent a new and specific ther- 
apeutic target. 
Signaling during preconditioning and ischemia 
Previous reports suggest that activation of p38 dur- 
ing preconditioning is responsible for the resulting 
protection (20,54,55). These conclusions were 
based on the ability of SB203580 to inhibit protec- 
don when given during preconditioning. If p38 
activation during preconditioning occurs down- 
stream of PKC, then we would expect overexpression 
of active PKC8, which we have shown protects myo- 
cytes during ischemia (29), to have activated the p38 
pathway. Our findings do not support this hypothe- 
sis, since p38 activation was inhibited rather than 
activated by active PKC-8. Expression of active PKC-E, 
another PKC isoform implicated in preconditioning 
(56), also inhibits p38 activation during simulated 
ischemia (results not shown). These findings support 
a protective role for PKC activation during lethal 
simulated ischemia since all studies addressing the 
role of p38 during ischemia, in the absence of 
preconditioning, demonstrate that activation is det- 
rimental, with SB203580 decreasing infarct size and 
enhancing postischemic functional recovery (23, 
24). 
The effect of preconditioning on p38 signaling 
during ischemia, 
Overexpression of active PKC mutants does not 
necessarily mimic physiological preconditioning, so 
we wanted to examine the effect of ischemic precon- 
ditioning on p38 activation during ischemia. As 
shown in Fig. 5, preconditioning significantly inhib- ited p38 activation during ischemia. Of course, the basis of this inhibition could be a consequence 
rather than a cause of protection. If a cause of protection, one would expect p38 inhibition to pro- tect during ischemia. As shown in Fig. 6 and in 
agreement with other reports (22-24), inhibition of 
p38 with SB203580 does protect against ischemic cell death. This is the first data, to our knowledge to document a mechanistic link between ischemic pre- 
conditioning and reduced p38 activation during ischemia. 
The contribution of p38 isoforms 
The limitations of this work became apparent when 
considering recent reports of various p38 isotypes, 
two of which (p38u- and P) are highly expressed in 
the heart. The likelihood that these isotypes carry 
out different, perhaps even opposite, intracellular 
functions casts doubt over the use of nonselective 
inhibitors (SB203580) and antibodies to infer the 
function of p38. Neglecting isoform-specific effects 
could lead to contradictory results. For example, a 
treatment such as preconditioning may switch the 
balance of activation from one isoform to another, 
which, if they have opposing roles may have a 
dramatic effect on cell fate. But the detection of p38 
phosphorylation using antibodies would be insensi- 
tive to this switch, and thus not show a significant 
change in overall activation. This may explain the 
findings in rabbit cardiomyocytes when SB203580 
given during ischemia actually accelerates injury 
(57). Examining the differential activation of p38 
isoforms allows a more complete appraisal of their 
effects on cell viability. 
To do this, we used adenoviral-mediated expres- 
sion of wild-type p38o- and P into rat neonatal 
cardiocytes, which, unlike whole heart preparations, 
produced transfection efficiencies greater than 95%. 
Assessment of isotype activation after 2.5 h ischemia 
showed that p38a was activated, whe 
' 
reas p38P was 
significantly inhibited (Fig. 7Q. To our knowledge, 
this is the first demonstration of differential activa- 
tion of p38 isoforms by a physiological stress. Accord- 
ing to Wang and co-workers, p38cL activation in 
cardiac myocytes is sufficient to cause apoptosis and 
cell death, whereas p38P is responsible for hypertro- 
phy and survival (52). In our model, this hypothesis 
would fit with a mechanism whereby p38cL is the 
specific detrimental NLAPK isoform activated by isch- 
emia. Preconditioning, which inhibits p38, also at- 
tenuates the p38ot pathway during ischemia, which 
should account at least in part for the associated 
protection (Fig. 7Q. 
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The consequence of p38ot activation during 
ischemia 
If decreased p38a_ activation does contribute to 
protection, then inhibition of this pathway should be 
sufficient to protect. Although SB203580 has been 
shown to protect, both in this study (Fig. 6) and 
others (22-24), it inhibits both p38oL and p38P. 
Moreover, recent reports have questioned its speci- 
ficity since it can inhibit (58,59) and even activate 
(60) other kinases. 
We used dominant negative p38 mutants to specif- 
ically inhibit the activation of individual isoforms 
during ischemia. Dominant negative p38ot decreased 
endogenous p38 activation during ischemia, which 
may reflect a decrease in endogenous p38P activa- 
tion (Fig. 8B). This inhibition of p38ot caused an 
increase in cell viability (Fig. 9), whereas the pres- 
ence of p38PDN had no effect (results not shown). 
In summary, sustained p38 activation occurs dur- 
ing lethal simulated ischemia in cultured rat neona- 
tal cardiocytes. This activation can be attenuated by 
cardioprotective treatments such as preconditioning 
and overexpression of active PKC-8. Moreover, our 
results support the concept that p38ot and p38P are 
differentially regulated during ischemia, since isch- 
emia is accompanied by an increase in p38u- and a 
decrease in p38P phosphorylation. In addition, spe- 
cific inhibition of p38ot activation, but not p38P, is 
protective. Taken together, these observations sugý- 
gest that the inhibition of p38ot activation during 
prolonged ischernia is the cause rather than the 
consequence of preconditioning. Ultimately, under- 
standing the signaling mechanisms that modulate 
ischemic cell injury will facilitate novel interventions 
that preserve ventricular function by reducing the 
rate of necrosis during myocardial infarction. M 
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